

# TH CONGRESS OF THE INTERNATIONAL SOCIETY FOR THE STUDY OF FATTY ACIDS AND LIPIDS



AT "THE BREWERY" – MÜNCHENBRYGGERIET



NOBEL LAUREATE LECTURE BY
Prof. Bengt I. Samuelsson
Karolinska Institutet, Sweden

Stockholm sweden 28 June - 2 July



**SPECIAL EVENT HIGHLIGHTS** SATURDAY **28** JUNE

Welcome Reception
At Stockholm City Hall
Hosted by the Stockholm City & County Councils

SUNDAY **29** JUNE

Dinner Debate/Social\* At Nalen Restaurang

MONDAY **30** JUNE New Investigator's Mixer\* Aboard The Lady Patricia

TUESDAY 1 JULY Gala Dinner At Vasa Museum







**ONE-DAY PRE-CONGRESS PROGRAMME** SATURDAY **28** JUNE

Lipid Update Seminar\* p. 17
In collaboration with Karolinska Institutet



ONE-DAY SPONSORED PROGRAMME
WEDNESDAY 2 JULY
Satellite Symposia\* p. 30

# Congre

Congress Programme

\*Please note that a separate registration is required to attend selected events.

At Artipielag

Learn about our latest research on lipids, human milk, and the gut-brain axis.



# Advancing Pediatric Science. Improving Children's Nutrition.





Early-life nutrition builds a foundation for lifelong health. Our only purpose is to be at the forefront of this unique and critical area of science.

OUR MISSION



We advance and apply the latest breakthroughs in nutrition science to benefit pediatric populations around the world.

OUR FOCUS



Our researchers, together with other world-leading experts, pioneer new discoveries that improve the health and well-being of children.

#### ISSFAL Executive Committee

President Susan Carlson, Ph.D. University of Kansas, USA

Immediate Past President Philip Calder, Ph.D., D.Phil Institute of Human Nutrition, University of Southampton, UK

Vice-President & President-Elect Tom Brenna, Ph.D. HE Nutritional Science, Cornell University, USA

Honorary Secretary Peter Clough, MSc

#### **Board of Directors**

**Richard Bazinet, Ph.D.**University of Toronto, Canada

Robert Block, M.D. University of Rochester, USA

Renate H.M. De Groote, Ph.D. Open University, The Netherlands

William Harris, Ph.D. University of South Dakota, USA

Hee-Yong Kim, Ph.D.\*

National Institutes of Health, USA
\*Dr. Kim serves as a member of the ISSFAL Board
of Director's in her personal capacity. Any views,
recommendations or decisions Dr. Kim makes as
a member of the Board are her own and not as a
representative of or an endorsement from the NIH.

Berthold Koletzko, M.D., Ph.D. University of Munich, Germany

Maria Makrides, Ph.D. Women & Children's Health Research Institute, Australia

Barbara Mayer, BSc (Hons), Ph.D., RNutr University of Wollongong, Australia

**Toru Moriguchi, Ph.D.** Azabu University, Japan

Norman Salem, Ph.D.
DSM Nutritional Products LLC, USA

Andrew Sinclair, Ph.D.
Deakin University, Australia

Birgitta Strandvik, M.D., Ph.D. Karolinska Institute, Sweden

> Julia Boettcher MeadJohnson, USA

Clemens von Schacky, M.D. University of Munich, Germany



#### TABLE OF CONTENTS

Detailed Programme	21
Pre-Congress Lipid Update Seminar	17
Transportation	15
The Brewery Meeting Rooms	14
Sponsors & Exhibitors Listing	12
Exhibit & Poster Hall	10
Delegate & Speaker Information	9
T-Bana (Metro) Map	8
Area Map	6
Nobel Laureate Lecture	5
New Investigator Awards	4
Welcome	3
Thank You	2

### Distinguished Faculty

Satellite Symposia

**Posters Sessions** 

30

33

41

#### **ISSFAL** Headquarters

**Graham S. Hauck** Administrator

Molly Shevlin
Membership & Meeting Coordinator
1025 Thomas Jefferson Street NW
Suite 500 East
Washington, DC 20007, USA
+1 (202) 521-6725 | Fax +1 (202) 833-3636
admin@issfal.org
www.issfal.org



Abstracts for all presentations and posters are available online at www.issfal.org





TH CONGRESS OF THE INTERNATIONAL SOCIETY FOR THE STUDY OF FATTY ACIDS AND LIPIDS - 2 JULY | STOCKHOLM, SWEDEN

" — MÜNCHENBRYGGERIET

## **SPONSORS & EXHIBITORS**



Thank You! The support that the ISSFAL 2014 Congress has received from sponsors, exhibitors and other supporters is critically important in keeping the cost of registration at a reasonable level, and also to enable the award of 40 free registrations (worth over \$20,000 USD) to New Investigator Award winners, thus encouraging good investigators into, and to remain in, the field of fatty acid research. The meeting organisers and the Society appreciate this support, and urge delegates to take every opportunity to express this appreciation to the representatives of sponsors, exhibitors and other supporters that they come into contact with during the meeting and afterwards.

#### PLATINUM





#### SILVER











**BOXED LUNCH & COFFEE BREAK** 

SUNTORY











DELEGATE BAGS



DELEGATE LANYARDS



#### SATELLITE SYMPOSIA

















#### EXHIBITORS



























# Välkommen

Welcome to Stockholm, the capital of Sweden and host city for the ISSFAL 2014 Biennial Congress! For the first time in the 20 year history of ISSFAL, the meeting will be in Sweden and, as a matter of fact, this is the first time we have met in any Nordic country. You are among the record number of attendees at this Congress, over 600!

This meeting will provide a unique occasion for the exchange of scientific results in the lipid area. It will facilitate interactions between old and new members and invited guests. The program covers three major topics: Biochemistry and Metabolism of Fatty Acids; Lipids in Health and Disease; and Lipids in Nutrition. These major themes will encompass all aspects of lipids, from cholesterol and its metabolites to metabolites of essential fatty acids and the interactions, and lipidomics and metabolomics, which are important complements to proteomics in understanding human physiology and pathophysiology. Presentations from basic research to translational research to clinical studies will be of interest to a diverse audience of basic researchers, physicians, and nutritionists. Evidence about the impact of lipids in different clinical diseases is increasing rapidly as is our understanding of the role that dietary lipids can play at all ages in preventing diseases related to lifestyle.

As is typical of our biennial ISSFAL meetings, we encourage you to take advantage of the many opportunities to strengthen cooperation among international researchers and clinicians. In addition to the plenary lectures and oral presentations chosen from over 400 abstract submissions, poster presentations and wonderful social occasions will offer opportunities for interaction among all participants.

Stockholm, one of the most beautiful capitals in the world, is built on 14 islands connected by 57 bridges. The beautiful buildings, the greenery, the fresh air and the proximity to the water are distinctive traits of this city. With its 750 year history and rich cultural life, Stockholm offers a wide selection of world-class museums and attractions. As a city built on 14 islands, it offers marvelous views over the water, and if 14 islands aren't enough, Stockholm offers a wonderful archipelago with 30,000 islands, islet rocks and skerries.

Stockholm has excellent transportation within the city that caters to making the most of everything the city has to offer. Details of the Congress venues and transportation are in the following pages as well as a detailed schedule of events.

Whether you are a long standing member or friend of ISSFAL and the conference, or this is your first time to take part, we assure you that we will work extremely hard to make sure that we meet your key objectives. Please do not hesitate to contact any of the ISSFAL staff or leadership on any matter for which we might be of assistance.

Welcome and enjoy the Congress!

Best regards,

#### ISSFAL 2014 Local Advisory Committee

#### Birgitta Strandvik MD,PhD

Karolinska Institutet Stockholm, Sweden

#### Jan Palmblad MD, PhD

Karolinska Institutet Stockholm, Sweden

#### Samar Basu, MSc, PhD

University d'Auvergne Clermont-Ferrand, France Uppsala University Uppsala, Sweden

#### Anders Jacobsson, PhD

Stockholm University Stockholm, Sweden

#### Jana Pickova, PhD

Swedish University of Agricultural Sciences Uppsala, Sweden

# Ad Hoc Members of the Organisation Committee

#### Susan Carlson, PhD

ISSFAL President University of Kansas Kansas City, USA

Peter Clough, MSc ISSFAL Honorary Secretary

Robert Gibson, PhD University of Adelaide

Adelaide, Australia





Birgitta Strandvik Chair of the Local Advisory Committee



Susan Carlson President of ISSFAL



# TH CONGRESS OF THE INTERNATIONAL SOCIETY FOR THE STUDY OF FATTY ACIDS AND LIPIDS

JUNE - 2 JULY | STOCKHOLM, SWEDEN "THE BREWERY" — MÜNCHENBRYGGERIET



#### **NEW INVESTIGATOR AWARDS**

We are pleased to announce the fifty New Investigator Award winners, which originate from 18 different countries. NIA winners are awarded a free registration for this Congress, the opportunity to apply for an ISSFAL travel award, and have received an invitation to a special New Investigator 'Meet the Professor' breakfast.

Travel awards were made for this Congress as a result of the funding of \$12,000 USD of Society funds allocated by the ISSFAL Board of Directors. In addition, ten New Investigator Award winners (selected by a panel of judges prior to the meeting) will be awarded a prize in recognition for their outstanding contribution. Their posters will be on display Sunday to Tuesday. Three of the top New Investigator Award winners will be chosen by a panel of judges (who will visit the poster hall sometime during the scheduled poster sessions) to present their findings.

We offer our congratulations to all NIA winners and look forward to their active participation in future ISSFAL activities.

Arnardottir, Hildur	Harvard Institute of Medicine/Brigham and Women's Hospital	
Bachmair, Eva-Maria	University of Aberdeen	
Baumgartner, Jeannine	North-West University	. South Africa
Bidu, Célia	UMR-INSERM/University of Burgundy	
Caligiuri, Stephanie	University of Manitoba	
Chang, Jane	China Medical University Hospital	. Taiwan
Chiu, Chih-Chiang	Taipei City Psychiatric Center, Taipei City Hospital	. Taiwan
Choque, Benjamin	Laboratoire de Biochimie et Nutrition Humaine	. France
Chouinard-Watkins, Raphael	Université de Sherbrooke, Sherbrooke	. Canada
Conway, Valérie	University Institute of Geriatrics of Sherbrooke	. Canada
Corsetto, Paola Antonia	University of Mllan	. Italy
Coventry, Krista	University of Guelph	. Canada
Daak, Ahmed	University of Khartoum	. Sudan
De Boer, Anna	University of Guelph	
Domenichiello, Anthony	University of Toronto	Canada
Freund-Levi, Yvonne	Karolinska Institutet	Sweden
Gibert, Yann	Deakin University	
Gibson, Deanna	University of British Columbia Okanagan.	
Gould, Jacqueline	Women's and Children's Health Research Institute	Australia
Hahm, Ki Baik	CHA University School of Medicine	
Hanley, Anthony	University of Toronto	
Hedengran, Anne	University of Copenhagen	. Callaud Donmark
Hidaka. Brandon	University of Kanasa Medical Contar	. Delillidik United States of America
	University of Kansas Medical Center	
Hopiavuori, Blake	University of Oklahoma Health Sciences Center	
Hopperton, Kathryn	University of Toronto	
Kitson, Alex	University of Toronto	. Canada
Lee, Kerry	University of Auckland	
Mahbouli, Sinda	Université d'Auvergne	
Mason, Julie	University of Toronto	
Molto-Puigmartí, Carolina	Maastricht University	. Netherlands
Muhlhausler, Bev	The University of Adelaide	
Na, Hye-Kyung	Sungshin Women's University	
Richter, Marilize	North-West University	
Rodrigo, Valenzuela	University of Chile	
Rosqvist, Fredrik	Uppsala University	. Sweden
Salem, Nicholas	National Institutes of Health	. United States of America
Santaren, Ingrid Dominique	University of Toronto	. Canada
Slim, Kenna	University of East Anglia	. United Kingdom (Great Britain)
Souza Junior, Alcione	Universidade de São Paulo	. Brazil
Su, Kuan-Pin	China Medical University	
Svobodova. Michaela	Institute of Physiology Academy of Sciences	. Czech Republic
Terrando, Niccolo	Karolinska Institutet	
Trépanier, Marc-Olivier	University of Toronto	
Vetri Villalan, Sharmila	University of Kansas Medical Center	
Voggt, Alessandra	Ludwig-Maximilians-University	Germany
West. Annette	University of Southampton	United Kingdom (Great Britain)
Wickramasinghe, Vithanage Pujitha	University of Colombo	
Wood. Katie	The University of Adelaide	Australia
Zhang, Jiyao	Cornell University	
Zouhar. Petr	Institute of Physiology Academy of Sciences	Czech Renublic
Zouliai, i eti	motitute of injuriously acqueing of seletiles	. ozcen nepublic



# 11 TH CONGRESS OF THE INTERNATIONAL SOCIETY FOR THE STUDY OF FATTY ACIDS AND LIPIDS 28 JUNE - 2 JULY | STOCKHOLM, SWEDEN AT "THE BREWERY" — MÜNCHENBRYGGERIET



#### NOBEL LAUREATE LECTURE



Prof. Bengt I. Samuelsson Karolinska Institutet, Solna, Sweden

# Sunday 29 June Progress in eicosanoid research

Dr. Bengt Samuelsson is a Professor of Physiological Chemistry at the Karolinska Institute. Dr. Samuelsson's research led to the discovery of various prostaglandins and related substances. Of particular interest are the thromboxanes which are involved in such common, severe thrombotic diseases as strokes and coronary infarcts. He also discovered the leukotrienes, substances that play a role in inflammation and asthma and other allergic diseases. For his discovery of prostanoids and leukotrienes he was awarded the Nobel Prize in Physiology or Medicine in 1982.

Dr. Samuelsson was born in Halmstad, Sweden in 1934. He obtained his Doctor of Medical Science degree in biochemistry and later, his M.D. degree, from the Karolinska Institute. He spent a year as a research fellow in the Department of Chemistry at Harvard University, Cambridge, Mass., USA. In 1972, Dr. Samuelsson was appointed professor at the Karolinska Institute. In 1973–1983, he was Chairman of the Department of Chemistry; in 1978–1983, Dean of the Medical Faculty and in 1983–1995, President of the Karolinska Institute.


In 1985–1988, he was a member of the Swedish Government Research Advisory Board and in 1987–1990, a member of the Swedish National Commission on Health Policy. Dr. Samuelsson has been a member of the Nobel Assembly and the Nobel Committee for Physiology or Medicine at the Karolinska Institute and in 1993–2005, he was Chairman of the Nobel Foundation in Stockholm.

In 1994–1997 Dr. Samuelsson was a member of the European Science and Technology Assembly (ESTA) and in 1995–1997 a special advisor to the Commissioner for Research and Education in the European Commission.

In addition to the Nobel Prize, Dr. Samuelsson has received a number of worldwide awards and honorary academic degrees. These include the Louisa Gross Horwitz Award, the Gairdner Foundation Award, the Albert Lasker Basic Medical Research Award and the Abraham White Distinguished Science Award. He holds honorary doctoral degrees from University of Chicago, Louisiana State University and University of Illinois, USA; University of Buenos Aires, Argentina; University of Rio de Janeiro, Brazil; Norman Bethune University of Medical Sciences, Changchun, China; Complutense University of Madrid, Spain, University of Milan, Italy and University of Uppsala, Sweden.

Dr. Samuelsson is a honorary member of the American Academy of Arts and Sciences, the American Society of Biological Chemists and the Association of American Physicians. He is a Foreign Associate of the US National Academy of Sciences and a Foreign Member of the Royal Society, London. He is a member of the Royal Swedish Academy of Sciences, the Royal National Academy of Medicine, Spain, the French Academy of Sciences and the Institute of Medicine, USA.





Gustav Adolfsparken



#### TAXI INFORMATION

There are several taxi companies to choose from in Stockholm. Approved taxis with metered fares always bear yellow number plates. Credit cards are readily accepted.

Sweden does not regulate prices; they may vary greatly. It is the customer's responsibility to check prices beforehand. Check the price on the yellow label (pictured at right), which is usually on the rear door window, before entering the vehicle. The price

on the yellow label is based on a 10 km, 15-minute journey. The price indicated on the taximeter is in Swedish kronor (SEK, or kr).

The highest unit price of most taxis is between SEK 290-390. For trips to and from Stockholm Arlanda Airport the major taxi companies have fixed prices of between SEK 450-500. Always ask the driver beforehand.

In addition to the major taxi companies there are several independent firms: caution is adviced. You can easily get hold of a taxi by calling a taxi company, hailing one on the street or by taking a one from a rank, e.g. at NK on Hamngatan. There is a manned taxi centre at Central Station that can help you with finding the right service, e.g. if you need child seats in the vehicle.

Several of the big Stockholm taxi companies have a very high proportion of eco-vehicles. A new rota system gives priority to cabs with low carbon emission levels.

#### **TAXI 020**

020-20 20 20 20 www.taxi029.se

# TAXIKURIR

08-30 00 00 www.taxikurir.se




#### TAXI STOCKHOLM

08-15 00 00 www.taxistockholm.se

Source: www.visitstockholm.com/en/Travel/In-Stockholm/Tips-In-Stockholm/Taxi-/



# Stockholm Metro System TUNNELBANA (T-bana)



# Delegate & Speaker Information

#### ■ ISSFAL REGISTRATION DESK / THE BREWERY - MAIN ENTRANCE FOYER

The ISSFAL Registration Desk is conveniently located **just inside the main entrance of the Brewery** (see floor plan on p. 12). Be sure to check-in at the Registration Desk to pick up your Congress materials, event tickets and name badge. Desk hours are as follows:

Saturday, 28 June	. 10:00 – 18:00
Sunday, 29 June	07:30 - 18:00
Monday, 30 June	. 07:30 - 18:00
Tuesday, 1 July	. 08:00 - 18:30
Wednesday, 2 July*	. 08:00 - 12:30

\*Note: On Wednesday, July 2, the ISSFAL Registration Desk will relocate to the HILTON SLUSSEN HOTEL LOBBY to assist those attending the Satellite Symposia at Artipelag.

#### **EXHIBIT & POSTER HALL** / THE BREWERY - MÄLARSALEN

See the floor plan on the next page and look for signage on site. The Exhibit and Poster Hall will be open for viewing throughout the day during the following times:

Sunday, 29 June	0:00 – 16:	15
Monday, 30 June 0	9:15 - 16:3	30
Tuesday, 1 July	9:45 - 16:3	30

All posters will be displayed throughout the Congress; however, formal presentation of posters will take place during lunch on the day specified in the chart on page 9. Please refer to the Poster section of this program for details on the posters displayed. Poster presenters are asked to refer to the guidelines that were previously distributed for details regarding format, size, content, set-up and tear-down times. Any material that remains after a designated session's teardown time is subject to removal and disposal by Congress management.

SCHEDULED EVENTS:	MORNING BREAK	LUNCH	AFTERNOON BREAK
Sunday, 29 June	10:00-10:40	12:00-13:30	15:30-16:15
Monday, 30 June	09:15-10:00	12:20-13:45	15:45-16:30
Tuesday, 1 July	09:45-10:30	12:05-13:45	15:45-16:30

#### SPEAKER READY ROOM / THE BREWERY - ABOVE MÄSSTORGET

Please identify yourself as a Congress presenter to the ISSFAL Registration Desk staff and you will be directed to the Speaker Ready Room. Speaker Ready Room hours are as follows:

Saturday, 28 June	14:00- 17:00
Sunday, 29 June	. 08:00 - 16:30
Monday, 30 June	. 08:00 - 16:30
Tuesday, 1 July	. 08:00 - 14:00

Due to the large number of presentations in the program, speakers are urged to visit the Speaker Ready Room no later than four (4) hours prior to the scheduled session, and preferably on the day prior to the presentation. An audio-visual technician will be available to assist speakers with pre-flighting their presentation. Please bring a copy of your presentation to the Speaker Ready Room on a flash drive/memory stick.

#### NAME BADGE POLICY

Your badge grants you access to the ISSFAL 2014 Congress. Please handle it with care. Delegates are required to wear their name badge at all times and will not be granted access to the Congress sessions or social events without it. A reprint convenience fee of \$5000 USD will be assessed for any lost or misplaced badge. This is to help ensure that access to the Congress is properly managed.

#### CERTIFICATE OF ATTENDANCE

A Certificate of Attendance will be distributed to each registered delegate while at the ISSFAL 2014 Congress. This is included in the delegate bag with Congress materials.

## Scheduled Meals & Social Program

**BREAKFAST:** As is customary in most European hotels, your room rate likely includes breakfast daily. As such, ISSFAL will not provide breakfast for delegates during Congress dates.

#### **COFFEE BREAKS & LUNCHES**

THE BREWERY - MÄLARSALEN

ISSFAL 2014 Congress registration includes morning and afternoon coffee breaks and lunch on Sunday, Monday and Tuesday, June 29–July 1.

#### ■ WELCOME RECEPTION AT CITY HALL SATURDAY, JUNE 28 / 19:00 - 21:00

Hosted by the City of Stockholm and the Stockholm County Council. Hors d'oeuvres and beverages will be be provided. It is strictly enforced by the City Hall that ONLY those attendees who registered for the congress PRIOR TO JUNE 13 may be allowed to attend this special event. You will receive your invitation card (not transferrable) when you pick up your Congress materials from the Registration Desk at The Brewery on Saturday, 28 June, between 10:00-18:00. We regret any inconvenience; however, invitations are not transferrable and late or on-site registrations are not allowed.

# ■ GALA DINNER AT VASA MUSEUM TUESDAY, JULY 1 / 19:00 - 23:00

Formal dinner in the main hall of the museum alongside the infamous ship.

#### ■ BUSINESS CENTRE - The

Business Centre at The Brewery is located by the ISSFAL Registration Desk. Payment via credit card may be required.

■ INTERNET ACCESS - ISSFAL attendees will have complimentary internet in all areas of The Brewery. Wi-fi Network: issfal2014
Password: lipid2014

■ SMOKING - The Brewery is a non-smoking facility. Smoking is only permitted outside the Brewery. This is the same policy for all local restaurants, bars and public buildings.

■ LOST PROPERTY − Please report any lost or unattended items immediately to Congress staff. Should you lose anything while at the Congress, do enquire at the ISSFAL Registration Desk where any found property will be held.



11 TH CONGRESS OF THE INTERNATIONAL SOCIETY
FOR THE STUDY OF FATTY ACIDS AND LIPIDS
28 JUNE - 2 JULY | STOCKHOLM, SWEDEN
AT "THE DEWERY" MÜNCHENBRYCCERIET



#### **EXHIBIT & POSTER HALL**

Exhibitors BOO	)TH #
AAK	. 6
AlaskOmega	11
BASF	10
DSM Nutritional Products	. 8
Efamol	. 7
GC Reiber	. 2
Larodan	. 5
MeadJohnson Nutrition	. 1
Nordic Naturals	. 4
OmegaQuant	. 3
RIMFROST	12
Smartfish	. 9

# Poster Presentations

Posters will be presented in three halls at the upper floor of The Brewery – **Nobelterassen (N), Mälarsalen (M)** and **Strindbergsalongen (S).** Here you will also find the Exhibit Hall, where Coffee Breaks and Lunch will also be served on Sunday, Monday and Tuesday (breakfast is on your own).


Posters will be available for review during all three full days of the Congress. Since we have a very full oral programme, it is important that all attendees have ample opportunity to see the Posters throughout the Congress.

We have created a schedule whereby you will be able to see presentations formally on **one day only during the lunch break,** to facilitate discussion with those interested and also make it possible for you to be able to meet other presenters of topical interest to you.

#### **VIEWING POSTERS**

Posters have been given a number for easy identification by delegates. This number has three parts:

- The initial letter refers to the "Poster Area" (there are three) where the Poster will be presented (see floor plan below and table at right).
- The next number refers to the designated screen row.
- The second number after the decimal refers to the specific screen within the designated row. This identification number will be found on the specific location as described above. The number will also appear wherever the corresponding Abstract is listed in the Program and online.



#### POSTER DISPLAY AREAS / PRESENTATION SCHEDULE

#### ATTENTION PRESENTERS:

You will formally present your Poster during lunch, on the day indicated for your row — which corresponds to the first two numbers of your new Poster Number.

For the complete Poster listings please see p. 41.

POSTER AREA	TOPIC	SUNDAY	MONDAY	TUESDAY
NOBELTERRASSEN POSTER AREA N	Nutrition/Food/Diary/Formula	N1 N4	N2	N3
	Programming/Epigenetics	N7	N5	N6
	Placenta/Pregnancy/Neonatology	N10	N8	N9
	Neurodevelopment/Neuroscience	-	N11	N12
MÄLARSALEN POSTER AREA M	Metabolism/Endocannabinoids	M1	-	_
	Metabolism/Oxidation	-	M2	M3
	Metabolism/Transformation	M4	M5	_
	Metabolism/Oxylipins	-	-	M6
	Cancer	M7	-	_
	Immunology/Clinical Diseases	-	M8	_
STRINDBERGSALONGEN POSTER AREA S	Exercise Obesity/ Diabetes mellitus Vitamin D Cardiovascular diseases/Cholesterol Neuropsychiatry Alzheimer/Apo E Aging/Pain Methodology Bioavailability Common Topics	\$1 - \$4 \$7 - \$10 - \$13 -	- \$2 - \$5 \$8 - - \$11 - \$14	- \$3 - \$6 \$9 - \$12 - - \$15





TH CONGRESS OF THE INTERNATIONAL SOCIETY FOR THE STUDY OF FATTY ACIDS AND LIPIDS

28 JUNE - 2 JULY | STOCKHOLM, SWEDEN AT "THE BREWERY" — MÜNCHENBRYGGERIET



#### SPONSORS & EXHIBITORS

AAK BOOTH 6

AAK is the first choice for healthy vegetable oil solutions, in the fields of for example, confectionery, dairy, infant nutrition and bakery. AAK has a global supply chain in which food safety and quality are top priorities.

#### Aker BioMarine

Aker BioMarine is an integrated biotechnology company dedicated to the sustainable harvest of krill and development of krill-derived biotech products. Aker BioMarine's Superba™ Krill products are provided with 100% traceability from sea to shelf. The uniqueness of Superba™ Krill is that EPA and DHA are provided in phospholipid form.

AlaskOmega BOOTH 11

AlaskOmega® is produced from wild-caught Alaska Pollock oil sourced from the Bering Sea that is certified sustainable by the Marine Stewardship Council. AlaskOmega® is available in ultra-high purity ethyl ester and triglyceride concentrates up to 80% EPA and DHA content.

BASF BOOTH 10

BASF is a global market leader for omega-3 fatty acids offering a full range from low to medium to high-concentrate omega-3 fatty acids for pharmaceuticals, dietary supplements and clinical nutrition – derived from nature, enhanced by science.

#### **BAXTER**

Baxter International Inc. through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.

#### B. Braun Melsungen AG

B. Braun Melsungen AG is a family owned company with 50,000 employees in 61 countries. Through exchanging knowledge, B. Braun helps to improve the medical environment and to increase the safety of patients and healthcare professionals alike. For more information: please see www.bbraun.com.

#### Carlson Laboratories

Founded in 1965, Carlson Laboratories began as a family owned and operated business dedicated to providing only the highest quality nutritional supplements. Their award-winning fish oil products are renowned for their purity and great taste.

#### DSM Nutritional Products

**8** HT008

DSM - Bright Science. Brighter Living.<sup>TM</sup> Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 24,500 employees deliver annual net sales of around 10 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com.

Efamol Ltd BOOTH 7

Efamol Ltd has for 30 years pioneered research, development, production and clinical testing of essential fatty acids. Current products are positioned for cognitive performance and decline, behaviour and learning skills, pregnancy/lactation and skin health. These products are sold in more than 30 countries worldwide

#### Fresenius Kabi

Fresenius Kabi is a global health care company specializing in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The products and services help to care for critically and chronically ill. Product portfolio: I.V. generic drugs, infusion therapies, clinical nutrition and related medical devices, products for whole blood and blood components collection and processing and transfusion medicine.

GC Rieber BOOTH 2

GC Rieber Oils has been a leading supplier of refined fish oil since 1965. GC Rieber Oils modern refining technologies guarantee a high and consistent quality, with state-of-the-art cleaning technologies that according to each specification can remove or reduce environmental pollutants, cholesterol and oxidation products. The company is fully approved under ISO 9001 with HACCP certification.

#### **GOED**

GOED is a proactive and accountable association of the finest manufacturers, marketers, and supporters of EPA and DHA omega-3s, working to educate consumers, government groups, and the healthcare community, while setting high ethical and quality standards for our business sector.

#### Golden Omega

Golden Omega is a direct to the source solution for companies requiring a deodorized, concentrated omega-3 fish oil. Located right next to the fishery in northern Chile, we offer a full range of products from 50–85 % EPA and DHA.

#### Lactalis

Lactalis is a multi-national dairy products corporation, owned by the Besnier family and based in Laval, Mayenne, France. It is the largest dairy products group in the world, and is the second largest food products group in France, behind Danone.

Larodan BOOTH 5 RI

Larodan develops, manufactures and market high quality research grade Lipids for the international laboratory market. Our products are used in a number of fields within research, product development and industrial processes. Larodan also provides select other Research Chemicals to the Nordic market, in collaboration with international principals that are as dedicated to their fields as we are. We focus on stable and radioactive isotopes, NMR consumables and biochemicals as well as environmental and forensic standards.

#### Mead Johnson Pediatric Nutrition Institute

B00TH **1** 

The Mead Johnson Pediatric Nutrition Institute is a global network dedicated to advancing and applying the latest breakthroughs in nutrition science to benefit infants and children worldwide. Our only purpose is to be at the forefront of pediatric nutrition research.

#### Mylnefield Lipid Analysis

Mylnefield Lipid Analysis is an independent analytical laboratory specialising in the analysis of oils and fats. We are approved by the MHRA for both GMP and GCP analyses and by the FDA for GMP analyses.

Nordic Naturals BOOTH 4

Nordic Naturals is a leading manufacturer of omega-3 fish oils and essential fatty acid supplements. With a complete line of omega oils for adults, children, and pets, Nordic Naturals promotes a lifetime of optimal health.

#### Nutegrity

Nutegrity's mission is to provide pure, sustainable nutrition products that support healthy living. We provide pure ingredients from sustainable land and sea sources by controlling quality through vertical integration and traceability programs, while working to protect the longevity of product supply.

#### Nutrogenics/WHC

WHC supplies the most environmentally friendly and unique Omega supplements, selected on the basis of the highest possible quality, ecomanagement, purity and safety requirements, via Nutrogenics. We guarantee 'the best of the best' when it comes to Omega-3 supplements, as demonstrated by their pharmaceutical quality and highest Omega-3 concentration. WHC Omega supplements are available from pharmacies, therapists and via Nutrogenics online.

#### Omega Protein Corporation

Omega Protein Corporation is a nutritional ingredient company dedicated to delivering healthy products to the animal and human nutrition industries. Omega Protein is the United States' leading vertically integrated producer of sustainable omega-3 fish oil and specialty fish meal products.

#### **OmegaQuant Analytics**

**B**00TH **3** 

OmegaQuant Analytics partners with academic and corporate researchers to provide a full range of fatty acid analytical services. We also consult in study design and assist in data interpretation.

RIMFROST BOOTH 12

Olympic Seafood, the company behind RIMFROST and the management of Juvel, a specialized krill-collecting vessel, focuses exclusively on Antarctic krill ingredients for consumer applications. Our operations aim for low emissions, low energy usage and climate impact. We guarantee 100% traceability.

Smartfish BOOTH 9

Smartfish is a Norwegian company developing synergistic omega 3 based pharmaconutrition products. The patented technology is basis for the product range of orally applied liquid emulsions. Smartfish`emulsions are characterized by its high EPA & DHA content. The EPA & DHA fatty acids enter the cell membrane effectively without carrying oxidative products and with a taste/tolerance providing superior compliance.

#### Suntory


Suntory Group offers food services and alcoholic beverages to achieve our mission "In Harmony with People and Nature." As part of Suntory Group, Suntory Wellness is making an innovative business for health care. Institute for Health Care Science is the center for research based on science and tradition.

#### Unilever

Unilever is one of the world's leading consumer goods companies with products sold in over 190 countries. Our ambition - Unilever Sustainable Living Plan - is to help more than 1 billion people improve their health and wellbeing by 2020.


#### Vifor Pharma / Equazen

Equazen offers a range of nutritional supplements with specific combinations of EPA, DHA, and GLA. Equazen products have been tested in clinical trials and demonstrated efficacy in supporting cognitive function of children and adolescents. Vifor Pharma is dedicated to furthering the scientific understanding of PUFAs and their health benefits.



# MÜNCHENBRYGGERIET "THE BREWERY"

Torkel Knutssonsgatan 2 118 25 Stockholm



# TRANSPORTATION

# Opening Reception at Stockholm City Hall Saturday, 28 June / 19:00–21:00 (INVITATION ONLY; NON-TRANSFERRABLE)

Hosted by the City of Stockholm and the Stockholm County Council Transportation to City Hall is on your own (please refer to the Area Map on page 4). The City Hall is about a 10 minute walk from the Hilton Slussen, 15 minutes from The Brewery, and a short taxi ride from any point in Stockholm Center City. PLEASE BE SURE TO HAVE YOUR OFFICIAL INVITE CARD TO GAIN ACCESS TO THE RECEPTION. The Invite will be given to you at the ISSFAL Registration Desk at the Brewery on Saturday, 28 May.

#### Dinner Debate at Nalen Restaurang

Sunday, 29 June / 19:00–21:00 (BY INVITATION)

Transportation to the Dinner Debate is on your own. We suggest referring to the map on page 4 for walking details and/or taxi information. The restaurant is about a 20-30 minute walk from the Slussen (Hilton). The closest T-Bana Station is **Hötorget** (via the Green line T17, T18 or T19 trains).

#### Gala Dinner at Vasa Museum

Tuesday, 1 July / 19:00-23:00

Transportation to the Gala Dinner is on your own. Please see the map on page 4 for walking details and/or taxi information. the Vasa Museum is a little over 30 minute walk from the Slussen (Hilton). You may also use the excellent public transportation options in Stockholm:

- TRAM: The easiest way to get to the museum is by tram. From the city centre (by Sergels Torg Square, on Hamngatan street) take tram number 7 towards Waldemarsudde.
- BUS: Bus 44 to bus stop Nordiska museet/Vasamuseet. Bus 69 and 76 to bus stop Djurgårdsbron.
- METRO (T-BANA): Red line to station Karlaplan. From there a 10 minute walk or bus 44 to bus stop Nordiska museet/Vasamuseet.

#### Satellite Symposia at Artipielag

Wednesday, 2 July / 9:30-17:30

Buses for the morning Satellites will depart at 08:30 from the Hilton Slussen. Buses for the afternoon satellites will depart from the Hilton Slussen at 11:30. Buses returning from Artipelag after the morning Satellites will depart after Lunch, at 13:30. A boat will take all remaining attendees at the end of the day back to Stockholm (boat trip is 90 minutes). If you have signed up for this event, please see your final confirmation email for the Satellites.



# 11 TH CONGRESS OF THE INTERNATIONAL SOCIETY FOR THE STUDY OF FATTY ACIDS AND LIPIDS

28 JUNE - 2 JULY | STOCKHOLM, SWEDEN AT "THE BREWERY" — MÜNCHENBRYGGERIET

PRE-CONGRESS PROGRAMME



Separate registration is required to attend

# Lipid Update Seminar

In collaboration with Karolinska Institutet

The **Lipid Update Seminar** on Saturday will present a comprehensive overview of the most important clinical aspects related to the studies of dietary fatty acids. All the presenters are leading, internationally recognized researchers and experts in their respective fields, which is the requirement for being invited by the Karolinska Institute.

This one-day seminar will cover the most discussed and developing areas of essential fatty acid research. Prof. Artemis Simopoulos is wellknown for introducing the discussion about the importance of the balance between the omega 6 and omega 3 fatty acids for metabolism and health; Prof. Michael Crawford has stressed the importance of DHA for the superiority of the human in the evolution; Prof. Daan Kromhaut is one of the world's foremost researchers in the field of the importance of the fatty acid balance for cardiovascular health and disease prevention. Prof. Nicolas Bazan is a prominent figure in the importance of DHA and lipid mediators for brain and retinal function; and Prof. Robert Gibson is a leading researcher regarding the importance of DHA during fetal and postnatal period for the development of the infant.

This program is designed to give a good introduction for those who want to learn about the importance of fatty acids in health and disease. It will be valuable both for those already in the field, who want a state-of-the-art overview, but also for those who have a new interest in the field. It will thus turn to both basic researchers and for clinicians not only in the fields covered by the speakers but also for those generally interested in fatty acid metabolism. Fatty acid metabolism is fundamental in all cells in the body and influence most functions and has attained more interest in recent years as lipidomics has been recognized as important as proteomics. It is of importance for all involved in care of patients and especially for those involved in nutrition, like nutritionists, dieticians and nurses. Students are also welcome to learn about these fundamental aspects of the relation between food and health.

28

JUNE 2014 AT THE MÜNCHEN BREWERY, STOCKHOLM |

#### 09.15-09.45 COFFEE SERVED

#### 09.45-10.00 WELCOME TBD

#### 10.00-11.00 Professor Artemis Simopoulos (Bethesda, Washington DC, USA)

The Clinician's Guide to Long Chain Fatty Acids

- The biochemistry of fatty acids learning to speak the language
- The omega-3 and omega-6 relationship
- What happens to omega-3s when we ingest them where do they end up, and what roles do they play?

#### 11.00-12.00 Professor Michael A.A. Crawford (London, UK)

Fatty acids in evolution, past, present and future

- Theories behind evolution
- DHAs irreplaceable role throughout neural evolution

#### 12.00-13.00 LUNCH

#### 13.00-14.00 Professor Daan Kromhout (Wageningen, The Netherlands)

Cardiovascular Diseases - The Role of Omega-3 Fatty Acids

- Fish consumption and cardiovascular diseases in prospective cohort studies
- Omega-3 fatty acid supplementation and indicators of endothelial function, inflammation and arrhythmias in RCTs
- Omega-3 fatty acid supplementation and cardiovascular diseases in RCTs

#### 14.00-15.00 Professor Robert Gibson (Adelaide, Australia)

Essential fatty acids for Pediatricians and Obstetricians

- Why pregnant and lactating women need omega-3s
- How much DHA is appropriate and in what form should it be given?
- Does DHA play a role in brain development after infancy?

#### 15.00-15.30 COFFEE BREAK

#### 15.30-16.30 Professor Nicolas G Bazan (New Orleans, USA)

Omega-3 fatty acids in CNS ischemia and neurodegenerative diseases

- · Neuroprotective properties of the DHA metabolites
- · Fatty acids in Alzheimer and Parkinsons diseases
- · Fatty acids and CNS injury

#### 16.30-17.00 DISCUSSION AND CONCLUSION

19.00- WELCOME RECEPTION at the City Hall (By invitation of Stockholm City Council)

#### ISSFAL 2014 PRE-CONGRESS PROGRAMME | JUNE 28

In collaboration with Karolinska Institutet

# Lipid Update Seminar Faculty





Nicolas Bazan, MD, PhD School of Medicine, LSUHSC, USA

Born in Tucuman, Argentina, Dr. Bazan studied molecular principles of early responses to disease underlying Alzheimer's, stroke, epilepsy, trau-

matic brain injury and retinal degenerations. Trained at Columbia University P&S in New York and Harvard Medical School, Bazan was appointed faculty at age 26 at the University of Toronto, Clarke Institute of Psychiatry, where he conducted seminal studies on docosahexaenoic (DHA) and arachidonic acids early brain responses to experimental seizures and ischemia. In the 1970s, he established a research institute in Argentina. In 1981, Bazan joined the faculty of LSUHSC, where he later established and now heads the Neuroscience Center of Excellence.

His laboratory has uncovered molecular principles of the retention/conservation of DHA and contributed to the understanding of cell survival signaling in retinal pigment epithelial (RPE) cells, photoreceptors and brain. He and his colleagues discovered the cell survival mediator neuroprotectin D1 (NPD1). Under conditions of uncompensated oxidative stress, NPD1 is made on demand from DHA when disruptors of homeostasis evolve and the initial inflammatory response needs to be modulated to protect neural cell integrity. NPD1 is the first biologically active mediator of the novel docosanoid family. His laboratory found that neurotrophins are agonists for the synthesis of this mediator, that 15-lipoxygenase-1 (15-LOX-1) is the enzyme that catalyzes its synthesis, that it targets protein phosphatase 2A (PP2A) to regulate anti-/pro-apoptotic proteins during oxidative stress, and that it regulates proteostasis. They also identified transcription of pro-inflammatory genes as a target of NPD1 and discovered that the CA1 hippocampal area from short-post mortem, early-stage AD patients displays a 25-fold loss of NPD1 as well as of the enzyme for the synthesis of this lipid mediator. A central theme of his laboratory is to understand early responses to oxidative stress and conditions that recapitulate Alzheimer's and other neurodegenerative diseases aiming to gain insight into the mechanisms that could contribute to preventing, ameliorating and eventually contributing to curing these diseases. A common thread of concepts includes neuroinflammatory signaling, DHA and bioactive lipid mediators. Because the essential omega-3 fatty acid DHA is enriched and avidly retained in the central nervous system, including photoreceptor cells, they postulated and then demonstrated that, as AA generates eicosanoids (20 C: prostaglandins, etc.), DHA generates docosanoids (from 22 C: DHA).

He is a Senate Member (2009-2015) for Deutsches Zentrum für Neurodegenerative, Erkrankungen (DZNE) in der Helmholtz-Gemeinschaft, a nationwide research program on Alzheimer's disease in Germany, Member of the Biology of the Visual System Study Section, NIH (2010-2015), and Chairman of the Board of Governors for the Association for Research in Vision and Ophthalmology (ARVO) Foundation (2011-2014). Among Dr. Bazan's awards are the Javits Neuroscience Investigator Award from the National Institute of Neurological Diseases and Stroke (1989); elected to the Royal Academy of Medicine, Spain (1996); elected fellow of the Royal College of Physicians of Ireland, Dublin (1999); President, American Society for Neurochemistry (1999-2001); Doctor Honoris Causa, Universidad de Tucuman, Argentina (1999); Endre A. Balazs Prize, International Society of Eye Research (2000); the Proctor Medal, ARVO (2007); the Alkmeon International Prize (2011); the Chevreul Medal, Paris, France (2011); the Excellence Award, Annual European Association for Vision and Eye Research, Nice, France (2013); and the Mossakowski Medal, Polish Academy of Sciences, Warsaw. Poland (2013).

His civic and artistic community involvement includes being a patron of the New Orleans Opera, and authoring Una Vida: A Fable of Music and the Mind, produced currently as a feature film; as well as The Dark Madonna: A Fable of Resiliency and Imagination—both novels exploring his lifelong intellectual quest to understand the interface between science, art and music. His goal with both novels, and others in the planning stages is to share this exploration for a better understanding of the deep beauty and complexity of human experience.



Michael Angus Crawford, PhD, FSB, FRCPath Chelsea & Westminster Hospital at Imperial College, UK

A graduate of Edinburgh he gained his PhD at the Royal Post Graduate Medical School, Hammersmith Hospital then part of London University.

During his work there with Maclolm Milne he uncovered the genetic cause of Hartnup Disease. Michael and his family moved in 1960 to Makerere Medical School, Uganda to establish chemical pathology and teach biochemistry. He set up a research group with funding from the MRC and Cancer Research UK on the role of nutrition in tropical heart disease and cancer in East Africa. He described the background aetiology to endomyocardial fibrosis, and the volvulus which was the commonest surgical emergency in Buganda. He reported the connection between aflatoxin and primary carcinoma of the liver.

In 1963, he participated in the establishment of the Muhumbili Medical School in Dar-es-Salaam. In 1965 he returned to the UK as head of Biochemistry at the Nuffield Institute of Comparative Medicine, while continuing the research in East Africa until 1972. He was a Welcome Trust Visiting Research Fellow, to Professor Ernst Baranay, Department of Pharmacology, University of Uppsala, Sweden and held a Special Chair in Biochemistry at the University of Nottingham. In 1972 his research with Andrew Sinclair led to the identification of omega 3 docosahexaenoic acid (DHA) as a major determinant of brain growth and a plausible role in evolution of the human brain. He recently put forward a quantum mechanical theory for the exclusive conservation of DHA in neural signalling membranes over the 600 m.y. of animal evolution.

As Director of the Institute of Brain Chemistry and Human Nutrition at the Queen Elizabeth Hospital for Children he established the Hackney project with Wendy Doyle which described the role of maternal nutrition during pregnancy as an independent determinant of being born small for gestational age. He has been a consultant to WHO, FAO and the three joint FAO/WHO consultations on dietary lipids 1978, 1994 and 2010. Michael has been awarded several international prizes and medals for his work, which included election to the Hall of Fame at the Royal Society of Medicine in London in 2010, an award from the University of Louisiana - for Neuroscience and Medicine in the same year - and was elected Brain of the Year in 2013 by the Brain Trust, UK. He serves as a trustee for four medical research charities and is an advisor to the Research Council of the Government of Oman.

He is presently at the Division of Reproductive Biology, Obstetrics and Gynaecology, Chelsea and Westminster Hospital at Imperial College, London, UK. Working with colleagues in Africa, China and the USA his present research is on neurogenesis and neurodevelopmental disorder. He has published over 300 peer reviewed papers and three books. A fourth is on the way.



**Prof. Robert Gibson**University of Adelaide, Australia

Professor Gibson is a clinical biochemist/nutritionist who has published 300 peer reviewed papers in a variety of paediatric, nutrition and biochem-

ical journals. He has designed and conducted a range of randomised clinical trials involving nutrition interventions in the perinatal period. He has tested the effects of interventions with iron, selenium, probiotics, nucleotides and long chain polyunsaturated fatty acids (PUFA) on infant biochemistry, growth, physiology and developmental outcome.

Professor Gibson was awarded the 2003 Nutrition Society of Australia, Research Medal and in 2004 was made a Fellow, Nutrition Society of Australia. In 2012 he was awarded the Alexander Leaf Distinguished Scientist Award for Lifetime Achievement. He recently established FOODplus Research Centre. www.adelaide.edu.au/foodplus



Daan Kromhout, MSc, PhD, MPH Royal Netherlands Academy of Arts and Sciences, Wageningen University, The Netherlands

Fields of interest: Human nutrition, cardiovascular epidemiology and public health. Present positions: Academy professor, Royal Netherlands

Academy of Arts and Sciences, 2010-present. Professor of Public Health Research, Wageningen University, The Netherlands, 1994-present. Adjunct professor, Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, USA, 2007-present. Vice-president of the Health Council of the Netherlands 2005-present.

Career & professional Appointment: Director Nutrition and Consumer Safety Division, National Institute of Public Health and the Environment, Bilthoven, The Netherlands, 2002-2005. Director, Division of Public Health Research, National Institute of Public Health and the Environment, Bilthoven, The Netherlands, 1991-2001. Head, Department of Epidemiology, National Institute of Public Health and the Environment, Bilthoven, The Netherlands, 1988-1991. Nutrition Foundation Professor of Nutrition and Epidemiology, Leiden University, The Netherlands, 1984-1994. Associate Professor, Dept. of Social Medicine, Leiden University, The Netherlands, 1982-1988. Assistant Professor, Dept. of Social Medicine, Leiden University, The Netherlands, 1977-1982. Ph.D. student, Dept. Human Nutrition Agricultural University Wageningen, The Netherlands, 1974-1978. Research Assistant, Dept. Hematology, Karolinska Hospital, Stockholm, Sweden, 1972.

Special Experience: Co-chair of the Coordinating Team of the Seven Countries Study, 2006-present. Principal Investigator of the Alpha Omega Trial on secondary prevention of cardiovascular diseases by N-3 polyunsaturated fatty acids, 2001-present. Principal Investigator of the HALE project on diet, lifestyle and healthy ageing in 11 European countries, 2001-2004. Member of the Evaluation Committee of the Robert Koch Institute, Berlin, Germany, 1997. Member of the Evaluation Committee of the National Institute of Public Health, Helsinki, Finland, 1995 and 2007. Temporary Advisor of the WHO study group on "Diet, nutrition and prevention of non-communicable diseases", 1989. Principal Investigator of the scenario project on chronic diseases, 1988-1992. Principal Investigator of the Monitoring Project on Cardiovascular Diseases in the Netherlands, 1987-1991. Visiting Professor University of Helsinki, 1987. Member Executive Committee of the Seven Countries Study, 1986-2006. Member Executive Committee of the INTERSALT Study, 1982-1988. Principal Investigator of the Zutphen Study, 1978-present.

Academic & Scientific Honours: Kritchevsky lecture, American Heart Association Council on Nutrition, Physical Activity and Metabolism, Atlanta, USA, 2011. Academy Professor, Royal Netherlands Academy of Arts and Sciences, 2009. Award of the Netherlands Federation of Medical Scientific Societies for his contributions to research on diet and coronary heart disease in the Zutphen and Seven Countries Study, 1999. Population Sciences Lecture and Silver Medal, European Society of Cardiology, Vienna, Austria 1998. Honor award of excellence, Oldways Preservation & Exchange Trust, Boston, USA for research on the health effects of the Mediterranean diet, 1997. Fellow European Society of Cardiology, 1994. Keynote lecture, Tercentenary Charter Celebration, Royal College of Physicians of Ireland, Dublin, 1992. Annie B. Cunning lecture, Royal Australasian College of Physicians, Melbourne, 1990. Liga Nutrition Award, Netherlands Nutrition Foundation, 1989. Travel Grant Netherlands Organization for Scientific Research for one-year stay at the Laboratory of Physiological Hygiene University, Minnesota, USA, 1980.

Committees & Offices: Chairman Committee Healthy Nutrition ZonMW, 2010-2013. Member committee of cardiovascular risk management in the Netherlands, 2003-2011. Chairman of Program Committee for a national research program on weight control. Dutch Heart Foundation, 2001-2007. Member Governing Council IARC, Lyon, France, 2001-2005. Member Health Council of the Netherlands 1999-present. Member Council for Health Research, 1999-2001. Chairman of Scientific Committee on Epidemiology and Prevention. Dutch Heart Foundation, 1998-2006. Member Standing Committee on Nutrition. Netherlands Health Council, 1996-2005. Member Scientific Council International Agency for Research on Cancer (IARC) WHO, Lyon, France, 1994-1998. Secretary & Chairman, Working group Nutrition of the Netherlands Organization for Research, 1991-1995. Chairman Committee Nutritional Surveillance, Nutrition Council, 1988-1992. Member & Vice-Chairman, Committee Socio-economic Health Differences, 1987-1993. Member Nutrition Council, 1984-1995. Chairman Foundation Quality Control Chemical Analyses, 1986-1990. Member Committee on Diet and Coronary Heart Disease, Nutrition Council, 1982-1986. Member Committee on Diet and Coronary Heart Disease, Nutrition Council 1979-1982.



Artemis P. Simopoulos, M.D. Center for Genetics, Nutrition and Health, USA


Artemis P. Simopoulos, M.D. is the Founder and President of the Center for Genetics, Nutrition and Health, a nonprofit educational organization in

Washington, D.C. since 1990. A graduate of Barnard College, Columbia University, with a major in Chemistry, and a graduate of the Boston University School of Medicine, she is a pediatrician and endocrinologist whose research at the National Institutes of Health (NIH) was on the nutritional aspects of genetic and endocrine disorders; evolutionary aspects of diet and fatty acids; and the importance of a balanced ratio of omega-6/omega-3 fatty acids in health and disease and in growth and development.

Dr. Simopoulos was chair of the Nutrition Coordinating Committee at the National Institutes of Health (NIH) that coordinated all Nutrition Research of the Federal Government in the U.S. in the Office of Science and Technology Policy at the White House. She was consultant to the Office of Consumer Affairs at the White House. Prior to that she was the Executive Secretary of the Division of Medical Sciences at the National Academy of Sciences (NAS) during which time she directed the Asilomar Conference on Recombinant DNA technology. While at the NAS she directed the Committee that developed the report Genetic Screening: Programs, Principles, and Research.

Dr. Simopoulos is a Founding Member of the International Society for the Study of Fatty Acids and Lipids (ISSFAL) in 1991, Secretary/Treasurer of ISSFAL from 1991 to 1998, and a member of the Editorial Board of the ISSFAL Newsletter from 1994 to 2000. She is the Founder of the International Society of Nutrigenetics/Nutrigenomics (ISNN) and was Past President of ISNN from 2005-2009. She is the author of The Omega Diet (HarperCollins, 1999) and has edited over 50 books and journal supplements, in addition to publishing over 350 scientific papers. She was the editor of the Karger series World Review of Nutrition and Dietetics from 1989-2011.







11TH CONGRESS OF THE INTERNATIONAL SOCIETY FOR THE STUDY OF FATTY ACIDS AND LIPIDS
28 JUNE - 2 JULY | STOCKHOLM, SWEDEN AT "THE BREWERY" — MÜNCHENBRYGGERIET

Programme at-a-Glance



#### SATURDAY 28 JUNE

10:00-18:00 REGISTRATION DESK OPEN

09:15–17:00 **LIPID UPDATE SEMINAR** In collaboration with Karolinska Institutet

See agenda on page 17

14:00-17:00 ISSFAL BOARD MEETING

19:00–21:00 WELCOME RECEPTION IN CITY HALL Hosted by City of Stockholm & Stockholm County Council

KEY TO BREWERY SESSION ROOMS

☑ Mässhallen ☑ Riddarsalen ☑ Fogelströmrummet ☑ Galleriet

08:00	SUNDAY 29 JUNE REGISTRATION DESK OPEN 07:30-18:00	MONDAY 30 JUNE REGISTRATION DESK OPEN 07:30-18:00	TUESDAY 1 JULY REGISTRATION DESK OPEN 08:00-18:30
09:00 —	OPENING CEREMONY ☑	PLENARY 2 - Prof. Guenther Daum, PhD M Lipids and mitochondrial function	BREAKFAST / MEET THE PROFESSORS  EARLY CAREER AWARD LECTURE M
10:00 —	NOBEL LAUREATE LECTURE M Prof. Bengt Samuelsson Progress in eicosanoid research	BREAK / POSTERS & EXHIBITS MÄLARSALEN	Dr. Alexander Bartelt Brown Fat in the Center of Metabolic Health BREAK / POSTERS & EXHIBITS
11:00 —	BREAK / POSTERS & EXHIBITS MÄLARSALEN  1. Lipid mediators, 2. DHA in brain 3. Maternal	12. Desaturases and elongases 13. Fatty acids in host defence 14. Fatty acids and aging 15. Maternal and infant nutrition, Part II	20. New aspects of lipid and disease  22. Fats and cardiovascular
	the new generation   function – from molecule to physiology   A PARALLEL SYMPOSIA –>	<pre></pre>	metabolism disease M
12:00 —	LUNCH / POSTERS & EXHIBITS	Prof. Andrew J. Sinclair	<pre></pre>
13:00 —	MÄLARSALEN	<b>LUNCH / POSTERS &amp; EXHIBITS</b> MÄLARSALEN	ISSFAL MEMBERS MEETING ☑
14:00 —	PLENARY 1 - Prof. Georg Kunos, MD L Endocannabinoids in the regulation of energy homeostasis in health and disease  4. Lipidomics 5. Fatty acids 6. Lipid 7. Fatty acids	PLENARY 3 − Prof. Erich Gulbins, MD M Ceramides, new actors in cell signaling	PLENARY 4 - Prof. Chris Ramsden, MD M Dietary modulation of nociceptive mediators and physical pain
15:00 —	- an expanding field C	16. The role of oxysterols and lipids for brain function 17. Fatty acids and the eye in obesity M. Neuroscience	23. Lipids and insulin homeostasis  and cancer  and fatty acids  acids
16:00 —	BREAK / POSTERS & EXHIBITS MÄLARSALEN	G <- PARALLEL SYMPOSIA ->  BREAK / POSTERS & EXHIBITS  MÄLARSALEN	<pre>&lt;- PARALLEL SYMPOSIA -&gt; BREAK / POSTERS &amp; EXHIBITS MÄLARSALEN</pre>
17:00 —	8. Brown fat metabolism and function R  9. Lipids in skin G in food M in food M in food M mediators F	WORKSHOP 1 Conducting omega-3 clinical trials F  WORKSHOP 2 Dairy fat in infant nutrition Infant nutrition R  SPECIAL EVENT DSM Science & Technology Award Europe 2014 M	PLENARY 5 - Dr. Prof. Michail Gladyshev  Aquatic ecosystems as the main source of essential lipids for humans  CLOSING CEREMONY / Welcome to South Africa
18:00 —	SANNY.	<- PARALLEL ->	CEOSING CEREMONT / Welcome to South Africa M
19:00 —		NEW INVESTIGATOR'S MIXER / THE LADY PATRICIA	GALA DINNER & NEW INVESTIGATOR AWARD PRESENTATIONS
20:00 —	DINNER DEBATE / SOCIAL  NALEN RESTAURANG  It is time to update saturated fat recommendations!	CORPORATE MEMBERS DINNER (By invitation)	VASA MUSEUM
21:00 —	WEDNIECDAY O HILV AT ADTENT		
22:00 —	WEDNESDAY 2 JULY AT ARTIPEL. REGISTRATION DESK OPEN 08:00-12:30 (LOCATED A  SPONSORED MORNING 1. LCPUFA in maternal, and child nutrition symposia	nfant 2. Use of lipids in intravenous	
23:00 —	See agenda on page 30 PARALLEL assential omega-3 fatty acid	PA: An 4. Effects of a Specific EPA/DHA/GLA	





# TH CONGRESS OF THE INTERNATIONAL SOCIETY FOR THE STUDY OF FATTY ACIDS AND LIPIDS

#### FINAL PROGRAMME



All ISSFAL 2014 events will take place at the brewery unless otherwise indicated.

#### Saturday 28 June

10:00 - 18:00 . . . . . REGISTRATION DESK OPEN / THE BREWERY - MAIN ENTRANCE FOYER

9:15 - 17:00 . . . . . .

LIPID UPDATE SEMINAR / THE BREWERY - RIDDARSALEN (Separate registration required; see agenda on p. 13) In collaboration with Karolinska Institutet

14:00 - 17:00 . . . . ISSFAL BOARD MEETING / THE BREWERY

19:00 – 21:00 . . . . . WELCOME RECEPTION IN CITY HALL (Invitation only; non transferrable) Hosted by the City of Stockholm and the Stockholm County Council

#### Sunday 29 June

07:30 - 18:00...... REGISTRATION DESK OPEN / THE BREWERY - MAIN ENTRANCE FOYER

08:30 - 09:00..... OPENING CEREMONY / MÄSSHALLEN

09:00 - 10:00 . . . .

**NOBEL LAUREATE LECTURE** 

Progress in eicosanoid research Prof. Bengt Samuelsson

10:00 - 10:4

10:40 - 12:

'			
	BREAK / POSTERS & EXHIBITS / N		
) – 12:00	PARALLEL SYMPOSIA (CONCURRE	(NT)	
	1. Lipid mediators, the new generation / M	2. DHA in brain function — from molecule to physiology /	3. Maternal and infant nutrition, Part I / $\square$
	Novel Pro-Resolving Mediators in Inflammation: Resolvins, Protectins and Maresins Charles Serhan, PhD, DSc (hc), Harvard Medical School & BWH, USA	Omega-3 fatty acid-derived neurodevelopment and neuroprotective function Hee-Yong Kim, PhD, National Institutes of Health, USA	Maternal and infant nutrition Maria Makrides, University of Adelaide, Australia
11:00	The Good, the Bad and the Ugly: Diversity of airway actions of eicosanoids may be used to improve the treatment of asthma Sven-Erik Dahlén (Sweden)	Coordinated transcriptional regulation of arachidonic and docosahexaenoic acid cascade enzymes during human brain development and aging Rapoport S. (USA)	LCPUFA supplementation in infancy improves response inhibition in childhood Gustafson K. (USA)
	Inhibitors against Microsomal Prostaglandin E Synthase-1 – Where do we stand? Per-Johan Jacobsson (Sweden)	Providing male rats deficient in iron & n-3 fatty acids with iron & alpha-linolenic acid alone affects brain serotonin & cognition differently from combined provision Baumgartner J. (South Africa)	Four Year Follow-up of Children Born to Women in a Randomized Controlled Trial of DHA Supplementation during Pregnancy Gould J. (Australia)
		Docosahexaenoic Acid And Brain Pathology Michael-Titus A. (UK)	FADS SNPs Are Associated with Behavioral Outcomes in Children in a Gender-Specific Way Lauritzen L. (Denmark)
	15-Lipoxygenase: a novel drug target for treatment of respiratory inflammatory dis- eases Hans-Erik Claesson (Sweden)	Maintaining brain polyunsaturated fatty acid concentrations: Uptake and rapid metaholism	Maternal but not fetal FADS gene variants modify the association between maternal DHA intake in prepagator, and birth weight

Bazinet R. (Canada)

Early Career Award 2008

**KEY TO SESSION ROOMS** 

M Mässhallen

Riddarsalen

Fogelströmrummet

**G** Galleriet

DHA intake in pregnancy and birth weight Thijs C. (Netherlands)

#### SUNDAY, 29 JUNE (continued)

12:00 - 13:30 . . . . LUNCH / POSTERS & EXHIBITS / MÄLARSALEN

13:30 - 14:15.....

#### PLENARY 1 Endocannabinoids in the regulation of energy homeostasis in health and disease

Prof. Georg Kunos, MD, National Institutes of Health, USA

Obesity and its metabolic complications are associated with increased activity of the endocannabinoid/CB1 receptor (CB1R) system, as indicated by the beneficial effects of CBIR antagonists. However, neuropsychiatric side effects halted the therapeutic development of this class of compounds. As these side effects are due to blockade of CBIR in the CNS, whereas blockade of CBIR in peripheral tissues contribute to metabolic improvements, limiting the brain penetrance of CBIR antagonists may be a way out of this conundrum. We have tested a novel, peripherally restricted CBIR inverse agonist, JD5037, in mice with diet-induced obesity/insulin resistance (DIO mice). Chronic treatment of DIO mice with JD5037 or its brain-penetrant parent compound SLV-319 was equieffective in reducing food intake and adiposity and reversing hepatic steatosis and insulin resistance. The JD5037-induced appetite and weight reduction, but not the improvements in steatosis or glycemic control, are due to resensitizing DIO mice to endogenous leptin. This is secondary to the rapid reversal of hyperleptinemia via inhibition of leptin production in adipocytes and facilitation of leptin clearance by the kidney. We next tested the effects of JD5037 in a rat model of overt T2DM. Young ZDF rats have compensated insulin resistance, which progresses to uncompensated hyperglycemia due to beta-cell failure. B-Cell failure in ZDF rats is associated with CB1R-activation of the NIrp3-ASC inflammasome in M1 macrophages infiltrating pancreatic islets. These effects are replicated in vitro by incubating human or rodent macrophages but not macrophages from CBIR-/- or NIrp3-/- mice with the endocannabinoid anandamide (AEA). Peripheral CBIR blockade, in vivo depletion of macrophages or macrophage-specific knockdown of CBIR prevents these changes, and restores normoglycemia and glucose-induced insulin secretion. We conclude that in diet-induced obesity peripheral CBIR blockade not only improves cardiometabolic risk, but also has antiobesity effects by reversing leptin resistance. Peripheral CB1R blockade also has weight-independent beneficial effects in overt T2DM by preventing  $\beta$ -cell loss due CBIR-mediated inflammasome activation in macrophages that infiltrate the pancreatic islets. These findings highlight the therapeutic potential of peripheral CBIR blockade in both the metabolic syndrome and in overt T2DM. Supported by intramural NIH funds.

14:15 - 15:30. PARALLEL SYMPOSIA (CONCURRENT)

	4. Lipidomics — an expanding field / 🖸	5. Fatty acids in psychiatry / M	6. Lipid membrane composition / <a>R</a>	7. Fatty acids and diabetes
14:35	Lipidomics — an expanding field. The example of fluxolipidomics Michel Lagarde, PhD, DSc, INSA/INSERM, France	Dietary patterns of pregnancy and childhood and risk of early onset addictions in the ALSPAC cohort Capt. Joseph Hibbeln, MD, National Institutes of Health, USA	Milk membrane lipid composition Christelle Lopez, INRA, France	Reversal of CLA-induced Non- Alcoholic Fatty Liver Disease (NAFLD) and Insulin Resistance (IR) by DHA in a mouse model Darshan Kelley, PhD, UC Davis, USA
	Targeted Lipidomics using a Novel Integrated Microfluidics-Mass Spectrometry Technology Astarita J. (USA)	Polyunsaturated fatty acids levels and initial presentation of somatic symptoms induced by interferon-alpha therapy in patients with chronic hepatitis C viral infection Chang J. (Taiwan)	Alternative transcripts in the human milk fat globule proteinogenic RNA transcrip- tome and a novel FADS2 transcript <b>Kothapalli K.</b> (USA)	Pentadecanoic Acid (15:0) is a Biomarker of Dairy Food intake and is inversely associat- ed with incident type 2 diabetes in the IRAS cohort Santaren I. (Canada)
	A lipidomic biosignature associated with the healthful phenotype of fat-1 transgenic mice Astarita J. (USA)	Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: a randomized placebo-controlled trial Su K. (Taiwan)	TLR4 and CD14 co-localization in lipid rafts: impact of stimulation status and membrane fatty acid pattern Schumann J. (Germany)	Regulation of energy homeostasis and glyc- erolipid metabolism in the phospholipid gene deficient mouse ETKO Bakovic M. (Canada)
	Lipidomic analysis during vertebrate embryonic development <b>Gibert Y.</b> (Australia)	Baseline omega-3 index correlates with aggressive and attention deficit behaviours in adult prisoners  Meyer B. (Australia)	A diet rich in DHA prevents visual and spatial memory loss in 12 months old mice carrying the human apolipoprotein E epsilon 4 allele  Chouinard-Watkins R. (Canada)	Very high rates of smoking, low-HDL choles- terol and renal disease among Indigenous Australian adults with poorly controlled diabetes: Implications for primary care and CV risk – McDermott R. (Australia)
		Lipid mediators and receptors of resolution in Alzheimer's disease – <i>in vivo</i> and <i>in vitro</i> studies  Schultzberg M. (Sweden)	Blood and brain fatty acid contents in aged rats supplemented with n-3 long-chain polyunsaturated fatty acids  Buaud B. (France)	Relationships between fatty acid status and cardiometabolic health in obese individuals with type 2 diabetes.  Murphy K. (Australia)

#### 15:30 - 16:15......BREAK / POSTERS & EXHIBITS / MÄLARSALEN

16:15 - 17:30 . . . . . PARALLEL SYMPOSIA (CONCURRENT)

	8. Brown fat metabolism and function / $\blacksquare$	9. Lipids in skin	10. Modulation of lipids in food $/  \underline{\mathbb{M}}$	11. Fatty acids and lipid mediators /
16:35	Brown fat metabolism and function Jan Nedergaard, University of Stockholm, Sweden	Lipid mediators of cutaneous inflammation Anna Nicolaou, PhD, University of Manchester, UK	Manipulation of lipids in animal- derived foods: Can it contribute to public health nutrition? lan Givens, University of Reading, UK	Liver X-receptor β= a multifunc- tional ligand activated transcrip- tion factor Jan-Ake Gustafsson, University of Houston Texas, USA
10.33	Brown adipose but not white adipose accumulate DHA in cultured cells provided with alpha-linolenic acid  Oin X. (USA)	Molecular structure determination <i>in situ</i> in native tissues using CEMOVIS combined with electron microscopy simulation <b>Norlen L.</b> (Sweden)	Toxic salmon membranes? Potential effects on biomembranes of polyaromatic hydrocarbons studied using model systems Liland N. (Norway)	Urinary LTE4 is a new strong predictor of TH2-driven asthma: Initial data from the Pan-European U-BIOPRED IMI project Kolmert J. (Sweden)
	Enhancement of brown fat thermogenesis using chenodeoxycholic acid in mice Zouhar P. (Czech Republic)	Levels of circulating sphingolipids increase with disease severity in psoriasis patients Xu N. (Sweden)	Use of high-EPA oil from transgenic Camelina sativa in feeds for aquaculture Betancor M. (UK)	Effect of short-term N-3 fatty acid supplementation and aspirin on circulating resolvins in healthy volunteers  Mori T. (Australia)
	A validation of proposed brown, brite and white adipose marker genes de Jong J. (Sweden)	Inflammation induced by solar radiation and facial preadipocytes Pappas A. (USA)	Potential for production of Atlantic salmon families with improved capacity for EPA and DHA production Berge G. (Norway)	The Novel Lipid Mediator PDIn-3 DPA: Structural Elucidation, Biosynthesis, Bioactions and Total Organic Synthesis Hansen T. (Norway)
	Induction of oxidative phosphorylation in white adipocytes: A key to lean phenotype <b>Kopecky J.</b> (Czech Republic)	California Sea Lions Have Vernix that Deliver Branched Chain Fatty Acids to the Fetal Gut Ran-Ressler R. (USA)	Heterologous synthesis of omega-3 long chain polyunsaturated fatty acids in trans- genic plants via iterative metabolic engi- neering: a terrestrial source of fish oils Napier J. (UK)	Non-redundant Transcriptional Target for Cell Survival of the Essential DHA derived Mediator Neuroprotectin D1 Bazan N. (USA)

17:30 - 19:00 . . . . . DAY 1 ADJOURNS

#### 19:00 – 21:00 . . . . DINNER DEBATE / SOCIAL AT NALEN RESTAURANG

#### IT IS TIME TO UPDATE SATURATED FAT RECOMMENDATIONS!

Separate registration required - \$100 USD per person

The Dinner Debate is fast becoming a tradition at ISSFAL meetings. Following a good meal in good company, a "hot topic" in the field is debated in a sometimes heated, but always good natured manner by invited speakers and the audience at large.

The 2014 debate Chair will be Connie Diekman, Director of University Nutrition at Washington University in Saint Louis (USA), under whose guidance the motion, "It is Time to Update Saturated Fat Recommendations!" will be proposed by Philippe Legrand, Professor and Chairman of the Laboratory of Biochemistry and Human Nutrition in the Agronomic University of Rennes (Agrocampus) (France), and opposed by Ronald P. Mensink, Professor of Molecular Nutrition at Maastricht University (The Netherlands).

The ISSFAL 2014 'Dinner Debate' is organized and supported by IEM, the International Expert Movement on the Health significance of fat quality in the diet (www.theiem.org). The IEM mission is "to disseminate sound scientific information about food & nutrition, especially fat quality in the diet, amongst professionals and the general public in actionable ways, in order to promote and advance nutritional improvement focusing on the quality of diets."

International activities of the IEM are held under the auspices of the International Union of Nutritional Sciences (IUNS) and funded by an unrestricted educational grant from Unilever.



Nalen boasts a remarkable history and many great headliners from around the globe have performed there. For those who are looking to discover Swedish food, Nalen Restaurang is among the city's best.

#### ▼ Monday 30 June

07:30 - 18:00 ..... **REGISTRATION DESK OPEN** / THE BREWERY MAIN ENTRANCE FOYER

08:30 - 09:15 . . . . .

#### PLENARY 2

#### Lipids and mitochondrial function

Prof. Guenther Daum, PhD, Graz University of Technology, Austria

Mitochondria are only partially autonomous organelles. The vast majority of their components, among them proteins and lipids need to be imported from other organelles. However, a small set of proteins and phospholipids, i.e. cardiolipin and phosphatidylethanolamine, are synthesized within mitochondria. In our laboratory the assembly of phospholipids into mitochondrial membranes has been studied in long term projects. As an experimental system for these investigations we employ the yeast Saccharomyces cerevisiae as a model system. Making use of molecular biological, cell biological and biochemical methods we were able to obtain a view of lipid traffic between organelles. Mitochondria play an important role in this process especially through their contribution to the pathway of aminoglycerophospholipid synthesis. The first lipid component of this pathway, phosphatidylserine, is formed in the endoplasmic reticulum; decarboxylation of phosphatidylserine by Psdlp, the major phosphatidylserine decarboxylase of the yeast, occurs in mitochondria; and further conversion of phosphatidylethanolamine to phosphatidylcholine by methyltransferases is localized to the endoplasmic reticulum. Thus, intense crosstalk of organelles is required for this pathway. Recently, we focussed on the molecular role and properties of the mitochondrial phosphatidylserine decarboxylase Psdlp. Biogenesis of this enzyme as well as defects in mitochondrial membranes caused by deletion of PSD1 and depletion of phosphatidylethanolamine were studied. These investigations demonstrated the important role of phosphatidylethanolamine as a mitochondrial lipid and revealed interesting counteracting effects of phosphatidylethanolamine with the mitochondria specific cardiolipin.

Supported by the Austrian Science Fund (FWF)

09:15 - 10:00 . . . . . BREAK / POSTERS & EXHIBITS / MÄLARSALEN

10:00 - 11:35 ..... PARALLEL SYMPOSIA (CONCURRENT)

	12. Desaturases and elongases	13. Fatty acids in host defence	14. Fatty acids and aging / ℝ	15. Maternal & infant nutrition, Part II / M
10:20	Desaturases and elongases Tom Brenna, PhD, Cornell University, USA	A role for the group-II secreted phospholipase A2 in the estab- lishment of lung microbiome in patients with cystic fibrosis Lhousseine Touqui, PhD, Institut Pasteur, France	Aging changes omega-3 fatty acid homeostasis; implications and challenges Stephen Cunnane, PhD, University of Sherbrooke, Canada	Maternal DHA supplementation during pregnancy & body composition in childhood: Results of the 3 & 5 year follow-up of children born to women in a randomized controlled trial of DHA supplementation during pregnancy – Bev Muhlhausler, Univ. of Adelaide, Australia
	A low omega-6 polyunsaturated fatty acid (n-6 PUFA) diet increases omega-3 (n-3) long chain PUFA status in plasma phospho- lipids in humans <b>Wood K.</b> (Australia)	Short chain fatty acids (SCFAs) modulate immune response to anaerobic bacteria <b>Vinolo M.</b> (Brazil)	Telomere shortening in elderly individuals with mild cognitive impairment may be attenuated with n-3 fatty acid supplementation  Parletta N. (Australia)	Maternal response to DHA supplementation during pregnancy and language perform- ance of mother and child <b>Shaddy J.</b> (USA)
	Transgenic mice convert carbohydrates to essential fatty acids: Implications for modern health epidemics  Kang J. (USA)	Eicosapentaenoic and docosahexaenoic acid differentially enhance humoral immunity in murine diet-induced obesity  Shaikh S. (USA)  Early Career Award 2012	Effects of n-3 polyunsaturated fatty acid supplementation on recurrence prevention in patients with late-life depression: a 48-week randomized double-blind placebo-controlled study - Chiu C. (Taiwan)	Gender differences in associations between dietary fatty acids and blood lipids: the PURE study South Africa <b>Richter M.</b> (South Africa)
	Dietary supplementation with fish or olive oil induces altered DNA methylation at spe- cific CpG loci in FADS2 in adult humans with renal disease Burdge G. (UK)	Effect of omega-3 fatty acids supplementa- tion on expression of NF-kB gene and blood cells integrins in patients with homozygous sickle cell disease Daak A. (Sudan)	Resolvins in Alzheimer disease patients supplemented with omega-3 fatty acids Fiala M. (USA)	Consumption of bioactive molecules from human milk and relationship to intestinal maturity in premature neonates  Armand M. (France)
	FADS polymorphisms and fatty acid composition in blood at age 2, 6 and 10 years.  Standl M. (Germany)	Fatty Acid and Glycerophospholipid Metabolism in Human T Cells <b>Robichaud P.</b> (Canada)	Can DHA enriched Omega 3 fatty acids affect APOE4 -positive patients cognition better in mild to moderate Alzheimer's dis- ease? The Omeg AD study Freund-Levi Y. (Sweden)	Effect of maternal DHA supplementation on body composition of 5-year-old children Vetri Villalan S. (USA)
	Fish oil and krill oil supplementation differentially regulate lipid metabolism in the mouse  Alexson S. (Sweden)	Postprandial regulation of toll-like receptors (TLRs) by omega-3 fatty acids in obese and normal weight subjects  Paras-Chavez C. (UK)	Effect of a whole diet intervention and FADS2 genotype on fatty acid status in the elderly  O'Neill C. (UK)	Nervonic acid in early plasma samples from premature infants correlates with birth size and mental and motor development up to 18 months corrected age Ntoumani E. (Sweden)

11:35 - 12:20 . . . . . .

#### **ALEXANDER LEAF AWARD LECTURE**

#### Prof. Andrew J. Sinclair,

М

Deakin University, Australia

The Alexander Leaf Distinguished Scientist Award for Lifetime Achievement was established by the Society in 2002, both to honour the work of Dr. Alexander Leaf and his support for ISSFAL, and to create a means to recognise and reward excellence in the areas of research of relevant to ISSFAL core interests.

12:20 - 13:45 . . . . . LUNCH / POSTERS & EXHIBITS / MÄLARSALEN

13:45 - 14:30 . . . . PLENARY 3

#### Ceramides, new actors in cell signaling

Prof. Erich Gulbins, MD, University of Duisburg-Essen, Germany

Although ceramides belong to the most hydrophobic molecules in a cell and are water insoluble, they are critically involved in many signalling pathways, in particular upon application of stress stimuli. Thus, activation of acid sphingomyelinase, which converts sphingomyelin to ceramide, is triggered by diverse receptors including those for CD95, TNF, IL-1, and PAF, and by cellular stress such as oxidative stress, chemotherapeutic agents or infection with bacterial and viral pathogens. We have introduced the concept that these stimuli trigger fusion of specialized secretory lysosomes with the plasma membrane, resulting in surface exposure of acid sphingomyelinase and generation of ceramide in the anti-cytoplasmic leaflet of cell membranes. Therein ceramide molecules spontaneously self associate to form small ceramide-enriched membrane domains that fuse to become large ceramide-enriched membrane platforms. These platforms serve to cluster cognate receptors and other signaling molecules to greatly amplify initial signal density, thereby mediating transmembrane effects of receptor activation or stress. Clustering of receptors seems to be mediated by the length and the aminoacid composition of the transmembrane domain. We applied these insights to cystic fibrosis and pulmonary infections with Pseudomonas aeruginosa. We have demonstrated that ceramide accumulates in tracheal and bronchial epithelial cells of cystic fibrosis mice and humans. In contrast, sphingosine is almost absent in these cells of cystic fibrosis mice and patients, while present in control mice and healthy individuals. Sphingosine very efficiently kills P. aeruginosa and prevents infection. Thus, cystic fibrosis mice and patients suffer from two defects of the sphingolipid metabolism, i.e. an increase of ceramide and a decrease of sphingosine that results in the marked sensitivity of cystic fibrosis animals and patients to develop P. aeruginosa infections. These insights may serve to develop novel strategies to prevent and treat pulmonary infection

14:30 – 15:45 . . . . . PARALLEL SYMPOSIA (CONCURRENT)

	16. The role of oxysterols and lipids for brain function /	17. Fatty acids and the eye	18. Fatty acid metabolism in obesity / M	19. Neuroscience / ☑
14:50	Oxysterols and the brain Ingemar Björkhem, MD, PhD, Karolinska Institutet, Sweden	Fatty acids and the child's eye Ann Hellström, Sahlgrenska Academy, Sweden	Fatty acid metabolism in obesity Antonio Vidal-Puig, University of Cambridge, UK	Transfer of Omega-3 FA across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid (DHA)-rich Omega-3 FA preparation in patients with Alzheimer's disease: The OmegAD study – Jan Palmblad, Karolinska Institutet, Sweden
	A novel role for very long chain fatty acids in brain function <b>Hopiavuori B.</b> (USA)	Dietary omega 3 long chain polyunsaturated fatty acids and metabolic syndrome in the rat retina: consequences on retinal functionality and complications  Thierry M. (France)	Association between metabolic syndrome and erythrocyte fatty acid profile in Mexican adolescents: a trans fatty acid approach Maldonado-Hernández J. (Mexico)	The role of endocannabinoid signalling in the divergent effects of EPA & DHA in neural stem cell fate  Dyall S. (UK)
	Full hydrogenation suppresses life-span shortening activity of canola oil in SHRSP <b>Tatematsu K.</b> (Japan)	Dietary fatty acids and the prevention of Age-related Macular Degeneration: retinal incorporation and beyond <b>Bretillon L.</b> (France)	Benefits of purified long chain omega-3 fatty acids in non-alcoholic fatty liver dis- ease (NAFLD): Results from the WELCOME study Calder P. (UK)	Fatty acids and sleep in UK children: Subjective and pilot objective sleep results from the DOLAB study - A randomized con- trolled trial Richardson A. (UK)
	Omega-3 fatty acids (Omegaven) protect from mitochondrial dysfunction in a MCAO mouse model of stroke Eckert G. (Germany)	DNA sequence variation in lipid-associated signaling pathway constituents, drug targets, and age-related macular degeneration SanGiovanni J. (USA)  Early Career Award 2010	Impact of long chain n-3 PUFA and flavanols on non-alcoholic fatty liver disease <b>Minihane A.</b> (UK)	AT-RvD1 modulates synaptic plasticity and prevents neuroinflammation in a mouse model of surgery-induced cognitive decline.  Terrando N. (Sweden)
	The influence of a single nucleotide poly- morphisim in the CYP4F2 gene on epoxye- icostrienoic acid and platelet aggregation Barden A. (Australia)	Molecular Principles for Retinal Pigment Epithelial Cell/Photoreceptor Survival Targeting the NALP3 Inflammasome by Lipid Mediators Bazan N. (USA)	N-3 polyunsaturated FA reduce metabolic endotoxemia and prevent metabolic disor- ders associated to obesity: A Fat-1 trans- genic mouse and Caco-2/TC7 cell study <b>Bidu C.</b> (France)	The role of polyunsaturated fatty acids mediators in the resolution of neuroinflammation  Trépanier M. (Canada)

15:45 - 16:30 . . . . . BREAK / POSTERS & EXHIBITS / MÄLARSALEN

#### MONDAY, 30 JUNE (continued)

16:30 - 17:45 ...... SPONSORED PARALLEL WORKSHOPS & SPECIAL EVENT (CONCURRENT)

Workshop 1 / E

Conducting Omega-3 Clinical Trials
Chair: Harry Rice, PhD

Sponsored by:

17:45 ...... DAY 2 ADJOURNS

19:00 - 21:00 . . . . **SPECIAL EVENT** 

#### FIRST BIENNIAL NEW INVESTIGATOR'S MIXER ABOARD 'THE LADY PATRICIA'

(Separate registration is required to attend)

Meet other graduate students and postdoctoral fellows in a casual atmosphere aboard **The Lady Patricia**. Relax and enjoy drinks, hors d'oeuvres and the beautiful view of the Stockholm harbour with other new investigators!

The Lady Patricia is docked only 5 minutes walking distance from the conference venue. Originally commissioned as a transport vessel during World War II, this boat now serves as a popular restaurant and night club.

This event is open to graduate students and postdoctoral fellows only. Admission is \$25.00 USD per person and there are only 70 spots available, so RSVP quickly to ensure your place at this exciting inaugural event! Each registered guest will receive tickets for 2 drinks, and hors d'oeuvres will be served throughout the evening. A cash bar will also be available. Payment can be made on-site when you board, through ISSFAL staff. Credit Card preferred.

19:30 - 21:00 . . . . . CORPORATE MEMBERS DINNER (BY INVITATION)



The DSM Science & Technology Award seeks to recognize and reward outstanding young researchers (PhD students and those who have recently obtained their PhD) for innovative research that has clear application potential.

This year the chosen field is "Polyunsaturated fatty acid (PUFA) nutrition and related topics." From the total number of nominations received from all over the world, four candidates have been selected for the final judging round. These four candidates are invited to present their research in a short lecture during a special DSM-ISSFAL Symposium to be held at the 11th Congress of the International Society for the Study of Fatty Acids and Lipids in Stockholm, Sweden on June 30, 2014 (see programme at right). A judging committee of leading scientists will select the winner.

The award will be presented during the plenary session of the ISSFAL 2014 congress on July 1, 2014, by **Dr. Marcel Wubbolts**, Chief Technology Officer of DSM

The winner will receive a cash prize of EUR 5,000 and each of the three runners-up will receive a cash prize of EUR 1,000. Travel expenses will also be paid for the four winners.

For further information on the award, please visit: www.dsm.com/awards



DSM Science & Technology Award 2014 - Europe

#### DSM-ISSFAL SYMPOSIUM PROGRAMME

# Outstanding PhD thesis work in PUFA Nutrition JUNE 30, 2014 / 16.30 - 18.20 / M

16.30 - 16.40 Welcome and introduction by Dr. Marcel Wubbolts, Chief Technology Officer, DSM

16.40 - 17.05 A novel role for very long chain fatty acids in brain function

• Blake Hopiavuori, University of Oklahoma, US;

Health Sciences Center, Neuroscience

PhD Supervisor: Prof. Robert Eugene Anderson MD, PhD

17.05 - 17.30 Omega-3 fatty acids exert protective actions in obesityrelated metabolic complications

> Christina López Vicario, Hospital Clinic/University of Barcelona, Spain; Department of Biochemistry and Molecular Genetics

PhD Supervisor: Joan Clària, PhD

17.30 - 17.55 Brain uptake and metabolism of eicosapentaenoic acid in rodents

• Chuck T. Chen, University of Toronto, Canada; Department of Nutritional Sciences, Faculty of Medicine PhD Supervisor: Associate Prof. Richard P.Bazinet, PhD

17.55 - 18.20 Polyunsaturated Ganglioside Catabolism is Elevated in IBD: Importance of Dietary Ganglioside Intake

> John Miklavcic, University of Alberta, Canada; Agricultural, Life and Environmental sciences
>  PhD Supervisor: Prof. Dr. M. Tom Clandinin

The winner of the DSM Science & Technology Award 2014 – Europe, will be announced on Tuesday, July 1, by Dr. Marcel Wubbolts. We look forward to welcoming you!

#### Tuesday 1 July

08:00 - 18:30 ..... REGISTRATION DESK OPEN / THE BREWERY MAIN ENTRANCE FOYER

08:00 - 09:00..... BREAKFAST / Meet the Professors

09:00 - 09:45.....

#### EARLY CAREER AWARD LECTURE

#### Brown Fat in the Center of Metabolic Health

Dr. Alexander Bartelt, Harvard School of Public Health, USA

Whereas white adipose tissue (WAT) serves mainly as an energy reservoir and endocrine organ, brown adipose tissue (BAT) is able to dissipate high-caloric nutrients such as carbohydrates and fatty acids to produce heat in order to defend the body against cold. Until 2011, the mechanistic details of fatty acid delivery as fuels for BAT thermogenesis were insufficiently understood. Moreover, the detailed contribution of BAT to systemic metabolism in terms of lipid and glucose homeostasis was not known. In a series of in vivo experiments, combining classical radioactive fatty acid tracer studies with state-of-the-art nanocrystal-based lipoprotein imaging techniques, we were able to demonstrate that BAT in quantitative terms controls plasma triglyceride and glucose metabolism. Activating BAT by overnight cold exposure reduced plasma triglyceride levels drastically, even in postprandial conditions. Furthermore, we identified a novel lipoprotein pathway involving lipolysis by lipoprotein lipase (LPL) and fatty acid uptake by CD36 into brown adipocytes. BAT consumed nearly as much as 50% of a meal in obese and lean animals, ameliorating glucose intolerance and insulin resistance. Beyond dissipating nutrients, BAT activation and also stimulating adipose tissue "browning" has a profound impact on systemic fatty acid fluxes and cholesterol homeostasis. BAT possesses high capacity for de novo lipogenesis, producing significant amounts of monounsaturated fatty acids. We were able to show that BAT-derived fatty acids can be used as markers of HDL turnover along with the discovery that BAT modulates HDL metabolism to facilitate cholesterol excretion. Our studies place BAT in the center of metabolic health, carrying great therapeutic potential for fighting obesity, insulin resistance and atherosclerosis.

09:45 - 10:30 ..... BREAK / POSTERS & EXHIBITS / MÄLARSALEN

10:30 - 12:05 . . . . PARALLEL SYMPOSIA (CONCURRENT)

	20. New aspects of lipid metabolism / <b>□</b>	21. Lipid oxidation and disease	22. Fats and Cardiovascular Disease / ☑
10:50	Bile acids and lipid metabolism Bo Angelin, MD, PhD, Karolinska Institutet, Sweden	Roles of some endogenous lipid mediators in cellular defense against oxidative stress-induced carcinogenesis Young-Joon Surh, PhD, Seoul National University College of Pharmacy, Korea	Mediterranean diet, carotid plaque progression ALA, long chain n-3 and all cause mortality Aleix Sala Vila, Hospital Clinic, IDIBAPS- Endocrinology & Nutrition, Spain
10.30	Serum triglyceride to HDL ratio and its rela- tionship to insulin resistance among 5-15 year old Sri Lankan children <b>Wickramasinghe V.</b> (Sri Lanka)	Docosahexaenoic acid (DHA) mixed with extra virgin olive oil significantly reduces liver oxidative stress in high fat-induced liver steatosis in mice Rodrigo V. (Chile)	Role of milk fat globule membrane (MFGM) for modulating atherogenic plasma lipopro- teins in humans: a randomized trial Rosqvist F. (Sweden)
	Association of erythrocyte long-chain omega-3 fatty acids and long-term clinical outcome - The Ludwigshafen risk and cardiovascular health study von Schacky C. (Germany)	Leptin induces in vitro and in vivo a lipid peroxidation and an inflammatory response, in neoplastic mammary epithelial cells <b>Mahbouli S.</b> (France)	EPA and DHA in whole-blood are differentially and sex-specifically associated with cardio-metabolic risk markers in 8–11-year-old children  Damsgaard C. (Denmark)
	Apolipoprotein E epsilon 4 genotype and Docosahexaenoic acid metabolism: data from mice and humans Plourde M. (Canada)	Lipid peroxidation and its relevance to pheromone production in marine fish under oxidative stress  Lee J. (Hong Kong)	Docosahexaenoic fatty acid favorably alters inflammatory pathways and macrophage polarization in the aorta of atherosclerotic mice  Gladine C. (France)
	Increases in whole body cholesterol synthesis and plasma clearance rates in sitosterolemia patients treated with ezetimibe  Othman R. (Canada)	Fatty acid and oxylipid preditors of platelet function in adults with diabetes mellitus Block R. (USA)	Association of trans fatty acids and clinical long-term outcome - The Ludwigshafen risk and vardiovascular health study von Schacky C. (Germany)
	Ethyl ester vs. triglyceride formulations of long chain omega-3 fatty acids: effect on nonfasting triglycerides in moderate hyper- triglyceridemia <b>Hedengran A.</b> (Denmark)	Lipid profiling following intake of the omega- 3 fatty acid DHA identifies the peroxidized metabolites F4-neuroprostanes as the best predictors of atherosclerosis prevention <b>Gladine C.</b> (France)	The omega-3 index in heart failure patents: associations with clinical data, comorbidies and progrnosis von Schacky C. (Germany)

#### TUESDAY, 1 JULY (continued)

12:05 – 13:45 . . . . . LUNCH / POSTERS & EXHIBITS / MÄLARSALEN

13:00 - 13:45 . . . . . ISSFAL MEMBERS MEETING / M

PLENARY 4

13:45 - 14:30 . . . . .

Dietary modulation of nociceptive mediators and physical pain Prof. Chris Ramsden, MD, National Institutes of Health, USA

Many patients with chronic pain continue to experience substantial pain and impaired quality of life despite taking numerous pain-related medications. It is therefore essential to investigate novel mechanisms and alternative approaches to manage pain. As major components of immune, myelin, glial, and neuronal cell membranes, n-3 and n-6 fatty acids can be endogenously converted to several families of bioactive lipid autacoids with pro- or antinociceptive properties (eq. endovanilloids, eicosanoids, endocannabinoids, resolvins).

With a few notable exceptions, mediators derived from n-6 linoleic (LA) and arachidonic (AA) promote nociception, while mediators derived from n-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) promote anti-nociception. Thus, an imbalance of mediators derived from n-3 and n-6 fatty acids is a plausible mechanism underlying initiation and perpetuation of chronic pain disorders including headaches. In a small randomized trial in 67 patients with chronic headaches, we found that increasing dietary n-3 with concurrent reduction in n-6 fatty acids (the H3-L6 diet) produced statistically significant reductions in headache frequency and severity. These clinical improvements were accompanied by increases in pathway precursors for n-3 derived lipid mediators of anti-nociception, and reductions in n-6 derived mediators of nociception in circulation. Therefore, targeted alterations in dietary n-6 and n-3 fatty acids may be able to modulate nociceptive lipid mediators to reduce physical pain. However, current understanding of the molecular pathways and specific lipid autacoids linking diet to physical pain is limited. In this presentation I will review emerging preclinical and clinical evidence and highlight key evidence gaps along the proposed causal chain linking dietary n-3 and n-6 fatty acids to the etiology of chronic pain.

#### 14:30 – 15:45 . . . . . PARALLEL SYMPOSIA (CONCURRENT)

	23. Lipids in insulin homeostasis / 🖬	24. Fatty acids and cancer	25. Gut microbiota and fatty acids / <b>R</b>
14:50	Lipid membranes and insulin sig- naling Jin-ichi Inokuchi, PhD, Tohoku Pharmaceutical University, Japan	Prostaglandin E2 pathway in inflammation-associated cancer development Masanobu Oshima, Kanazawa University, Japan	Gut microbiota and fatty acids Tore Midtvedt, MD, PhD, Karolinska Institutet, Sweden
14.50	Dose-dependent effects of thiazolidine- diones in dietary obese mice <b>Svobodova M.</b> (Czech Republic)	Delta-6 desaturase as a novel anti-cancer target Kang J. (USA)	Lipid hydrolysis products characteristic for breast milk increase the relative abundance of Bifidobacterium and Lactobacillus in microbiota isolated from infant fecal samples after <i>in vitro</i> fermentation <b>Bennike R.</b> (Denmark)
	A diet rich in omega-6 polyunsaturated fatty acids (omega-6 pufa) reduces spontaneous activity in mice  Ghosh S. (Canada)	Fat-1 transgenic mice producing n-3 PUFA prevented Helicobacter pylori-induced gastric carcinogenesis; the efficacy and novel mechanism  Hahm K. (Korea)	Fish oil attenuates omega-6 polyunsaturat- ed fatty acid-induced dysbiosis and infec- tious colitis but impairs LPS dephosphory- lation activity causing sepsis. <b>Gibson D.</b> (Canada)
	Asian and Caucasian type 2 diabetes have different response to n-3 polyunsaturated fatty acids Li D. (China)	Novel statistical method using nutrients to define a food-based dietary pattern that distinguishes women with and without a short-term risk biomarker of developing breast cancer - Hidaka B. (USA)	Milk lipids in infant formulas modifies the proteolysis, microbiota and intestinal physiology in neonatal piglets  Le Hueron-Luron I. (France)
	Lower serum non-esterified eicosapen- taenoic acid (EPA) is associated with insulin resistance in the PROspective Metabolism and ISlet Cell Evaluation (PROMISE) Cohort Johnston L. (Canada)	DHA alters lipid raft organization and cho- lesterol metabolism in cancer cells <b>Corsetto P.</b> (Italy)	Elevated tissue omega-3 fatty acid status prevents chronic low-grade inflammation by altering gut microbiota Kang J. (USA)

15:45 - 16:30 . . . . . BREAK / POSTERS & EXHIBITS / MÄLARSALEN

16:30 - 17:15.....

#### PLENARY 5 Aquatic ecosystems as the main source of essential lipids for humans

Dr. Prof. Michail Gladyshev, Siberian Branch of the Russian Academy of Sciences, Russia

Humans and most other animals need food sources of physiologically important highly unsaturated fatty acids (HUFA), such as eicosapentaenoic acid, (EPA) and docosahexaenoic acid (DHA), because their own synthesis of these HUFA can cover only around 5% of their physiological requirements. Among all organisms only some microalgae, diatoms, cryptophytes and dinophytes can synthesize de novo high amounts of EPA and DHA. HUFA, synthesized by microalgae, are transferred through trophic chains to organisms of higher levels, invertebrates and fish. Thus, aquatic ecosystems play the unique role in the Biosphere as the principal source of EPA and DHA for most animals, including inhabitants of terrestrial ecosystems and humans. HUFA are transferred from aquatic to terrestrial ecosystems through riparian predators, shore drift, emergence of amphibiotic insects and water birds. These essential nutrients are transferred through trophic chains with about twice higher efficiency than bulk carbon. Thereby, HUFA are accumulated, rather than diluted in biomass of organisms of higher trophic levels, e.g., in fish. Humans withdraw from aquatic ecosystems through fish catch ~180 106 kg y-1 of EPA+DHA. However, global average personal daily consumption of EPA+DHA is only about 0.1 g, while healthy personal intake is 0.5 - 1.0 g day-1. Thus, humankind face with a deficiency of the physiologically important HUFA in diet. Potential ways to increase HUFA consumption are discussed. Aquaculture is based on forage, obtained from wild catch and thereby cannot substitute fishery. Microbial biotechnology - single cell oil production is cost-prohibitive. Thereby, natural fish production of aquatic ecosystems will remain the main sources of the essential PUFA for humans. Aquatic ecosystems differ significantly in HUFA production of microalgae and thereby various fish species, getting PUFA from microalgae through trophic chains, differ in EPA and DHA contents in their biomass in two orders of magnitude. Ways to increase HUFA production in natural

17:15 - 17:45 . . . . . . CLOSING CEREMONY / WELCOME TO SOUTH AFRICA 2016 / M

17:45 . . . . . DAY 3 ADJOURNS

19:00 – 23:00 ..... GALA DINNER AT VASA MUSEUM & NEW INVESTIGATOR AWARD PRESENTATIONS





# 11 TH CONGRESS OF THE INTERNATIONAL SOCIETY FOR THE STUDY OF FATTY ACIDS AND LIPIDS

<mark>28 JUNE – 2 JULY | STOCKHOLM, SWEDEN</mark> AT "THE BREWERY" — MÜNCHENBRYGGERIET

#### SATELLITE SYMPOSIA



ISSFAL will host four **Sponsored Satellite Symposia** on Wednesday, 2 July, following the Congress. This programme will be held at **Artipelag**, a unique museum facility set among the archipelago just outside Stockholm. A separate registration is required to attend. The fee includes lunch, transportation, and admission to any of the symposia. If you have signed up for this event, please see your final confirmation email for the Satellites. **The ISSFAL Registration Desk will be located at the HILTON SLUSSEN HOTEL LOBBY** on Wednesday to assist those attending the symposia.

**TRANSPORTATION:** Buses for the morning Satellites will depart at 08:30 from the Hilton Slussen. Buses for the afternoon satellites will depart from the Hilton Slussen at 11:30. Buses returning from Artipelag after the morning Satellites will depart after lunch, at 13:30. A boat will take all remaining attendees at the end of the day back to Stockholm (boat trip is 90 minutes).

#### ▼ Wednesday 2 July — ALL DAY AT ARTIPELAG

09:30 - 12:30. .... SPONSORED SATELLITE SYMPOSIA - MORNING (CONCURRENT)

#### 1. LCPUFA in Maternal, Infant and Child Nutrition

Organizers: Marius Smuts, North West University, South Africa Renate de Groot, Open Universiteit Nederland, Netherlands

#### Reasons for Variability in Status and Outcomes

LCPUFA are nutrients with widely variable intakes both among cultures and to a lesser extent within cultures. The workshop will focus on LCPUFA as a nutrient during earliest development (intrauterine, infancy) and at ages after development (childhood, adolescence, young adulthood). The implications of this variability and other variables for the results of observational and supplementation studies and the kinds of studies needed to make decisions about what is a safe and adequate amount of LCPUFA for individuals and populations will be discussed/debated. The workshop will result in a summary of promising directions for future translational research on LCPUFA that address this and other questions about these nutrients.

Attendees are warmly invited to participate in the below mentioned discussion topics. Of course you can bring in your own points/remarks at any moment during the discussion. But there is also an alternative possibility; in case you want to have something brought in you can send the organizers of this satellite (Marius.Smuts@nwu.ac.za or Renate.deGroot@ou.nl) from now on an email with your statement or 1 or 2 slides. The organizers take care that the speaker of the session or the facilitator will mention the points raised by you.

#### **Detailed Program:**

**Welcome & Introductions:** Speakers will have 10-15 min for presentations to set the scene for discussions that will last for about 45 min per session.

Session 1: LCPUFA supplementation and long-term outcomes Speaker: Susan Carlson / Facilitator: Renate de Groot

Session 2: LCPUFA and body composition

Speaker: Bev Muhlhauser / Facilitator: Lotte Lauritzen

Session 3: Interactions with nutrients and others factors Speaker: Jeannine Baumgartner / Facilitator: Marius Smuts

Overall Summary and Closing remarks

Facilitator: Alex Richardson

Sponsored by DSM Nutritionals

# 2. Use of Lipids in Intravenous Nutrition: Rationale and Reality

Chairs: **Prof. Philip Calder**, University of Southampton **Konstantin Mayer**, University of Giessen, Germany

Lipids have been in clinical use as components of intravenous nutrition for over 50 years. Nevertheless, the field is rife with controversy. Some clinicians question whether lipids should even be used, while others argue that the profile of the most widely used lipids is not optimal and may compromise patient outcome. Over the last 15 years new lipids that include olive oil and/or fish oil have been introduced with some remarkable findings seen when these new lipids replace the more traditional ones. This session will bring together leading global authorities in the area of intravenous lipids to debate and discuss the latest findings in the field, from pre-clinical research to the most recent clinical trials. Lipid functionality and utility in pediatric, adult surgical and critically ill patients will be covered with the aim of developing a clearer picture of the current situation. The Symposium will appeal equally to basic scientists, to clinical researchers and to clinical practitioners and will serve to provide significant advances in the knowledge and understanding of delegates.

#### Speakers & Topics:

Philip Calder (Southampton, UK): Lipids available for intravenous nutrition - composition, metabolism and functional effects

Mark Puder (Boston, USA): Use of fish oil containing lipids to prevent and to treat liver disease in pediatric patients

**Loris Pironi** (Bologna, Italy): Which lipids for those on long term home parenteral nutrition?

**Lucy Norling** (London, UK): Pro-resolving lipid mediators – a strategy to control inflammatory responses

Adina Michael-Titus (London, UK): Omega-3 fatty acids for treating brain and spinal cord injury

**Ashley Dennison** (Leicester, UK): Use of intravenous lipids in surgical patients with cancer and sepsis

**Konstantin Mayer** (Giessen, Germany): Preclinical and clinical studies of intravenous lipids in sepsis and tissue injury

#### Sponsored by

Baxter • B.Braun Melsingen • Fresenius Kabi • Pronova Biopharma

12:30 - 14:00 . . . . LUNCH

#### 14:00 - 17:30 ...... SPONSORED SATELLITE SYMPOSIA - AFTERNOON (CONCURRENT)

## 3. Research Update on DPA: An Essential Omega-3 Fatty Acid for Health

Chairs: **Edward Dennis**, University of California, USA **Andrew Sinclair**, Deakin University, Australia

It is well established that Omega-3s are important in neural development and function, and in preventing various health conditions with inflammatory or immune components. Most health benefiting studies on Omega-3s were performed using fish oil, which are mixtures of various fatty acids, and the positive effects were often attributed to eicosapentaenoic (EPA) and docosahexaenoic acids (DHA). The significance of docosapentaenoic fatty acid (DPA), an elongated version of EPA, is only now starting to be better understood. For example, several large studies have demonstrated that blood levels of DPA are independently and positively correlate with reduced risk of cardiovascular disease to the same or greater extent than EPA and DHA. Additionally, studies on purified DPA in animal and cell cultures showed that DPA has potential to improve various aspects of human health. The Symposium will bring together the leading scientists from universities and industry. Its goal is to increase the understanding of biological effects of this important Omega-3 on lipid metabolism in health and disease.

#### Speakers & Topics:

**Doug Bibus** (Lipid Technologies): Blood and tissue levels of DPA: what is nature trying to tell us

Andrew Sinclair (Deakin University): What is known about the biological roles of DPA

**Bruce Holub** (University of Guelph): Docosapentaenoic acid: a long-chain Omega-3 fatty acid with unique metabolism and potential health effects

Edward A. Dennis (University of California): DPA and other omega-3 fatty acids cause dramatic changes in TLR4 and purinergic eicosanoid signaling

Kaisa Linderborg (University of Turku): Postprandial lipidomics in response to DPA and EPA rich meals

Michael Ballou (Texas Tech): Effects of DPAn3 compared to EPA and DHA on inflammation in various tissues

Samuel Fortin (SCF Pharma): Omega-3 docosapentaenoic monoglyceride for inflammation resolution and cancer treatment

Marina Lynch (Trinity College): DPA exerts neuroprotective effects in age

Sponsored by Nutegrity / Omega Protein

# 4. Effects of a Specific EPA/DHA/GLA Combination on ADHD and Cognition

Chair: Philip Calder, University of Southampton, UK

Accumulating evidence from epidemiological, biochemical and interventional studies indicate that dietary intakes of the omega-3 polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) may influence cognitive development, reading performance, learning and behavior. Different mechanisms have been proposed to explain these effects including increased hippocampal acetylcholine levels, anti-inflammatory effects, or increased neuroplasticity. Nevertheless it has to be emphasized how little is still known about the effects of various PUFAs and their interactions with each other in the context of brain health and functioning.

Given the plethora of omega-3 products with different mixtures now available, the issue of the optimal dosage, PUFA ratio and bioavailability of the different PUFAs is often questioned by the health care professionals and generate confusion for the consumer. The aim of this symposium is to be updated by experts about the current clinical evidence in the field of cognition and ADHD in children, and particularly about the effects of a specific EPA/DHA/GLA combination on ADHD and cognition.

#### Speakers & Topics:

Mats Johnson (Sweden): Polyunsaturated fatty acids in ADHD and cognition: does the product composition matter?

Philip Calder (UK): Bioavailability of different forms of fatty acids

Natalie Parletta (Australia): Omega-3/6 fatty acids: The scientific experience in ADHD and mainstream children in Australia

**Eduardo Barragan** (Mexico): Efficacy and safety of Omega-3/6 fatty acids, methylphenidate, and a combined treatment in children with ADHD

Sponsored by Vifor Pharma

#### SATELLITE SYMPOSIA SPONSORS




















**About Artipelag:** In the year 2000, Björn Jakobson, founder of the well-known company, "BabyBjörn", was struck with the idea of creating a beautiful building for art and cultural experiences somewhere in the Stockholm archipelago. Maybe he considered it a means of, after many profitable years in Swedish business, manifesting his own deep interest in nature and combining that with his wife Lillemor's background in art and design. Maybe he wanted to repay something of all that he had, throughout a long life in the archipelago and during numerous sailing and skiing trips, been able to experience. Whichever the case, now everyone can enjoy the results of his vision at the wonderful Hålludden by Baggen's Bay in Värmdö.



Highest omega-3 concentration
Best absorbable triglyceride form
Cold production process, through ECO-friendly technology
The smart choice!



#### UnoCardio

Scientific dose of omega-3 to support heart health, based on the GISSI study (Lancet 1999; 354(9177):447-55): 910 mg omega-3, of which 460 mg EPA and 380 mg DHA



#### UnoCardio 1000 + vit. D<sub>3</sub>

1000 mg EPA/DHA for rapid increase in Omega-3 Index 1000 IU vitamin D<sub>3</sub>, the most physiologically active form High in EPA (750 mg), to support emotional well-being



#### QuattroCardio

Quadruple top formula for men and women over the age of 35

- Scientifically proven dose of omega-3 to support heart health: 460 mg EPA and 380 mg DHA
- 2. 90 mcg vitamin K<sub>2</sub>, menaquinone-7 from natto (original MenaQ7)
- 3. 1000 IU vitamin D<sub>3</sub>, the most physiologically active form
- 4. 100 mg coenzyme Q10 as ubiquinol, the ready-to-use antioxidant form



#### UnoCardio Complex QuattrO4 + Junior Complex

Four unique ingredients, for adults and children who don't like swallowing capsules

- 1. Natural, purified fish oil
- 2. GLA from evening primrose oil
- 3. Phospholipids
- 4. Vitamin D<sub>3</sub>











11TH CONGRESS OF THE INTERNATIONAL SOCIETY FOR THE STUDY OF FATTY ACIDS AND LIPIDS

28 JUNE - 2 JULY | STOCKHOLM, SWEDEN AT "THE BREWERY" — MÜNCHENBRYGGERIET

# Distinguished Faculty



11 TH CONGRESS OF THE INTERNATIONAL SOCIETY FOR THE STUDY OF FATTY ACIDS AND LIPIDS
28 JUNE - 2 JULY | STOCKHOLM, SWEDEN AT "THE BREWERY" — MÜNCHENBRYGGERIET

### DISTINGUISHED FACULTY



### Plenary Speakers



Prof. Georg Kunos, MD National Institutes of Health, USA

1 Endocannabinoids in the regulation of energy homeostasis in health and disease

Dr. Kunos received his M.D. degree in 1966 from Semmelweis University in Budapest and his Ph.D. in 1973 from McGill University in Montreal where he worked with Mark Nickerson on adrenergic receptors. In 1974 he joined the faculty in Pharmacology and Medicine at McGill University and then in 1987 joined the NIAAA as Chief of the Laboratory of Physiologic and Pharmacologic Studies. Dr. Kunos moved to the Medical College of Virginia in 1992 to Chair the Department of Pharmacology & Toxicology. In 2000 he returned to NIH as Scientific Director of NIAAA. He is an elected fellow of the High Blood Pressure Research Council of the American Heart Association and a foreign member of the Hungarian Academy of Sciences. He is recipient of the Mechoulam Award of the Intl. Cannabinoid Research Society and the NIH Director's Award. Dr. Kunos' laboratory is studying the role of endocannabinoids in neuroendocrine, metabolic and cardiovascular regulation.



**Prof. Günther Daum, PhD**Graz University of Technology, Germany

☐ Lipids and mitochondrial function ■

Günther Daum studied Chemistry, Biochemistry and Biotechnology at the Graz University of Technology, Austria, where he also received his PhD. During his scientific career he spent several years abroad as Post Doc at the Biocenter Basel, Switzerland, in the lab of G. Schatz, and as a visiting researcher at the UC Berkeley, CA, USA, in the lab of R. Schekman. Back to the Graz University of Technology he became Group Leader of the Cell Biology Group at the Institute of Biochemistry. The main subjects studied in Günther Daum's laboratory are synthesis and intracellular dynamics of lipids in the yeast with a focus on lipid assembly into organelle membranes and lipid storage. For his scientific work he received the Normann Medal of the Deutsche Gesellschaft für Fettforschung (German Society of Lipid Research) in 2011. As career related activities he has been President of the International Conference on the Bioscience of Lipids (ICBL). Currently, he is Chairman of the Yeast Lipid Conference, Board Member of the Austrian Science Fund (FWF) and Director of the Doctoral School Molecular Biosciences and Biotechnology at the Graz University of Technology.



**Prof. Erich Gulbins, MD**University of Duisburg-Essen, Germany

Ceramides, new actors in cell signaling ■

Dr. Gulbins received his M.D. degree in 1992 at the Institute of Physiology of the University of Heidelberg, Heidelberg, Germany. He habilitated for Physiology in 1996 and Immunology 1999. From 1992-1994 he worked as postdoctoral fellow at the La Jolla Institute for Allergy and Immunology, La Jolla, California, USA. 1994-2000 he worked as Assistant Professor at the Institute of Physiology at the University of Tübingen, Tübingen, Germany, from 2000-2002 as Associate Professor at the Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Since 2002 he is full Professor and Chair of the Institute Molecular Biology, University of Duisburg-Essen, Essen, Germany. Since 2011 Dr. Gulbins is

also Adjunct Professor at the Dept. of Surgery, University of Cincinnati, Cincinnati, USA. He is member of the German National Scholarship Foundation since 1986 and Member of the National Academy of Sciences Leopoldina since 2011. Dr. Gulbins studies the biomedicine of sphingolipids with a special focus on the role of sphingolipids in bacterial infections, cystic fibrosis, lung diseases and major depression.



Prof. Christopher Ramsden, MD National Institutes of Health, USA

Dietary modulation of nociceptive mediators and physical pain

Dr. Ramsden is a Clinical Investigator in the Laboratory of Membrane Biophysics and Biochemistry at the National Institute on Alcohol Abuse and Alcoholism, NIH. He is a Lieutenant Commander in the US Public Health Service, and an Adjunct Assistant Professor at the University of North Carolina-Chapel Hill. After completing residency training in Physical Medicine and Rehabilitation at Northwestern/Rehabilitation Institute of Chicago, he was a postdoctoral fellow at UNC-Chapel Hill before joining the National Institutes of Health in 2009. Dr. Ramsden's research is directed toward elucidation of molecular mechanisms linking fatty acids and their bioactive derivatives to physical pain, and to translation of these findings into novel therapeutic interventions that can provide clinically meaningful pain relief. He has been principal investigator on collaborative human trials assessing the clinical and biochemical effects of altering dietary omega-6 and omega-3 fatty acids. He is also involved in animal and in vitro studies evaluating the bioactivities of endogenous lipid mediators.



Dr., Prof. Michail Gladyshev Russian Academy of Sciences, Russia

Aquatic ecosystems as the main source of essential lipids for humans

Dr. Prof. Gladyshev graduated from Krasnoyarsk State University (now Siberian Federal University, Krasnoyarsk, Russia) in 1981 and got a position of Senior Laboratory Fellow in the Institute of Biophysics (Krasnoyarsk), where at present he is Vice-Director and Head of Laboratory of Experimental Hydroecology. He is also Professor of Siberian Federal University (Chair of Aquatic and Terrestrial Ecosystems). He is member of Presidium of the Central Council of Russian Hydrobiological Society. He is recipient of the SCOPUS Award Russia. His Laboratory of Experimental Hydroecology studied production and transfer of essential biochemicals, including fatty acids, in trophic webs of natural aquatic ecosystems.



### **Award Winner Lectures**

#### ALEXANDER LEAF AWARD



Prof. Andrew J Sinclair Deakin University, Australia

Andrew Sinclair is Professor of Nutrition Science, School of Medicine at Deakin University. AWARDS: Honorary Fellow of the Australasian College of Nutritional and Environmental Medicine, 2012; Elected Fellow of the

Nutrition Society of Australia, 2003; Elected Fellow of the Australian Institute of Food Science & Technology, 2001; Supelco/Nicholas Pellick AOCS Research Award, 1999. HONORARY POSITIONS: *British Journal of Nutrition*, Deputy Editor, 2013; British Nutrition Foundation, Editorial Board, 2012, Adjunct Professor, Department of Nutrition and Dietetics, Monash University, 2012; Chair of the Australian Academy of Science, National Nutrition Committee, 2011-2013; ILSI Australasia, (ILSI), 2008-2011, President; Nutrition Society of Australia (NSA), 2008-09 President; American Oil Chemists' Society, Senior Associate Editor, Lipids, 2006-2009; Editorial Board, *Prostaglandins, Leukotrienes & Essential Fatty Acids*, 2005- to date. CURRENT RESEARCH INTERESTS: Essential fatty acids in brain development (pre- and post-natal nutrition, the role of omega 3, polyunsaturated fatty acids in brain and retina on neural function); Food Science (composition of food), Nutrition (fatty acid metabolism in man and animals); Functional foods (omega3 PUFA, lycopene, olive oil, polyphenols, stearic acid); Professor Sinclair has more than 260 publications in peer-reviewed journals.

#### **EARLY CAREER AWARD**



**Dr. Alexander Bartelt**Harvard School of Public Health, USA

Dr. Alexander Bartelt is currently a Postdoctoral Research Fellow at the Department of Genetics and Complex Diseases, Harvard School of Public Health in Boston, MA, USA. His research is dedicated to understanding

the molecular basics of lipid and lipoprotein metabolism and related pathologies such as obesity, atherosclerosis and osteoporosis. He received his Diploma in Biochemistry and Molecular Cell Biology from University of Hamburg, Germany in 2007 with honors. During his PhD at University Medical Center Hamburg-Eppendorf he pioneered brown adipose tissue metabolic research with Prof. Joerg Heeren. Dr. Bartelt is also interested in the relationship of lipid and bone metabolism. In his postdoctoral studies he investigates metabolic adaptations of adipose tissue in extreme conditions such as cold or obesity. Dr. Bartelt's contributions to the general understanding of systemic nutrient homeostasis have been recognized by national and international awards, fellowships and honors. His work has been funded by the Schering Foundation, the European Atherosclerosis Society and the German Research Foundation DFG.

### Parallel Symposia Keynote Speakers



Bo Angelin, MD, PhD Karolinska Institutet, Sweden

20 Bile acids and lipid metabolism

Bo Angelin is Professor of Clinical Metabolic Research at Karolinska Institutet and Consultant at the Department of Endocrinology, Metabolism & Diabetes (Head 1993-2011) at Karolinska University Hospital, where he has also served as Director of Research. He is studying mechanisms for regulation of lipid and cholesterol metabolism with special emphasis on humans, and how this knowledge can be used for development of new forms of diagnostics and treatments.

Prof. Angelin's major scientific contributions include: Discovery of regulation of hepatic triglyceride synthesis by bile acids and its disturbance in monogenic familial hypertriglyceridemia; Elucidation of how estrogen and growth hormone interact in the regulation of hepatic cholesterol metabolism; The finding that reduced cholesterol elimination explains the normal increase in plasma LDL with age; Demonstration that thyroid hormone exerts distinct effects on hepatic and intestinal cholesterol metabolism and that drugs that combine selectivity for the thyroid hormone receptor beta and specific uptake by the liver can promote cholesterol excretion from the body; Discovery that cholesterol excretion from the body is enhanced after infusion of recombinant apoA-I; Discovery that hormone-sensitive lipase activity is reduced in adipose tissue of patients with familial combined hyperlipidemia; Demonstration that mutations in the COPII- associated Sar 1b cause chylomicron retention disease; Discovery of posttranslational, cholesterol nondependent regulation of hepatic LDL receptors and its explanation by hormonal regulation of PCSK9; Description of increased LDL catabolism through malignant cells; and Characterization of a different diurnal rhythm in bile acid synthesis in humans compared to rodents and of how fibroblast growth factors 19 and 21 are involved in its regulation.

Prof. Angelin has had many commissions of trust at Karolinska Institutet, the Swedish Foundation for Strategic Research, the Swedish Research Council and the Heart-Lung Foundation. He has a vast experience of international research evaluations, participates in the Nobel Committee work since 1993 (chair, 2003) and is a member of the Royal Academy of Sciences. He has also research co-operations with several drug and biotech companies, and has served as a board member of AstraZeneca PLC.



Ingemar Björkhem, MD, PhD Karolinska Institutet, Sweden

16 Oxysterols and the brain

Present positions: Professor Emeritus since 2008, Senior professor since Jan 2012, Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge

Education, Training, Professional Appointments & Degrees: Medical studies at the Karolinska Institutet, 1961-1969; Dissertation at the Karolinska Institutet 1969; Assistant Professor & MD, 1969; Specialist in Clinical Chemistry, 1981; Prof. in "Biochemical Research on Atherosclerosis", 1986-2008; Member of the Nobel Assembly, 1989-2008; Head of the Dept. of Clinical Chemistry, Karolinska Institutet, Huddinge Hospital, 1987-1993; Head of the Division of Clinical Chemistry, Dept. of Laboratory Medicine, Huddinge, 1994-2008; Head of Clinical Research Centre, Karolinska; Institutet, Huddinge Hospital, 1993-2000.

Awards & Honorary Appointments: Adolf Windaus prize for "Outstanding contributions in the field of bile acid research", Freiburg, Germany 1986; Astrup Legat (second prize), Denmark, 1984; Honorary Professor, Institute of Microcirculation, Chinese Academy of Medical Sciences, Beijing, China, 1993; Honorary Professor University of Qindau and University of Taian, China, 2008; Member of the Norwegian Academy of Science, 2000; Doctor medicinae honoris causa, University of Oslo, 2000; The Schroepfer Award, 2006.

Author or co-author of more than 500 published articles (of which about 470 are original contributions). In 2012 my papers had got more than 17,000 citations and the H-index was 67. Emphasis has been put on mechanism of biosynthesis of bile acids, regulatory mechanisms in connection with cholesterol homeostasis in liver and brain, role of oxysterols, atherogenic mechanisms and role of antioxidants. During the last decade I have focussed on cholesterol homeostasis in the brain and the role of this homeostasis in neurodegeneration. Participated as formal tutor in the supervision of 36 students who have defended PhD thesis and 4 students who have defended licentiate thesis, 1970-2010.



Tom Brenna, PhD Cornell University, USA

#### 19 Desaturases and Elongases

Tom (J. Thomas) Brenna is Professor of Human Nutrition, of Chemistry & Chemical Biology, and of Food Science & Technology at Cornell University in Ithaca, New York, USA. He is also Adjunct Professor in the Dept. of Public Health Sciences at University of Rochester (NY) School of Medicine and Dentistry. In 2013, he received the annual Robert Herman Award for Clinical Nutrition from the American Society for Nutrition and was appointed jointly by President Obama's Secretary of Health and Human Services Kathleen Sebelius and Secretary of Agriculture Tom Vilsack to the Dietary Guidelines Advisory Committee advising on food policy for the 2015 U.S. Dietary Guidelines for Americans.

His interdisciplinary research group focuses on studies of fatty acid nutrition in the perinatal period, especially polyunsaturated fatty acids (PUFA) and their role in neural and retinal development. Their studies of the efficacy of highly unsaturated PUFA as structural components of the central nervous system have helped to define the mechanism by which these fats support optimal visual and neural function. He has developed tracer methods based on stable isotopes and uses them extensively in metabolic studies. More recently he has been interested in the nutritional role of saturated branched chain fatty acids (BCFA) and their possible influence on the early development of the fetal and newborn gastrointestinal tract. His research is supported by numerous private and public grants, including the competitive grants from the National Institutes of Health (NIH) continuously since 1991.

Professor Tom Brenna's research couples Nutrition and Chemistry in a broadly interdisciplinary program. He is a member of graduate fields in Cornell's four large colleges: Nutrition (CHE and CALS), Food Science and Technology (CALS); Chemistry and Chemical Biology (Arts); Geological Sciences (Engineering and CALS), and in a long-standing collaboration with a prominent former member of Cornell's College of Veterinary Medicine. His research group has been funded by institutes/centers at the NIH (NIGMS, NEI, NICHD, NCRR) and has included at least one active R01 continuously since 1992. These grants have supported fundamental work in the nutrition of polyunsaturated fatty acids, and development of advanced mass spectrometry instrumentation and techniques.

Most of the work of the Brenna Lab is translational, tying basic research to biomedicine and human nutrition. Some studies are designed with particular, topical human health questions in mind, and these studies have occasionally had immediate implications. The most prominent examples of this work are animal studies to evaluate the efficacy, safety, and metabolism of food sources of polyunsaturated fatty acids. This work often employs stable isotope tracer techniques and molecular or isotope ratio mass spectrometry to probe metabolism. Other projects, particularly those that develop instrumentation and methods for mass spectrometry techniques, have a longer term payoff. They are sometimes undertaken for the challenge of making measurements that have never been possible previously, with an eye toward eventual applications. An example of this area is the development of a novel gas phase reaction for derivatization of polyunsaturated fatty acids for facile determination of double bond structure, which has found applications associated with safety of edible oils, including detection of trans fatty acids. More recent research is on nutrition of saturated branched chain fatty acids, a neglected class of dietary fatty acids. Recent work involves development of methods for more precise and rapid detection of endogenous performance enhancing drugs, particularly testosterone, as well as methods for detecting exogenous drugs. - See more at: http://www.human.cornell.edu/bio.cfm?netid=jtb4#sthash.519ou7NC.dpuf



Stephen Cunnane, PhD University of Sherbrooke, Canada

14 Aging changes omega-3 fatty acid homeostasis; implications and challenges

Stephen Cunnane obtained a PhD in Physiology at McGill University in 1980, followed by post-doctoral research on nutrition and brain development in Aberdeen, London, and Nova Scotia. He was a faculty member in the Department of Nutritional Sciences, University of Toronto (1986-2003), where his research was in two overlapping areas - (i) the role of omega-3 fatty acids in brain development and human health, and (ii) the relation between ketones, the very high fat ketogenic diet and brain development. In 2003, Dr. Cunnane was awarded a senior Canada Research Chair at the Research Center on Aging and became a full professor in the departments of Medicine and Physiology & Biophysics at Université de Sherbrooke. The main themes of his current research are to use brain imaging techniques

to study changing brain fuel metabolism and cognitive function during aging, and to understand how and why omega-3 fatty acid homeostasis changes during aging. He has published over 280 peer-reviewed research papers and was elected to the French National Academy of Medicine in 2009. Dr. Cunnane has published five books including two on flaxseed in human health and two on nutritional and metabolic constraints on human brain evolution – Survival of the Fattest: The Key to Human Brain Evolution (World Scientific 2005), and Human Brain Evolution: Influence of Fresh and Coastal Food Resources (Wiley, 2010).



Ian Givens University of Reading, UK

Manipulation of lipids in animal-derived foods:
Can it contribute to public health nutrition?

Professor Ian Givens has background training in biochemistry and nutrition and is currently Professor of Food Chain Nutrition and Director of the Food Production and Quality Research Division in the Faculty of Life Sciences, University of Reading. His research interests focus on food chain nutrition with emphasis on the relationship between consumption of animal-derived foods, nutrient supply and chronic disease outcome with particular emphasis on vascular disease and saturated, trans and n-3 fats. Current work focuses on lipids and proteins in milk and dairy products and their influence on cardiovascular disease. It also includes the use of animal nutrition to modify the lipid composition of these foods along with development of valid markers of chronic disease risk associated with consumption of normal and modified foods.



Jan-Åke Gustafsson, M.D., Ph.D. University of Houston Texas, USA

11 Liver X-receptor β= a multifunctional ligand activated transcription factor

Jan-Åke Gustafsson is a leading scientist in the field of steroid hormone receptors/nuclear receptors. Several of his achievements have led to true paradigm shifts in the field and represent breakthrough discoveries. He was first to show that a nuclear receptor, the glucocorticoid receptor, is composed of three separate structural and functional domains, a ligand binding domain, a DNA binding domain and a third domain identified by its immunogenic properties. Furthermore, the Gustafsson laboratory was first to purify a nuclear receptor, the glucocorticoid receptor, to homogeneity and thereby to show that it represents a single molecular species rather than a complex of multiple smaller subunits. At the time, this was an especially important finding since the literature was muddled with misconcepts based on impure and/or partially proteolyzed receptor preparations. Also, access to a homogeneous nuclear receptor made it possible for Gustafsson to demonstrate specific DNA binding of glucocorticoid receptor to a glucocorticoid sensitive gene, the murine mammary tumor virus. This theretofore impossible achievement spurred a new, mechanistic era in nuclear receptor research, since in follow-up studies, Gustafsson et al. could show that the specific glucocorticoid binding sites also represent glucocorticoid response elements, able to confer hormone responsiveness onto nearby genes. It is essential to point out that all of the above seminal discoveries were made prior to the cloning of nuclear receptors.

Furthermore, Gustafsson et al. cloned the first (partial) cDNA of a nuclear receptor, the glucocorticoid receptor; the unique probes making this possible were the poly- and monoclonal antibodies against the glucocorticoid receptor developed by the Gustafsson laboratory. Another important milestone was the structure determination of the DNA-binding domain of the glucocorticoid receptor, the first ever nuclear receptor structure to be deciphered. During recent years, Gustafsson has continued to be responsible for paradigm shifts in the field of nuclear receptor research. It was Gustafsson who first identified physiological ligands for a so-called "orphan receptor", namely fatty acids for the peroxisome proliferator activated receptor (PPAR), thereby integrating fatty acids into molecular endocrinology. Furthermore, Gustafsson discovered OR-1, later renamed LXRbeta, an oxysterol-activated nuclear receptor of paramount significance in the regulation of cholesterol homeostasis and brain function. Finally, and most importantly, Gustafsson and colleagues made the completely unexpected discovery of estrogen receptor beta, a second estrogen receptor, which has turned out to have functions far outside reproductive physiology, and to be a very promising target in pharmaceutical development of novel drugs.



**Ann Hellström** Sahlgrenska Academy, Sweden

#### 7 Fatty acids and the child's eye

Ann Hellström is Professor in Paediatric Ophthalmology, at the Sahlgrenska Academy at Göteborg University.

Academic career: 1984-1986, Amanuensis, Department of Pathology, Medical Faculty, Göteborg University; 1986, University Medical degree, Medical Faculty, Göteborg University; 996-1998, Research position, Medical Faculty, Göteborg University; 1997, PhD, Institute of Clinical Neuroscience, Department of Ophthalmology; 1999, Docent, Göteborg University; 1999-2004, Junior research position at the Swedish Medical Research Council (VR); 2004, Professor in Paediatric Ophthalmology

Clinical career: 1985, Resident, Department of Internal Medicine, Sahlgrenska University Hospital (SU), Gbg; 1986, Internship, Sahlgrenska University Hospital, Göteborg; 1986-1990, Maternal leave and abroad, 1993-1994 Maternal leave; 1990-1992, Internship, Sahlgrenska University Hospital, Göteborg; 1992-1996, Resident, general practitioner; 1993-1997, PhD studies; 1997-2002, Resident at the Department of Paediatric Ophthalmology, SU/Östra; 2002-2004, Resident at the Department of Ophthalmology, SU/Mölndal, Göteborg; 2004, Specialist Ophthalmology

Research Supervisor: 9 PhD students, fulfilled 7 PhD & 1 Med Lic

Post Doc Research Supervisor: Chatarina Löfqvist, molecular biologist, GP/GRC, Göteborg, 2001 and onwards; Gunnel Hellgren, molecular biologist, GP/GRC, Göteborg, 2001 and onwards; Doctor Yahua Chen, Dep of Ophthalmology, Institute of Clinical Neuroscience, 1994-97; Two students, 6 points research project, Biomed Cell Biology, Med Faculty, Göteborg, 1998.

Five medical students, 10 points research project, Medical Faculty, Göteborg, 1999, 2007 and 2008. Two ophthalmologists (W Wonnenberg & A Seyedi-Honorvar) doing their research project (6 months) during ST, Medical Faculty, Göteborg 2008-10.

Arranging international meetings: Ahrnbergssymposium, Göteborgs Medical Society, February 2000; Berzeliussymposium, Swedish Medical Society "Perinatal brain injury", September 2003. Nordic Pediatric Ophthalmology Group, Göteborg September 2013; Invited speaker at national meetings approximately 75 times and at international meetings approximately 100 times.

Journals that continuously consult the applicant as an expert reviewer: *JAMA, PNAS, JCEM, PLOS One, Pediatrics, Pediatric Research, Acta Pediatrica, IOVS, Acta Ophthalmologica, Eye, British Journal of Ophthalmology, Archives of Ophthalmology.* 

Board member: "PhD evaluation" at >40 dissertations; Institute of Clinical Neuroscience August 2001-July 2003.; Medical Faculty, Sahlgrenska Academy, June 2003-July 2005; Academic appointment committee at the Sahlgrenska Academy, 2004- 2006; Institute of Clinical Neuroscience and Physiology February 2006 - 2012; "Biobanksrådet", region of Western Sweden, from January 2006; Swedish national register for retinopathy of prematurity (SWEDROP) 2006; ALF evaluation in the Skåne region 2005-2009; Board member of The Swedish Research Council application evaluation 2007-2009; Board member of Kronprinsessan Margaretas fond för synskadade, Lilla Barnets Fond and Ögonfonden research application evaluation groups 2011 and ongoing; hairman for



Neurosciences at Vetenskapsrådet 2010 & 2012 and 2013; orking member of The Royal Society of Arts and Sciences in Gothenburg 2013

Awards: Knut & Alice Wallenbergs stiftelse for promising female researchers 1997 (200.000 SKR); Marianne Bernadottes pris för framstående barnögonforskning 2006 (50.000 SKR); SOE grant for excellent ophthalmologic research 2009 (50.000 SKR); Pfizers Oftalmologistipendium 2011 (100 000 SKR); Synskadades Riksförbunds Ögonvårdspris 2011 (30 000 SKR); Athenapriset (the most prominent prize for clinical research) provided by Dagens Medicin, Lif, Sveriges Kommuner och Landsting, Sweden Bio, Swedish Medtech and Vetenskapsrådet 2012 (150 000 SKR); THE ROBERT McCance Lecture 2012 - ROP pathogenesis, diagnosis & therapies (today's and future), The Neonatal Society, Great Britain.



**Jin-ichi Inokuchi** Tohoku Pharmaceutical University, Japan

23 Lipid membranes and insulin signaling

Jin-ichi Inokuchi received a Ph.D. degree in 1984 from the Department of Biochemistry, Faculty of Pharmaceutical Sciences, Fukuoka University. In 1985 he moved to the Mental Health Research Institute, University of Michigan as a postdoctoral fellow with Fulbright scholarship (the late Prof. Norman Radin), and. in 1992, became the head of the Glycolipid Section, Tokyo Research Institute, SEIKAGAKU CORPORATION. In 1998 he moved to Hokkaido University as an associate professor. In 2006, he became a professor at the Institute of Molecular Biomembranes and Glycobiology, Tohoku Pharmaceutical University. His current research is focused on the pathophysiological roles of glycosphingolipids in metabolic syndrome, immune function and hearing function with a specific focus on membrabe microdomains (lipid rafts) and on the development of novel diagnosis and therapeutic intervention based on the discovery in his laboratory.



Capt. Joseph Hibbeln, MD National Institutes of Health, USA

5 Dietary patterns of pregnancy and childhood and risk of early onset addictions in the ALSPAC cohort

Joseph R. Hibbeln, MD, is Acting Chief of Section of Nutritional Neurosciences, Laboratory of Membrane Biophysics and Biochemistry, National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health, Bethesda, Maryland, USA.

A psychiatrist and lipid biochemist by training, Dr. Hibbeln is now one of the world's leading experts on the importance of dietary fats for human brain development and function. His work is focused on translating basic neuroscience on the omega-3 essential fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) (found in fish and seafood) into direct clinical applications, and he has published more than 80 peerreviewed scientific papers to date. His research interests range from severe pathological states, including suicide and psychosis, through depression and antisocial behaviour, to normative personality in adulthood and early development. He believes that a substantial proportion of emotional distress in modern society might be reversed by adequate intakes of omega-3 fatty acids.

He has extensive international collaborations for clinical trials of omega-3 fatty acids for the prevention of suicide, postpartum depression, and violence. He is a primary collaborator in the Avon Longitudinal Study of Parents and Children, Bristol, UK, examining the residual effect of nutritional insufficiencies in pregnancy in childhood neurodevelopmental outcomes and relevant gene-nutrient interactions. Joe was one of the very first investigators to draw attention to the importance of omega-3 fatty acids in psychiatric disorders (he organized a key international conference on this theme at NIH in 1998), and he is frequently sought out to communicate scientific findings in this field though major public media.

His numerous honours include the TL Cleave Award from the McCarrison Society, London, United States Public Health Service (USPHS), Outstanding Service medal, three USPHS Crisis Response Awards, the Gerald Klerman award from the National Association for Research in Schizophrenia and Depression, Independent Investigator and Young Investigator awards from NARSAD and Eagle Scout, BSA. Dr Hibbeln received a BA with special honours from the University of Chicago in 1983 and an MD from the University of Illinois at Chicago in 1988. He is a board certified physician in psychiatry and serves as a Captain in the USPHS.



**Darshan S. Kelley, PhD**Western Human Nutrition Research Center, ARS, USDA, and University of California, Davis, CA, USA

7 Reversal of CLA-induced Non-alcoholic Fatty Liver Disease (NAFLD) & Insulin Resistance (IR) by DHA in a mouse model

Dr. Kelley obtained an M. Sc. degree in Biochemistry from Punjab Agricultural University in Ludhiana, India and then received his Ph. D. degree in Biochemistry in1974 from the University of Oklahoma, under the mentorship of Dr. B Connor Johnson. Here, he compared the effects of high fat and high carbohydrate diets on the regulation of hepatic lipid synthesis and the mechanisms involved. Dr. Kelley worked as a research associate in the laboratory of Dr. Van R Potter at McArdle Laboratory for Cancer Research, at the University of Wisconsin (UW) 1975-1980. Research conducted by Dr. Kelley at UW contributed to an understanding of hormonal and nutritional regulation of amino acid transport in normal and malignant hepatocytes. Dr. Kelley then served on the faculty of West Virginia University for 3 years before starting his career with the USDA, ARS, Western Human Nutrition Research Center (WHNRC) as a research chemist in 1983. He served as the Research Leader for the Bioenergetics Research Unit of WHNRC from 1990-1996, and as the Lead Scientist for the project on Dietary Fat and Health from 1990-2008. Within the ARS, Dr. Kelley's research initially focused on the effects of the amount and type of dietary fats on immune status, but he also examined the effects of energy intake, vitamins and minerals on immune response. His research showed that a reduction in fat intake enhanced several indices of immune response in human subjects. Increased consumption of omega-6 and trans fatty acids increased inflammatory response, while increased intake of omega-3 fatty acids decreased the production of inflammatory cytokines and eicosanoids. Subsequent studies of Dr. Kelley dealt with the effects of individual dietary fatty acids (docosahexaenoic acid, arachidonic acid, and conjugated linoleic acid) on risk factors for cardiovascular disease (CVD), nonalcoholic fatty liver disease (NAFLD) and insulin resistance, and an understanding of the mechanisms involved. DHA supplementation of the diets decreased several risk factors for CVD in human subjects and prevented NAFLD and insulin resistance induced by CLA in the mouse model. Dr. Kelley's laboratory demonstrated the CLA induced NAFLD progresses to nonalcoholic steatohepatitis (NASH) and shares many characteristics of human NASH. Dr. Kelley has also investigated the health effects of phytonutrients (polyphenols and limonoids) in human subjects. Results from his study with Bing sweet cherries demonstrated that cherry consumption decreased the circulating biomarkers for several inflammatory diseases. His study with purified citrus limonin glucoside (LG) indicated LG supplementation improved several biomarkers for liver health in over weight human subjects. A US patent has been filed by USDA regarding these findings. In addition to his employment with ARS, Dr. Kelley has also been an adjunct professor in the Department of Nutrition at the University of California Davis since 1999.



Hee-Yong Kim, PhD National Institutes of Health, USA

20mega-3 fatty acid-derived neurodevelopment and neuroprotective function

Dr. Hee-Yong Kim is Chief of the Laboratory of Molecular Signaling, National Institute on Alcohol Abuse and Alcoholism (NIAAA) of the National Institutes of Health (NIH). Dr. Kim is internationally recognized for her research contributions concerning the mechanistic role of n-3 essential fatty acids, especially docosahexaenoic acid (DHA), in brain development and function. Her laboratory investigates the effects of DHA on neuronal membrane remodeling, membrane-protein interaction, biomediator formation and related signaling processes leading to cell survival and differentiation as well as neuroprotection. To this end, her laboratory develops novel biochemical, cell and molecular biological approaches, and modern mass spectormetric techniques for lipidomic, proteomic and metabolomic analyses. Her findings have provided fundamental new insight into the effects of lipid nutrition on the central nervous system. Although many of her studies are performed using animal models and cultured cells, the results are directly applicable to some of the pressing questions concerning the effects of dietary lipids on human health. She publishes in competitive peer-reviewed biomedical journals and has written many invited chapters and scholarly reviews.



Michel Lagarde, PhD, DSc INSA/INSERM, France

4 Lipidomics — an expanding field. The example of fluxolipidomics

Starting to work at Pasteur Institute in Lyon on 1972 as Research Assistant • Research Scientist at INSERM (French MRC) (1976-1986) • University Professor in Biochemistry & Molecular Biology (1987-) • Doctorate in Biochemistry (1974), Doctorate ès-Sciences (1979), Doctorate in Human Biology (1983) • Post-doctoral fellow at the Department of Biochemistry, Royal College of Surgeons (RCS) of England (London, 1980) • Short sabbaticals at RCS (1981, 1982, 1983); Dept. Pharmacology at University of Illinois (Chicago, 1984); Dept. Biochemistry at Michigan State University (East Lansing, 1993); Depts. Biochemistry & Chemistry at University of California (San Diego, 2006) • Former president of GERLI (1994-2001), ICBL (2006-2010), ISSFAL (2006-2009) • Director of an INSERM research unit from 1988 to 2006 • Founder of the Institute for Multidisciplinary Biochemistry of Lipids (IMBL) and president (2002-2012) • Co-founder of the "Lipids for Industry and SAfety & health" (LISA) Carnot institute, and research director (2007-2012) • Research topics on the metabolism of PUFA of nutritional value, especially oxygenated metabolism, in blood and vascular cells, in pathophysiological situations (co-author of 360 articles according to PubMed, H index 44).



Christelle Lopez INRA, France

6 Milk membrane lipid composition

In 33 years, Christelle Lopez already has 36 international scientific publications. Responsible for research within the Unité mixte de recherche Inra/Agrocampus Western Science and technology of milk and the egg, centre Inra in Rennes, Department characterization and development of products of agriculture, Christelle participates in several research programs and coordinates an important project supported by the national agency of research (ANR), rarely function as early in the career of a researcher.



Maria Makrides University of Adelaide, Australia

3 Maternal and infant nutrition

As a research dietitian, Maria is committed to improving the nutrition and health of mothers and their babies through the translation of high quality research. She has published widely and her work has been recognised nationally and internationally with a number of prestigious awards and appointments. She currently serves on the Board of Directors of the International Society for the Study of Fatty Acids and Lipids (ISSFAL) and is a member of the Nutrition Committee, Australian Academy of Science. Maria currently leads 4 national large-scale trials in the area of perinatal nutrition funded by the NHMRC.





Tore Midtvedt, MD, PhD Karolinska Institutet, Sweden

### 25 Gut microbiota and fatty acids

GRADUATE & POSTGRADUATE TRAINING: Faculty of Medicine, Univ. of Oslo, Norway, 1952.1956 • Faculty of Medicine, Univ. of Bergen, Norway 1956-1958 • Board of Health, Licence, Norway 1959 · Doctor of Medicine, Karolinska Institute, Stockholm, Sweden, 1968 · ACADEMIC APPOINTMENTS: Lecturer in Medical Microbiology, Dept. of Bacteriology, Faculty of Medicine, Univ. of Oslo, 1961-1963 • Visiting scientist, Dept. of Germfree Research, Karolinska Institute, 1963-1966 • Lecturer in Bacteriological Pharmacology, Faculty of Medicine, Univ. of Oslo, 1966-1969 • Associated Professor in Medical Microbiology, Univ. of Oslo, 1973-1982 • Prof. in Medical Microbiology, Univ. of Oslo, 1982-1983 • Prof. and Chairman, Dept. of Medical Microbial Ecology, Cell and Molecular Biology, Karolinska Institute, 1983-1999 • Professor emeritus, Karolinska Institute, since 1999 • Doctor Med Vet Honores Causae. Norw Sch Vet Med, Oslo, 2010 • MEMBERSHIPS: Member of several domestic and international societies in Antibiotics, Gnotobiology, Infectious Diseases, Microbiology, Pharmacology. Member of New York Academy of Sciences. Past President, International Assn. for Gnotobiology and Society for Medical Microbial Ecology • SCIENTIFIC PUBLICATIONS: More than 355 publications cited in PubMED in Antibiotics, Ecology, Gnotobiology, Infectious Diseases, Microbiology, Pharmacology. More than 500 articles, abstracts, book chapters, etc. • OTHER ACTIVITIES: Editor-in-chief for the journal Microbial Ecology in Health & Disease • Member of editorial board in 3 intl. journals; reviewer for several more journals. • Opponent at several PhD dissertations in 6 countries, supervisor or co-author for more than 50 PhD students. Member of committees for evaluation of position as professor in 5 countries; evaluated applications for scientific councils in 7 countries.



Bev Muhlhausler, PhD Univ. of Adelaide, Australia

### 15 Maternal & infant nutrition, Part II

Dr Muhlhausler graduated from her PhD in August 2006. She is a physiologist and molecular biologist who has a long standing interest in obesity and metabolic health, with a particular focus on the role of maternal and infant nutrition in determining the future metabolic health of the child. In her PhD, Dr Muhlhausler demonstrated that prenatal exposure to an increased nutrient supply resulted in increased expression of adipogenic and lipogenic genes in fat cells before birth, which permanently increased their capacity for fat storage (Muhlhausler et al, Endocrinolgy, 2007a and 2007b). This led Dr Muhlhausler to the hypothesis that altered development of the adipocyte was the primary event through which prenatal nutritional excess resulted in an increased propensity to obesity and diabetes in the child, and a subsequent search for potential nutritional interventions that could be applied during pregnancy or early infancy to optimize the future metabolic health of the child (Muhlhausler et al, Trends Endocrinol Metabol, 2009). This search led Dr Muhlhausler the omega-3 LCPUFA - and in recent years, Dr Muhlhausler's research has focused on the potential for increased supply of omega-3 LCPUFA in the maternal/infant diet to inhibit excess fat accumulation and improve insulin sensitivity early in life, and therefore reduce an individual's subsequent risk of obesity and diabetes in adult life.

Dr Muhlhausler has published 12 original research articles in the past 5 years which have investigated the role of the omega-3 LCPUFA in the maternal diet on offspring outcomes in animal models, which have systematically evaluated the (currently relatively limited) literature base which has attempted to address whether maternal/infant n-3 LCPUFA supplementation can reduce obesity risk in the child. Her work has provided novel insights into the role that the balance of lipids in the maternal and early infant diet play in determining long term metabolic health, and has led to 5 invited reviews/commentaries in this area in the past 2 years.

For the past 5 years, Dr Muhlhausler has led a follow-up of the DOMInO randomized controlled trial in Adelaide investigating the hypothesis that maternal omega-3 supplementation in the second half of pregnancy results in reduced BMI z-score and percentage body fat mass in children at 3 and 5 years. This study was awarded competitive funding from the leading funding body for Medical Research in Australia, the National Health and Medical Research Council of Australia, and involved detailed assessments of growth, body composition and metabolic status in over 1500 children at 3 and 5 years of age Data collection for the study was completed in October 2013, with a follow-up rate of >85%. Dr Muhlhausler's 2014 ISSFAL presentation will be the first presentation of the primary results of this study, which are expected to provide the most robust data to date as to the potential for mater-

nal omega-3 LCPUFA supplementation to improve metabolic health in human children.

As a physiologist and molecular biologist, Dr Muhlhausler has a long-standing interest in understanding the biological mechanisms through which omega-3 fatty acids act to influence development. She has led studies in animal models to investigate the impact of different fatty acid classes (in particular omega-3 and omega-6 PUFA) on the expression of key metabolic genes, and demonstrated the lipogenic effect of the omega-6 PUFA in adults. More recently, Dr Muhlhausler has extended her mechanistic work to human studies, and is currently undertaking epigenetic analyses of DNA samples collected from the DOMInO children at 5 years of age, in order to determine whether maternal omega-3 LCPUFA supplementation is associated with altered DNA methylation of the genome, and whether these changes could explain the phenotypic effects of the intervention.



Jan Nedergaard University of Stockholm, Sweden

### Brown fat metabolism and function

Jan Nedergaard is professor of physiology at The Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University. Since 1975, his scientific efforts have concentrated on the understanding of the function and physiological significance of brown adipose tissue. In recent years, he has played a significant role in the establishment of new concepts in brown adipose tissue research: - that brown adipocyte precursors are principally different from white adipocytes in that they display a myogenic gene expression phenotype (2007); - that the absence of brown adipose tissue is sufficient to cause or aggravate obesity (2009); - that existing radiological data implied that brown adipose tissue is present and active in adult humans (2007), - and that the gene expression profile observed in UCP1-expressing cells in white adipose depots is so distinct from that of classical brown adipocytes that these cells/depots should be considered to be of a different nature ("brite adipocytes") (2010). Jan Nedergaard was dean of biological sciences at Stockholm University 2002-2008.



Anna Nicolaou, PhD University of Manchester, UK

#### OLipid mediators of cutaneous inflammation

Anna Nicolaou is Professor of Biological Chemistry in the Manchester Pharmacy School. Prof Nicolaou received her BSc in Chemistry and PhD in Biological Chemistry from University of Athens and trained as postdoctoral fellow at the School of Pharmacy, University of London. Prof Nicolaou joined the Bradford School of Pharmacy in 1997 and was awarded a personal chair in Biological Chemistry in 2008 before moving to University of Manchester in 2013. Her main research focus has been the molecular mechanism of action of bioactive lipids using mass spectrometry-based lipidomics, with emphasis on the role of fatty acids and their metabolites in cutaneous inflammation, the cardiovascular system, neuroinflammation and ocular health. Her work has been supported by research councils, charities and industry. Prof Nicolaou is co-chair of the lipidomics division of European Federation for the Science and Technology of Lipids, and associate editor for *Prostaglandins Leukotrienes and Essential Fatty Acids*, and the *European Journal of Lipid Science and Technology*.



Masanobu Oshima Kanazawa University, Japan

24 Prostaglandin E2 pathway in inflammation-associated cancer development ■

Masanobu Oshima is Professor, Genetics Division, and Director of the Cancer Research Institute at Kanazawa University in Kanazawa, Japan. His research interest is a molecular pathogenesis of gastrointestinal tumorigenesis and malignant progression by using unique mouse models. Professor Oshima explains, "We previously investigated the role of COX-2 in intestinal tumorigenesis by construction of genetic models. Recently, we have constructed gastric cancer model, *Gan* mice, by transgenic activation Wnt signaling and PGE2-associated inflammatory responses. Using *Gan* mice, we have been studying the role of PGE2 and inflammatory cytokines in gastric tumorigenesis."



Jan Palmblad, MD, PhD Karolinska Institutet, Sweden

19 Transfer of omega-3 FA across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid (DHA)-rich omega-3 FA preparation in patients with Alzheimer's disease: the OmegAD study

Prof. Jan Palmblad obtained his MD in 1969 and PhD 1977 from the Karolinska Institute (KI), Stockholm, Sweden, and was appointed Associated Professor of Medicine in 1982 and full Professor of Medicine and chairman of the Dept of Södersjukhuset at KI in 1995. In 1998 he was appointed to the chair of Medicine and as Chief of Dept. of Medicine at Huddinge University Hospital, KI, Stockholm; he stepped down from the latter position in Dec 2004. In 1982-1983 he was Visiting Professor of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.

He is a member of several societies (incl. being an Honorary Emeritus Member of the American Society of Hematology, European Hematology Assciation, American Federation of Medical Research), has served as a council or board member of The International Immunocompromised Host Society and several national societies, is a member of the Severe Chronic Neutropenia International Registry, and has been on several national and international advisory committees and editorial boards.

His areas of research interest are in essential fatty acids and lipoxygenase products, particularly in relation to phagocyte and endothelial cell function as well as Alzheimer disease, acute and chronic neutropenias, angiogenesis in haematological, particularly myeloproliferative, diseases, and infections and nutritional state in hematological patients. He has also been engaged in research relating stress and sleep deprivation to inflammatory and immunological reactions. PubMed lists 280 of his totally >400 publications. He has been the tutor for 21 PhD students (out of the 23, presenting PhD thesis from the Center for Hematology and Inflammation Research, founded in 1974 by JP).

Six relevant papers: (1.) Palmblad J, Malmsten CL, Udén AM, Rådmark O, Engstedt L Samuelsson B: Leukotriene B4 is a potent and stereospecific stimulator of neutrophil chemo→taxis and adherence. Blood 1981;58:658-661. (2.) Feinmark SJ, Udén AM, Palmblad J, Malmsten CL: Leukotriene biosynthesis by PMN from two patients with chronic granulomatous disease. J Clin Invest 1983;72:1839-1843. (3.) Lerner R, Lindström P, Berg A, Karlman G, Ro-sendahl K, Palmblad J: Deve-lopment and characterization of essential fatty acid defici→ency in human endothelial cells in culture. Proc Natl Acad Sci, USA 1995;92: 1147-1151. (4.) Klein C, Grudzien M, Appaswamy G, Germeshausen M, Sandrock I, Schäffer AA, Rathinam C, Boztug K, Schwinzer B, Rezaei N, Bohn G, Malin M, Carlsson G, Fadeel B, Dahl N, Palmblad J, Henter JI, Zeidler C, Grimbacher B, Welte K. Deficiency of HAX1 causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nature Genetics 2007;39:86-92. (5.) Qui H, Johansson A-S, Sjöström M, Wan M, Schröder O, Palmblad J, Haeggström JZ. Differential induction of BLT receptor expression on human endothelial cells by lipopolysaccharide, cytokines and leukotriene B4. Proc Natl Acad Sci, USA 2006;103:6913-8. (6.) Freund Levi Y, Cederholm T, Eriksdotter-Jönhagen M, Basun H, Faxén Irving G, Garlind A, Tysén-Backström A, Vedin I, Vessby B, Wahlund L-O, Palmblad J. Omega-3 fatty acid supplementation delays the cognitive decline in patients with very mild Alzheimer's disease - a 1-year randomised placebo-controlled study of 174 patients. Arch Neurol, 2006; 63:1402-08.





Aleix Sala-Vila
Hospital Clinic, IDIBAPS- Endocrinology & Nutrition, Spain

22 Mediterranean diet, carotid plaque progression ALA, long chain n-3 and all cause mortality

Aleix Sala-Vila received his BSc in Pharmacy (1999), BSc in Food Science and Technology (2002) and PhD in Biomedical Sciences (2004) from the University of Barcelona. He was a post-doctoral fellow with Professor Philip Calder at the University of Southampton (2005-2007). In January 2008 he joined the team led by Emilio Ros at the Hospital Clínic de Barcelona and pursued clinical studies of the influence of dietary n-3 fatty acids of either marine or vegetable origin on atherosclerosis as assessed by non-invasive imaging techniques. His whole scientific career has focussed on investigating how the intake of foods and nutrients characteristic of the Mediterranean diet (n-3 fatty acids in particular) can help protect from chronic diseases. His main research interests are atherosclerosis development, plaque stability, myocardial salvage after acute myocardial infarction, neurodegeneration and healthy aging. He has been involved in specific projects within the PREDIMED (PREvención con Dleta MEDiterranea) study, for which the group directed the nutritional intervention. These projects deal with the effects of PREDIMED diets on: blood pressure as assessed by 24-h ambulatory monitoring (sub-cohort); age-related cognitive decline after intervention for 4 y (sub-cohort); changes in carotid plaque by ultrasound and magnetic resonance imaging after intervention for 2 y (sub-cohort); 5-y incidence of dementia (whole cohort); and consumption of alpha-linolenic acid and mortality (whole cohort). He is also a co-investigator of the randomized controlled trial WAHA (WAlnuts for Healthy Aging http://www.clinicaltrials.gov NCT01634841) aimed at studying the effect of a diet enriched with walnuts (15% of energy) for 2 y in comparison with a control diet on age-related cognitive decline and macular degeneration in 700 cognitively healthy older persons.



Charles N. Serhan, PhD, DSc (hc)
Harvard Medical School & BWH, USA

Novel Pro-Resolving Mediators in Inflammation: Resolvins, Protectins and Maresins

Since 1995, Prof. Serhan is Director of the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Women's Hospital in Boston. He is the Simon Gelman Professor of Anaesthesia (Biochemistry and Molecular Pharmacology) at Harvard Medical School and Professor of Oral Medicine, Infection and Immunity at HSDM Harvard University. Professor Serhan received his Bachelor of Science Degree in biochemistry from Stony Brook University, New York, and went on to receive his doctorate in experimental pathology and medical sciences from New York University (NYU) School of Medicine. From 1981-86, he was a visiting scientist at the Karolinska Institutet, Stockholm and post-doctoral fellow with Professor Bengt Samuelsson. In 1996, he received an honorary degree from Harvard University.

Dr. Serhan was awarded an NIH MERIT Award (2000), the MacArthur Research Service Award in 2003, and the Outstanding Scientist Award in Inflammation Research at BioDefense, 2004. He delivered the 2005 NIH Kreshover Lecture and received the LSU Chancellor's Award in Neuroscience in 2006 and in 2007 the Dart/New York University Biotechnology Outstanding Achievement Award. In 2008, he delivered the Sir John Vane Memorial Lecture and received the 2008 William Harvey Outstanding Scientist Medal. In 2010, he delivered the Kern Lecture "in recognition of outstanding research on lipids" and received the Society for Leukocyte Biology 2010-Bonazinga Award for "excellence in leukocyte research, SLB's highest honor". Dr. Serhan was elected Fellow of AAAS in 2011, delivered the Lawrence Tabak NIH-Lectureship for excellence in Oral Biology and the 2011 American College of Rheumatology Hench Lecture awarded by the Mayo Clinic Hench Society, and was named Honorary Fellow from Queen Mary University London. He was also NIH/NCI Distinguished Lecturer STARS in Nutrition and Cancer (2012) and the NIH STEPS lectureship. He received the 2013 Journal of Lipid Research Lectureship Award and Mérieux Research Grants, 2013 Laureate.

He also received the Honorary Degree of Doctor of Science, University College of Dublin, Ireland and the 2013 Oh Dang International Prize from the Korean Pharmaceutical Society "in recognition of an internationally recognized scholar who has had a major impact on pharmaceutical research and related areas of life sciences."

Charles is a member of several scientific advisory boards including recent appointments (2013) to the Scientific Advisory Board of the Pasteur Institute, France and was appointed to the NIH Board of Scientific Counselors for the intramural research program of NIAAA, Rockville, MD. Author of >460 publications, 4 books and >348 awarded patents.



Young-Joon Surh, PhD Seoul National University College of Pharmacy, Korea

21 Roles of some endogenous lipid mediators in cellular defense against oxidative stress and inflammation

Dr. Young-Joon Surh is a Professor of Biochemistry at the College of Pharmacy, Seoul National University, South Korea. He currently serves as Director of Tumor Microenvironment Global Core Research Center Research Center (GCRC), which is supported by the National Research Foundation of Republic of Korea. Prof. Surh graduated from Seoul National University with BS (Pharmacy) and MS (Biochemistry) and earned his PhD degree at the McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, USA. He had postdoctoral training at the Massachusetts Institute of Technology (MIT). In 1992, he was appointed as a tenure-track Assistant Professor at Yale University School of Medicine. Since relocating to Seoul National University in 1996, Prof. Surh has been investigating the molecular mechanisms of cancer prevention with natural products, with special focus on redox modulation of antioxidant and anti-inflammatory signaling molecules as prime targets. Served as a member of the editorial board member of more than 30 international journals, including Carcinogenesis, International Journal of Cancer, Molecular Carcinogenesis, Cancer Letters, Cancer Prevention Research, Mutation Research, Life Sciences, Molecular and Cellular Biochemistry, Free Radical Research, Food and Chemical Toxicology, Biofactors, Genes and Nutrition, Molecular Nutrition and Food Research, etc. He is also editor of the following books: Oxidative Stress, Inflammation and Health (CRC Press), Molecular Targets and Therapeutic Use of Curcumin (Springer-Veralg), and Dietary Modulation of Cell Signaling Pathways (CRC Press). Prof. Surh has published more than 250 papers in peer-reviewed international journals and more than 70 invited editorials, reviews and book chapters. The total number of citations of his publications is more than 10,000 (excluding self-citations). He received numerous awards including Elizabeth C. Miller and James A. Miller Distinguished Scholar Award from Rutgers University (2011), McCormic Science Institute Award from American Society for Nutrition (2009), Merit Award from the International Society of Nutraceuticals and Functional Foods (2010). He published a seminal review article, titled cancer chemoprevention with dietary phytochemicals, in Nature Reviews Cancer which has been highly cited (more than 1.000 times).



Lhousseine Touqui, PhD Institut Pasteur, France

13A role for the group-II secreted phospholipase A2 in the establishment of lung microbiome in patients with cystic fibrosis

Present position: Research Director, Institut Pasteur and Leader of the team "Roles of TLRs and phospholipases in lung infectious and inflammatory diseases".

Member of Scientific Instances: Scientific Council of the French Foundation of Cystic Fibrosis, ABCF proteins; Expert for the International Foundation For Science; Expert for the Canadian Cystic Fibrosis Fundation; Expert for Ministère de la Recherche, Mission Scientifique, Technique et Pédagogique; Consultant for the Pharmaceutical Company "Galderma"; Co-fonder of an European Network for new strategies to eradicate multi-resistant bacteria; Member of the Committee for Scientific Evaluation (COMESP) in Pasteur Institute

Informations and Communications (since 2005): Organisation of the EuroConference Infections & Lung Diseases (Paris, June 2006); Organisation of the Shanghai International Symposium on Respiratory Diseases (Shanghai, October 2008); Organisation of the Third European Workshop on Lipid Mediators (Paris, June 2010); Organisation of the Forth European Workshop on Lipid Mediators (Paris, June 2012); Organisation of 2 Pasteur Departement Meetings, in 2009 and 2010 "Le point sur les thérapies antibactériennes" on antibiotic resistance and possible "alternative" therapeutic strategies.

Invitation to scientific meetings as a speaker since 2005: 15th Congress of the Asia Pacific Association for Respiratory Care (Shanghai, October 2005); 1st Mediterranean Clinical Immunology Meeting (Evora, October 2006); 3rd International Conference on Phospholipases and Lipid Mediators (Naples, May 2007); 2nd Mediterranean Clinical Immunology Meeting (Antalya, October 2008); European Cystic Fibrosis Congress (Tavira, April, 2009); European workshop "Molecular and Cellular aspects of Chronic Lung Disease" (Rotterdam, June 2009); 3rd European Workshop on Lipid Mediators (Paris, June 2010); The 35th European Cystic Fibrosis Society Conference (Dublin, June 2012); ECFS conference - New Frontiers in Basic Science of Cystic Fibrosis (Malaga, March 2013)



Antonio Vidal-Puig University of Cambridge, UK

18 Fatty acid metabolism in obesity

Research Interests – Molecular Mechanisms of Energy Balance: Our program of research explores the molecular mechanisms involved in controlling energy expenditure, fat deposition, and the mechanisms controlling the partition of energy towards oxidation or storage. Specifically we are interested in the following interrelated questions: A. How the expansion of adipose tissue typically associated with obesity relates to the development of the Metabolic Syndrome. More specifically we are exploring whether lipotoxicity and/or changes in adipokines secreted by adipose tissue affect insulin sensitivity in other organs (skeletal muscle, heart, liver, brain, beta cells and macrophages). B. Whether modifications in adipogenesis and remodeling of adipose tissue may be good strategies to ameliorate the metabolic effects associated with obesity. C. The molecular mechanisms that control energy expenditure and brown fat activation. D. Whether modulation of partitioning of nutrients towards fatty acid oxidation in skeletal muscle and away from storage in adipose tissue may prevent the devastating metabolic effects of obesity.

To address these challenges is a daunting task that requires the modulation of highly integrated and complex mechanisms of energy homeostasis designed to prevent negative energy balances. According to this integrated concept of energy homeostasis, my laboratory is using an Integrated Physiology approach that relies greatly upon the generation and detailed in vivo phenotyping of genetically modified organisms. Together with Systems Biology approach integrating transcriptomic and lipidomic analysis, using bioinformatics to identify organ specific lipid metabolic networks relevant for insulin resistance and metabolic disease.

Our research is funded by the Wellcome trust, MRC, Diabetes UK, British Heart Foundation, EU FP6 HEPADIP, EU FP7 MITIN, EU FP7 Etherpaths and BBSRC.







11 TH CONGRESS OF THE INTERNATIONAL SOCIETY FOR THE STUDY OF FATTY ACIDS AND LIPIDS

28 JUNE – 2 JULY | STOCKHOLM, SWEDEN AT "THE BREWERY" — MÜNCHENBRYGGERIET

# Poster Sessions

# Poster Sessions

Posters listed in the following pages are indexed by location and also organized by the day on which the presenter will present their Poster, alphabetized by last name of the presenter. A floor plan of the Poster Hall is on page 10.

Posters will be presented in three halls at the upper floor of The Brewery – **Nobelterassen (N), Mälarsalen (M)** and **Strindbergsalongen (S).** Here you will also find the Exhibit Hall, where Coffee Breaks and Lunch will also be served on Sunday, Monday and Tuesday (please note that breakfast is on your own).

Posters will be available for review during all three full days of the Congress. Since we have a very full oral programme, it is important that all attendees have ample opportunity to see the Posters throughout the Congress.

We have created a schedule whereby you will be able to see presentations formally on **one day only during the lunch break**, to facilitate discussion with those interested and also make it possible for you to be able to meet other presenters of topical interest to you.

#### **VIEWING POSTERS**

Posters have been given a number for easy identification by delegates. This number has three parts:

- The initial letter refers to the "Poster Area" (there are three) where the Poster will be presented (see the floor plan on page 10 and the table below).
- The next number refers to the designated screen row.
- The second number after the decimal refers to the specific screen within the designated row.

This identification number will be found on the specific location as described above. The number will also appear wherever the corresponding Abstract is listed in the Program and online.

#### POSTER DISPLAY AREAS / PRESENTATION SCHEDULE

#### ATTENTION PRESENTERS:

You will formally present your Poster during lunch, on the day indicated for your row — which corresponds to the first two numbers of your new Poster Number.

POSTER AREA	TOPIC	SUNDAY	MONDAY	TUESDAY
NOBELTERRASSEN POSTER AREA N	Nutrition/Food/Diary/Formula Programming/Epigenetics Placenta/Pregnancy/Neonatology Neurodevelopment/Neuroscience	N1 N4 N7 N10 -	N2 N5 N8 N11	N3 N6 N9 N12
MÄLARSALEN POSTER AREA M	Metabolism/Endocannabinoids Metabolism/Oxidation Metabolism/Transformation Metabolism/Oxylipins Cancer Immunology/Clinical Diseases	M1 - M4 - M7	- M2 M5 - - M8	- M3 - M6 - -
STRINDBERGSALONGEN POSTER AREA S	Exercise Obesity/ Diabetes mellitus Vitamin D Cardiovascular diseases/Cholesterol Neuropsychiatry Alzheimer/Apo E Aging/Pain Methodology Bioavailability Common Topics	\$1 - \$4 \$7 - \$10 - \$13 -	- S2 - S5 S8 - - S11 - S14 -	- S3 - S6 S9 - S12 - - S15

### POSTER INDEX BY LOCATION

Model	POS	TER AREA M	M6.03	Allain	N4.03	Banavara	N12.02	Ben Zvi	\$7.06	Bachmair
Minol	Mäla	rsalen	M6.04	Willenberg	N4.04	Bourlieu	N12.03	Parletta		Li
Midarycin	M1.01	Yamada	M6.05	Kuipers	N4.05	Carlson	N12.04	Kitson	\$7.08	Teng
Mistarcic   Mo.07	M1.02	Lin	M6.06	Idborg	N4.06	Colombo	N12.05	Ghebremeskel	\$8.01	Hammoda
MILOS   Banni			M6.07	•	N4.07	Harris	N12.06	Gow	\$8.02	Hammoda
Mode			M6.08	Surette	N4.08	Van Rooijen	N12.07	Lewis	\$8.03	Dhyani
Mod   Sabour   Mod   Caliquir   NS0.2   Petron					N5.01	•				
Month										
Millor   M				•			POS	TER AREA S		
Mill										
Martins										•
Martins										
Martins										
Macrewsta   M7.05   Su   N.6.01   C. De Velasco   S1.05   Dyall   S9.04   Buaud   Warewho   M7.06   Kock   N.6.02   Spraafico Fernandes   S1.05   Curry-Boxentura   S9.05   Coales   M2.04   Marchix   M7.07   Field   N.6.03   Van der Wurff   S1.07   Fischer   S9.06   Hamazaki   M2.05   Samborm   S2.01   Petrovic   S9.08   Yao   Mocking   Mockin				•						
Muchaerho   Mr.206   Kock   McG02   Spreafico Fernandes   SL06   Cury-Boaventura   Sy05   Coates   C						•		,		
Marchiv								•		
								•		
M2.07   Shabalina										
M2.07   Shabalina   M7.10   Colquhoun   N6.06   Spreafico Fernandes   S2.02   Pauler   S1.00   Iwanaga   M2.08   Kozinski   M7.11   Su   N6.07   Birberg Thornberg   S2.03   Suh   S10.02   Hopperton   M2.09   Morigicchi   M7.12   Magnusson   N6.08   Hellgren   S2.05   Riberg Madsen   S10.04   Yehuda   M2.10   Rossary   M8.01   Magnusson   N7.01   Dinel   S2.05   Riberg Madsen   S10.04   Yehuda   M2.11   Jackson   M8.02   Hardardottir   N7.02   Hibbelin   S2.06   Aukema   S10.05   Fisik   M2.12   M3.03   Malan   N7.03   Bernadette   S2.07   López-Vicario   S10.06   Choulard-Watkins   M3.01   Urita   M8.04   Juman   N7.04   Holle   S2.05   Ge Grad   S10.07   Conway   M3.02   Lin   M8.05   Sorjaio   N7.05   Casas-Agustench   S3.01   Park   S10.08   Conway   M3.03   Arnardottir   M8.06   Spreafico Fernandes   N7.06   Lind   S3.02   Nath   S10.05   Tokuda   N7.07   Dávalos   S3.03   Slim   S10.05   Tokuda   N7.07   Dávalos   S3.03   Slim   S10.05   Tokuda   N3.05   Fuhrmann   M8.08   Maghool   N7.08   Na   S3.04   Ghebremeskel   S10.03   Kato   N3.05   Fuhrmann   M8.08   Maghool   N7.08   Na   S3.04   Ghebremeskel   S10.03   Kato   N3.05   Fuhrmann   M8.08   Kristensen   N8.02   Kielberg   S3.06   Al-Ghannami   S10.05   Sorokin   N3.07   Dannenberger   M3.10   Kristensen   N8.02   Kielberg   S3.06   Al-Ghannami   S10.05   Sorokin   N3.07   Malahuti   Malahuti   Na.08   M8.09   Checa   N8.01   Barros Mucci   S3.08   Reg   S10.07   Hadley   N3.01   Hiddak   N9.02   Kielberg   S3.06   Al-Ghannami   S10.05   Sorokin   N3.01   Hiddak   N3.01   Malahuti   N3.02   Malahuti   N3.02   Malahuti   N3.02   Malahuti   N3.03   Malahuti						•				
Mozinski   Mr.11   Su'   Mozinski   Mr.11   Su'   Mozinski   Moz										
M2-19   Moriguchi   M712   Mason   N6-08   Hellgren   S2-04   Jiang   S10.03   Palmiblad   M2-10   Rossary   M8-01   Magnusson   N7-01   Dinel   S2-05   Ribel-Madsen   S10.05   Fisk   S10.04   Yehuda   M2-10   Magnusson   N7-01   Dinel   S2-05   Ribel-Madsen   S10.05   Fisk   S10.04   Yehuda   M2-10   M3-10				· ·						
M210   Jackson   M8.01   Magnusson   N7.01   Dine    \$2.05   Ribel-Madsen   \$10.04   Vehuda   M211   Jackson   M8.02   Hardardtitr   N7.02   Hibbeln   \$2.06   Aukema   \$10.05   Fisk   M211   Jackson   M8.04   Juman   N7.03   Bernadette   \$2.07   Lópe-Vicario   \$10.06   Chouinard-Watkins   M3.01   Urita   M8.04   Juman   N7.04   Hoile   \$2.08   de Graaf   \$10.07   Conway   M3.02   Lin   M8.05   Sorjão   N7.05   Casas-Agustench   \$3.01   Park   \$10.08   Conway   M3.03   Arnardottir   M8.06   Sorgafico Fernandes   N7.06   Lind   \$3.02   Naito   \$11.01   Sueyasu   M3.04   Rustan   M8.07   Radzioch   N7.07   Dávalos   \$3.03   Slim   \$11.02   Tokuda   M3.05   Filhrmann   M8.08   Maghool   N7.08   N8.07   M3.05   Filhrmann   M8.08   Maghool   N7.08   N8.07   M3.07   Dannebrepre   M8.09   Checa   N8.01   Barros Mucci   \$3.05   Aichannami   \$11.03   Sorokin   M3.07   Dannebrepre   M8.10   Kristensen   N8.02   Kjellberg   \$3.06   Aichannami   \$11.03   Sorokin   M3.08   Maghool   N7.08   N8.02   Kjellberg   \$3.00   Aichannami   \$11.05   Sorokin   M3.09   Puebla   M8.12   Giera   N8.04   Hellgren   \$3.08   Tenpo   \$11.07   Hadley   M3.10   Irvine   N8.01   Linu   \$4.01   Montgomery   \$11.08   Dyall   M3.11   Hidaka   Puebla   M8.12   Giera   N8.05   Linu   \$4.01   Montgomery   \$11.08   Dyall   M3.11   Hidaka   Postratasen   N8.07   Simmer   \$4.02   Wopereis   \$12.01   Hennebelle   M4.01   Piotrowitz   N1.01   Samuelsson   N8.08   Gura   \$4.04   Giesbertz   \$12.03   Courchesne-Loyer   M4.02   Fiamoncini   N1.02   Kalachova   N9.01   Meyer   \$4.04   Giesbertz   \$12.03   Courchesne-Loyer   M4.03   Bjorndal   N1.03   Niazmand   N9.02   P. Assumpção   \$4.06   Ai-Ghannami   \$12.05   Rernadette   M4.05   Linu   N1.01   Makhutova   N9.03   Jansson   \$4.07   Skuladottir   \$12.06   Ringel   M4.04   M6.05   M6.0						, ,				
M212   Jackson   M8.02   Hardardottir   N7.02   Hibbeln   S2.06   Aukema   S10.05   Fisk						•		,		
M3.01   Urita   M8.04   Juman   N7.03   Bernadette   S.2.07   López-Vicario   S10.06   Chouinard-Watkins   M3.01   Urita   M8.04   Juman   N7.04   Hoile   S.2.08   de Graaf   S10.07   Conway   S10.08   Chouinard-Watkins   S2.08   Archardottir   M8.05   Gorjão   N7.05   Casas-Agustench   S3.01   Park   S10.08   Conway   S10.04   Conway   S10.05   Conw		Rossary		•						
M3.01   Urita		Jackson								
M3.02   Lin		Østbye				Bernadette				
M3.03   Arnardottir   M8.06   Spreafico Fernandes   M3.04   Rustan   M8.07   Radzicoh   M7.07   Dávalos   S3.02   Silim   S11.02   Tokuda   M3.05   Fuhrmann   M8.08   Magbool   M7.08   Na   S3.04   Ghebremeskel   S11.03   Kato   M3.05   Fuhrmann   M8.08   Magbool   M7.08   Na   S3.04   Ghebremeskel   S11.03   Kato   M3.05   Fuhrmann   M8.08   Magbool   M7.08   Na   S3.04   Ghebremeskel   S11.03   Kato   M3.07   Dannenberger   M8.10   Kristensen   N8.02   Kjellberg   S3.06   Achanami   S11.05   Sorokin   M3.08   Minghetti   M8.11   Hudek   N8.03   Löfqvist   S3.07   De Boer   S11.06   Barros   M3.09   Puebla   M8.12   Giera   N8.04   Hellgren   S3.08   Teng   S11.07   Hadley   M3.10   Trivie   N8.05   Liu   S4.01   Montgomery   S11.08   Dyall   M3.11   Hidaka   POSTER AREA N   N8.06   Simmer   S4.02   Wopereis   S12.01   Hennebelle   M3.12   Opperman   Nobelterrassen   N8.07   Simmer   S4.03   Nunes Masi   S12.02   Hennebelle   M4.01   Poltrowitz   N1.01   Samuelsson   N8.08   Gura   S4.04   Giesbertz   S12.03   Courchesne-Loyer   M4.02   Fiamoncini   N1.02   Kalachova   N9.01   Meyer   S4.05   Taylor   S12.04   Courchesne-Loyer   M4.03   Bjorndal   N1.03   Niazmand   N9.02   P. Assumção   S4.04   Achanami   S12.05   Rernadette   M4.04   Kitson   N1.04   Makhutova   N9.03   Jansson   S4.07   Skuladottir   S12.06   Ringel   M4.05   Liu   N1.05   Nuora   N9.04   Powell   S4.08   Feki   S12.07   Ness   M4.06   Salem   N1.06   Filipiak-Florkiewicz   N9.05   Citelli   S5.01   Dobrzyn   S12.08   Ness   M4.07   Lee   N1.07   Franczyk-Zarow   N9.06   Leung   S5.02   Lee   S13.01   Fauland   M4.08   Filipiak-Florkiewicz   N9.05   Citelli   S5.01   Dobrzyn   S12.08   Ness   M4.06   Salem   N1.06   Filipiak-Florkiewicz   N9.05   Citelli   S5.01   Dobrzyn   S12.08   Ness   M4.06   Salem   N1.06   Ripiak-Florkiewicz   N9.05   Citelli   S5.01   Dobrzyn   S13.06   Liu   N5.02   Park   N3.03   Vurko-Mauro   N1.00   Carlson   S5.05   Marangoni   S13.04   Liu   N5.02   Park   N3.03   Vurko-Mauro   N1.00   Salem   N1.00   Salema	M3.01	Urita	M8.04			Hoile			S10.07	
National   Rustan   M8.07   Radzioch   N7.07   Dávalos   S3.03   Slim   S11.02   Tokuda   National   Tultimann   M8.08   Maqbool   N7.08   National   Na	M3.02	Lin	M8.05	Gorjão	N7.05	Casas-Agustench		Park	\$10.08	Conway
M3.05   Fuhrmann   M8.08   Magbool   N7.08   Na   S3.04   Ghebremeskel   S11.03   Kato   M3.06   Tillander   M8.09   Checa   N8.01   Barros Mucci   S3.05   Rossmels   S11.04   Hashimoto   M3.07   Dannenberger   M8.10   Kristensen   N8.02   Kjellberg   S3.06   Al-Ghannami   S11.05   Sorokin   M3.08   Minghetti   M8.11   Hudek   N8.03   Löfqvist   S3.07   De Boer   S11.06   Barros   M3.09   Puebla   M8.12   Giera   N8.04   Hellgren   S3.08   Teng   S11.07   Hadley   M3.10   Irvine   N8.05   Liu   S4.01   Montgomery   S11.08   Dyall   M3.11   Hidaka   POSTER AREA N   N8.06   Simmer   S4.02   Wopereis   S12.01   Hennebelle   M3.12   Opperman   Nobelterrassen   N8.07   Simmer   S4.02   Wopereis   S12.01   Hennebelle   M4.01   Piotrowitz   N1.01   Samuelsson   N8.08   Gura   S4.04   Wopereis   S12.02   Hennebelle   M4.02   Fiamoncini   N1.02   Kalachova   N9.01   Meyer   S4.05   Taylor   S12.04   Courchesne-Loyer   M4.03   Bjorndal   N1.03   Niazamand   N9.02   P. Assumpção   S4.06   Al-Ghannami   S12.05   Bernadette   M4.04   Kitson   N1.04   Makhutova   N9.03   Jansson   S4.07   Skuladottir   S12.06   Ringel   M4.05   Li   N1.05   Nuora   N9.04   Powell   S4.08   Feki   S12.07   Ness   M4.06   Salem   N1.06   Filipiak-Florkiewicz   N9.05   Citelli   S5.01   Dobrzyn   S12.08   Ness   M4.07   Lee   N1.07   Franczyk-Zarow   N9.06   Leung   S5.02   Lee   S13.01   Fauland   M4.09   Morita   N2.01   Estuty   N9.08   Meyer   S5.04   Von Schacky   S13.02   Yang   M4.09   Morita   N2.03   Holub   N10.02   Yaetes   S5.06   Dubourdeau   S13.05   Fauland   M4.12   Grillitsch   N2.04   Smuts   N10.03   Stark   S5.07   Souza Junior   S13.06   Liu   M5.05   Roux   N3.01   Jones   N10.05   N10.07   Layé   S6.03   Norrison   S13.08   Saac   M5.04   Halley   N10.07   Layé   S6.03   N10.05   N10.06   M5.07   M5.	M3.03	Arnardottir	M8.06	Spreafico Fernandes	N7.06				S11.01	Sueyasu
M3.06         Tillander         M8.09         Checa         N8.01         Barros Mucci         33.05         Rossmeisl         \$11.04         Hashimoto           M3.07         Dannenberger         M8.10         Kristensen         N8.02         Kjellberg         33.06         Al-Ghannami         \$11.05         Sorokin           M3.09         Puebla         M8.12         Giera         N8.04         Hellgren         33.08         Teng         \$11.07         Hadley           M3.10         Irvine         N8.05         Liu         \$4.01         Montgomery         \$11.08         Dyall           M3.11         Hidaka         POSTER AREA N         N8.05         Simmer         \$4.02         Wopereis         \$12.01         Hennebelle           M3.12         Opperman         Nobelterrassen         N8.07         Simmer         \$4.03         Nunes Masi         \$12.02         Hennebelle           M4.01         Piotrowitz         N1.01         Samuelsson         N8.06         Gura         \$4.04         Giesbertz         \$12.03         Courchesne-Loyer           M4.02         Fiamoncini         N1.02         Kalachova         N9.01         Meyer         \$4.05         Al-Ghannami         \$12.05         Bernadette	M3.04	Rustan	M8.07	Radzioch	N7.07	Dávalos	\$3.03	Slim	S11.02	Tokuda
M3.07         Dannenberger         M8.10         Kristensen         N8.02         Kjellberg         S3.06         Al-Ghannami         S11.05         Sorokin           M3.08         Minghetti         M8.11         Hudek         N8.03         Löfqvist         S3.07         De Boer         S11.06         Barros           M3.09         Puebla         M8.12         Giera         N8.04         Hellgren         S3.08         Teng         S11.07         Hadley           M3.10         Irvine         N8.06         Simmer         S4.02         Wopereis         S12.01         Hennebelle           M3.11         Hidaka         POSTER AREA N         N8.06         Simmer         S4.02         Wopereis         S12.01         Hennebelle           M4.01         Piotrowitz         N1.01         Samuelsson         N8.08         Gura         S4.04         Giesbertz         S12.03         Courchesne-Loyer           M4.02         Fiamoncini         N1.02         Kalachova         N9.01         Meyer         S4.05         Taylor         S12.04         Courchesne-Loyer           M4.03         Björndal         N1.03         Miazmand         N9.02         P. Assumpção         S4.06         Al-Ghannami         S12.03         Cour	M3.05	Fuhrmann	M8.08	Maqbool	N7.08	Na	\$3.04	Ghebremeskel	S11.03	Kato
M3.08         Minghetti         M8.11         Hudek         N8.03         Löfqvist         S3.07         De Boer         S11.05         Barros           M3.09         Puebla         M8.12         Giera         N8.04         Hellgren         S3.08         Teng         S11.07         Hadley           M3.10         Irvine         N8.05         Liu         S4.01         Montgomery         S11.08         Dyall           M3.11         Hidaka         POSTER AREA N         N8.06         Simmer         S4.02         Wopereis         S12.01         Hennebelle           M4.01         Piotrowitz         N1.01         Samuelsson         N8.08         Gura         S4.02         Wopereis         S12.01         Hennebelle           M4.01         Piotrowitz         N1.01         Samuelsson         N8.08         Gura         S4.05         Taylor         S12.03         Courchesne-Loyer           M4.02         Filamoncini         N1.02         Kalachova         N9.01         Meyer         S4.05         Taylor         S12.03         Courchesne-Loyer           M4.04         Kitson         N1.04         Makhutova         N9.03         Jansson         S4.07         Skuladottir         S12.03         Renadette	M3.06	Tillander	M8.09	Checa	N8.01	Barros Mucci	\$3.05	Rossmeisl	S11.04	Hashimoto
M3.08         Minghetti         M8.12         Hudek         N8.03         Lófqvist         S3.07         De Boer         \$11.05         Barros           M3.09         Puebla         M8.12         Giera         N8.04         Hellgren         \$3.08         Teng         \$11.07         Hadley           M3.10         Irvine         N8.05         Líu         \$4.01         Montgomery         \$11.08         Dyall           M3.11         Hidaka         POSTER AREA N         N8.06         Simmer         \$4.02         Wopereis         \$12.01         Hennebelle           M4.01         Pitorwitz         N1.01         Samuelsson         N8.08         Gura         \$4.04         Giesbertz         \$12.03         Courchesne-Loyer           M4.02         Fiamoncini         N1.02         Kalachova         N9.01         Meyer         \$4.05         Taylor         \$12.04         Courchesne-Loyer           M4.03         Bjorndal         N1.03         Niazmand         N9.02         P. Assumpção         \$4.05         Skuladottir         \$12.05         Reinadette           M4.04         Kitson         N1.04         Makhutova         N9.03         Jansson         \$4.07         Skuladottir         \$12.06         Ringue     <	M3.07	Dannenberger	M8.10	Kristensen	N8.02	Kjellberg	\$3.06	Al-Ghannami	S11.05	Sorokin
M3.09   Puebla   M8.12   Giera   N8.04   Hellgren   S3.08   Teng   S1.07   Hadley   M3.10   Irvine   N8.05   Liu   S4.01   Montgomery   S11.08   Dyall   M3.11   Hidaka   POSTER AREA N   N8.06   Simmer   S4.02   Wopereis   S12.01   Hennebelle   M3.12   Opperman   Nobelterrassen   N8.07   Simmer   S4.03   Nunes Masi   S12.02   Hennebelle   M3.12   Opperman   N1.01   Samuelsson   N8.08   Gura   S4.04   Giesbertz   S12.03   Courchesne-Loyer   M4.01   Diotrowitz   N1.01   Samuelsson   N8.08   Gura   S4.04   Giesbertz   S12.03   Courchesne-Loyer   M4.02   Fiamoncini   N1.02   Kalachova   N9.01   Meyer   S4.05   Taylor   S12.04   Courchesne-Loyer   M4.04   Kitson   N1.04   Makhutova   N9.03   Jansson   S4.07   Skuladottir   S12.06   Ringel   M4.05   Li   N1.05   Nuora   N9.04   Powell   S4.08   Feki   S12.07   Ness   M4.05   Li   N1.05   Nuora   N9.04   Powell   S4.08   Feki   S12.07   Ness   M4.06   Salem   N1.06   Filipiak-Florkiewicz   N9.05   Citelli   S5.01   Dobrzyn   S12.08   Ness   M4.08   Tillander   N1.08   Grimmer   N9.07   Mulhern   S5.03   Coventry   S13.02   Yang   M4.08   Tillander   N1.08   Grimmer   N9.07   Mulhern   S5.03   Coventry   S13.02   Yang   M4.09   Morita   N2.01   Estuty   N9.08   Meyer   S5.04   von Schacky   S13.03   Wei   M4.11   Zhang   N2.03   Holub   N10.02   Yearlson   S5.05   Dubourdeau   S13.05   Fauland   M5.04   Zhou   S13.05   Fauland   M5.04   Zhou   S13.05   Fauland   M5.04   Zhou   S13.06   Liu   M5.01   Pu   N2.05   Niazmand   N10.04   Zhao   S5.08   Sioriki   S13.07   Liu   M5.07   Park   N2.08   Hadley   N10.07   Layé   S6.03   von Schacky   S13.03   Saac   M5.04   Bernabe-Garcia   N2.08   Hadley   N10.07   Layé   S6.03   Von Schacky   S14.02   Astwood   M5.05   Rioux   N3.01   Jones   N10.06   Tatebayashi   S6.02   Bittner   S14.04   Astwood   M5.05   Rioux   N3.03   Yurko-Mauro   N10.05   Rioardson   S7.01   Purcell   S14.06   M5.06   M5.07   M5.07   Park   N3.03   Yurko-Mauro   N10.05   Rioardson   S7.01   Purcell   S14.06   Ghasmi Fard   M5.10   M5.10   M5.10   M5.1		•	M8.11	Hudek	N8.03	Löfqvist	\$3.07	De Boer	S11.06	Barros
M3.10         Irvine         MS.05         Liu         S4.01         Montgomery         S11.08         Dyall           M3.11         Hidaka         POSTER AREA N         N8.06         Simmer         S4.02         Wopereis         S12.01         Hennebelle           M4.01         Piotrowitz         N1.01         Samuelsson         N8.08         Gura         S4.04         Giesbertz         S12.01         Hennebelle           M4.01         Piotrowitz         N1.01         Samuelsson         N8.08         Gura         S4.04         Giesbertz         S12.03         Courchesne-Loyer           M4.02         Fiamoncini         N1.02         Kalachova         N9.01         Meyer         S4.05         Taylor         S12.04         Courchesne-Loyer           M4.03         Bjorndal         N1.03         Niazmand         N9.02         P. Assumpção         S4.06         Al-Gannami         S12.05         Bernadette           M4.04         Kitson         N1.05         Nuora         N9.02         Powell         S4.08         Feki         S12.07         Ness           M4.05         Salem         N1.06         Filipiak-Florkiewicz         N9.05         Citelli         S5.01         Dobrzyn         S12.08         Ness <td></td> <td>•</td> <td>M8.12</td> <td>Giera</td> <td>N8.04</td> <td>Hellgren</td> <td>\$3.08</td> <td>Teng</td> <td>S11.07</td> <td>Hadley</td>		•	M8.12	Giera	N8.04	Hellgren	\$3.08	Teng	S11.07	Hadley
M3.11         Hidaka         POSTER AREA N         N8.06         Simmer         S4.02         Wopereis         S12.01         Hennebelle           M3.12         Opperman         Nobelterrassen         N8.07         Simmer         S4.03         Nunes Masi         S12.02         Hennebelle           M4.01         Piotrowitz         N1.01         Samuelsson         N8.08         Gura         S4.04         Giesbertz         S12.02         Hennebelle           M4.02         Fiamoncini         N1.02         Kalachova         N9.01         Meyer         S4.05         Taylor         S12.04         Courchesne-Loyer           M4.03         Bjorndal         N1.03         Niazamand         N9.02         P. Assumpção         S4.06         Al-Ghannami         S12.05         Bernadette           M4.05         Li         N1.04         Makhutova         N9.03         Jansson         S4.07         Skuladottir         S12.06         Ringel           M4.05         Li         N1.06         Filipiak-Florkiewicz         N9.05         Citelli         S5.01         Dobrzyn         S12.08         Ress           M4.08         Tillander         N1.06         Filipiak-Florkiewicz         N9.05         Leung         S5.02         Lee		Irvine			N8.05	Liu	\$4.01	Montgomery	S11.08	Dyall
M3.12         Opperman         Nobelterrassen         N8.07         Simmer         S4.03         Nunes Masi         S12.02         Hennebelle           M4.01         Piotrowitz         N1.01         Samuelsson         N8.08         Gura         S4.04         Giesbertz         S12.03         Courchesne-Loyer           M4.02         Fiamoncini         N1.02         Kalachova         N9.01         Meyer         S4.05         Taylor         S12.04         Courchesne-Loyer           M4.03         Björndal         N1.03         Niazmand         N9.02         P. Assumpção         S4.06         Al-Ghannami         S12.05         Bernadette           M4.05         Li         N1.05         Nuora         N9.03         Jansson         S4.07         Skuladottir         S12.06         Ringel           M4.05         Li         N1.05         Nuora         N9.04         Powell         S4.08         Feki         S12.07         Ness           M4.07         Lee         N1.07         Franczyk-Zarow         N9.05         Citelli         S5.01         Dobrzyn         S12.08         Ness           M4.07         Lee         N1.07         Franczyk-Zarow         N9.06         Leung         S5.02         Lee         S13			POS	TER AREA N	N8.06	Simmer	\$4.02	Wopereis	S12.01	Hennebelle
M4.01         Piotrowitz         NI.01         Samuelsson         N8.08         Gura         \$4.04         Giesbertz         \$12.03         Courchesne-Loyer           M4.02         Fiamoncini         NI.03         Niazmand         N9.01         Meyer         \$4.05         Taylor         \$12.04         Courchesne-Loyer           M4.03         Bjorndal         NI.03         Niazmand         N9.02         P. Assumpção         \$4.06         Al-Ghannami         \$12.05         Bernadette           M4.04         Kitson         NI.04         Makhutova         N9.03         Jansson         \$4.07         Skuladottir         \$12.06         Ringel           M4.05         Li         NI.05         Nuora         N9.04         Powell         \$4.08         Feki         \$12.07         Ness           M4.07         Lee         NI.07         Franczyk-Zarow         N9.05         Citelli         \$5.01         Dobrzyn         \$12.08         Ness           M4.08         Tillander         NI.08         Grimmer         N9.07         Mulhern         \$5.02         Lee         \$13.01         Fauland           M4.10         Benediktsdóttir         N2.01         Estuty         N9.08         Meyer         \$5.04         von S			Nobe	elterrassen	N8.07	Simmer	\$4.03	Nunes Masi	S12.02	Hennebelle
M4.02         Fiamoncini         N1.02         Kalachova         N9.01         Meyer         S4.05         Taylor         S12.04         Courchesne-Loyer           M4.03         Bjorndal         N1.03         Niazamand         N9.02         P. Assumpção         S4.06         Al-Ghannami         S12.05         Bernadette           M4.04         Kitson         N1.04         Makhutova         N9.03         Jansson         S4.07         Skuladottir         S12.06         Ringel           M4.05         Li         N1.05         Nuora         N9.04         Powell         S4.08         Feki         S12.07         Ness           M4.06         Salem         N1.06         Filipiak-Florkiewicz         N9.05         Citelli         S5.01         Dobrzyn         S12.08         Ness           M4.07         Lee         N1.07         Franczyk-Zarow         N9.06         Leung         S5.02         Lee         S13.01         Fauland           M4.09         Morita         N2.01         Estuty         N9.08         Meyer         S5.03         Coventry         S13.02         Yang           M4.10         Benediktsdóttir         N2.02         Tavares do Carmo         N10.01         Carlson         S5.05         Mar			N1.01	Samuelsson	N8.08	Gura	\$4.04	Giesbertz	S12.03	Courchesne-Loyer
M4.03         Bjorndal         N1.03         Niazmand         N9.02         P. Assumpção         S4.06         Al-Ghannami         S12.05         Bernadette           M4.04         Kitson         N1.04         Makhutova         N9.03         Jansson         S4.07         Skuladottir         S12.05         Ringel           M4.05         Li         N1.05         Nuora         N9.04         Powell         S4.08         Feki         S12.07         Ness           M4.06         Salem         N1.06         Filipiak-Florkiewicz         N9.05         Citelli         S5.01         Dobrzyn         S12.08         Ness           M4.07         Lee         N1.07         Franczyk-Zarow         N9.06         Leung         S5.02         Lee         S13.01         Fauland           M4.08         Tillander         N1.08         Grimmer         N9.07         Mulhern         S5.03         Coventry         S13.02         Yang           M4.10         Benediktsdóttir         N2.02         Tavares do Carmo         N10.01         Carlson         S5.04         Dubourdeau         S13.05         Fauland           M4.12         Grillitsch         N2.04         Smuts         N10.02         Yeates         S5.06         Dubou			N1.02	Kalachova		Mever	\$4.05	Taylor	S12.04	
M4.04         Kitson         NI.04         Makhutova         N9.03         Jansson         S4.07         Skuladottir         S12.06         Ringel           M4.05         Li         NI.05         Nuora         N9.04         Powell         S4.08         Feki         S12.07         Ness           M4.06         Salem         NI.06         Filipiak-Florkiewicz         N9.05         Citelli         S5.01         Dobrzyn         S12.08         Ness           M4.07         Lee         NI.07         Franczyk-Zarow         N9.06         Leung         S5.02         Lee         S13.01         Fauland           M4.08         Tillander         NI.08         Grimmer         N9.07         Mulhern         S5.03         Coventry         S13.02         Yang           M4.09         Morita         N2.01         Estuty         N9.08         Meyer         S5.04         von Schacky         S13.02         Yang           M4.10         Benediktsdóttir         N2.02         Tavares do Carmo         NI0.01         Carlson         S5.05         Marangoni         S13.04         Zhou           M4.11         Zhang         N2.04         Smuts         NI0.03         Stark         S5.07         Souza Junior         S1				Niazmand		,		•		
M4.05         Li         N1.05         Nuora         N9.04         Powell         \$4.08         Feki         \$12.07         Ness           M4.06         Salem         N1.06         Filipiak-Florkiewicz         N9.05         Citelli         \$5.01         Dobrzyn         \$12.08         Ness           M4.07         Lee         N1.07         Franczyk-Zarow         N9.06         Leung         \$5.02         Lee         \$13.01         Fauland           M4.08         Tillander         N1.08         Grimmer         N9.07         Mulhern         \$5.03         Coventry         \$13.02         Yang           M4.10         Benediktsdóttir         N2.01         Estuty         N9.08         Meyer         \$5.04         von Schacky         \$13.03         Wei           M4.11         Zhang         N2.03         Holub         N10.01         Carlson         \$5.05         Marangoni         \$13.04         Zhou           M4.12         Grillitsch         N2.03         Holub         N10.02         Yeates         \$5.06         Dubourdeau         \$13.05         Fauland           M5.01         Pu         N2.05         Niazmand         N10.02         Yeates         \$5.07         Souza Junior         \$13.06				Makhutova			\$4.07	Skuladottir		
M4.06         Salem         N1.06         Filipiak-Florkiewicz         N9.05         Citelli         S5.01         Dobrzyn         S12.08         Ness           M4.07         Lee         N1.07         Franczyk-Zarow         N9.06         Leung         S5.02         Lee         S13.01         Fauland           M4.08         Tillander         N1.08         Grimmer         N9.07         Mulhern         S5.03         Coventry         S13.02         Yang           M4.10         Benediktsdóttir         N2.01         Estuty         N9.08         Meyer         S5.04         von Schacky         S13.03         Wei           M4.11         Zhang         N2.02         Tavares do Carmo         N10.01         Carlson         S5.05         Marangoni         S13.04         Zhou           M4.11         Zhang         N2.03         Holub         N10.02         Yeates         S5.06         Dubourdeau         S13.05         Fauland           M4.12         Grillitsch         N2.04         Smuts         N10.03         Stark         S5.07         Souza Junior         S13.06         Liu           M5.01         Pur         N2.05         Niazmand         N10.04         Zhao         S5.08         Sioriki <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>•</td></td<>										•
M4.07         Lee         N1.07         Franczyk-Zarow         N9.06         Leung         S5.02         Lee         S13.01         Fauland           M4.08         Tillander         N1.08         Grimmer         N9.07         Mulhern         S5.03         Coventry         S13.02         Yang           M4.10         Morita         N2.01         Estuty         N9.08         Meyer         S5.04         von Schacky         S13.03         Wei           M4.10         Benediktsdóttir         N2.02         Tavares do Carmo         N10.01         Carlson         S5.05         Marangoni         S13.04         Zhou           M4.11         Zhang         N2.03         Holub         N10.02         Yeates         S5.06         Dubourdeau         S13.05         Fauland           M4.12         Grillitsch         N2.04         Smuts         N10.03         Stark         S5.07         Souza Junior         S13.06         Liu           M5.01         Pu         N2.05         Niazmand         N10.03         Stark         S5.07         Souza Junior         S13.06         Liu           M5.02         Park         N2.05         Kostogrys         N10.05         Osumi         S6.08         Bitner         S13.06 </td <td></td>										
M4.08         Tillander         N1.08         Grimmer         N9.07         Mulhern         S5.03         Coventry         S13.02         Yang           M4.09         Morita         N2.01         Estuty         N9.08         Meyer         S5.04         von Schacky         S13.03         Wei           M4.10         Benediktsdóttir         N2.02         Tavares do Carmo         N10.01         Carlson         S5.05         Marangoni         S13.04         Zhou           M4.11         Zhang         N2.03         Holub         N10.02         Yeates         S5.06         Dubourdeau         S13.05         Fauland           M4.12         Grillitsch         N2.04         Smuts         N10.03         Stark         S5.07         Souza Junior         S13.06         Liu           M5.01         Pu         N2.05         Niazmand         N10.04         Zhao         S5.08         Sioriki         S13.07         Liu           M5.02         Park         N2.06         Kostogrys         N10.05         Osumi         S6.01         Morrison         S13.08         Isaac           M5.02         Park         N2.06         Kostogrys         N10.05         Osumi         S6.01         Morrison         S13.08										
M4.09         Morita         N2.01         Estuty         N9.08         Meyer         S5.04         von Schacky         S13.03         Wei           M4.10         Benediktsdóttir         N2.02         Tavares do Carmo         N10.01         Carlson         S5.05         Marangoni         S13.04         Zhou           M4.11         Zhang         N2.03         Holub         N10.02         Yeates         S5.06         Dubourdeau         S13.05         Fauland           M4.12         Grillitsch         N2.04         Smuts         N10.03         Stark         S5.07         Souza Junior         S13.06         Liu           M5.01         Pu         N2.05         Niazmand         N10.04         Zhao         S5.08         Sioriki         S13.07         Liu           M5.02         Park         N2.06         Kostogrys         N10.05         Osumi         S6.01         Morrison         S13.08         Isaac           M5.03         Rodrigues         N2.07         de Roos         N10.06         Tatebayashi         S6.02         Bittner         S14.01         Astwood           M5.04         Bernabe-Garcia         N2.08         Hadley         N10.07         Layé         S6.03         von Schacky						•				
M4.10         Benediktsdóttir         N2.02         Tavares do Carmo         N10.01         Carlson         S5.05         Marangoni         S13.04         Zhou           M4.11         Zhang         N2.03         Holub         N10.02         Yeates         S5.06         Dubourdeau         S13.05         Fauland           M4.12         Grillitsch         N2.04         Smuts         N10.03         Stark         S5.07         Souza Junior         S13.06         Liu           M5.01         Pu         N2.05         Niazmand         N10.04         Zhao         S5.08         Sioriki         S13.07         Liu           M5.02         Park         N2.06         Kostogrys         N10.05         Osumi         S6.01         Morrison         S13.08         Isaac           M5.03         Rodrigues         N2.07         de Roos         N10.06         Tatebayashi         S6.02         Bittner         S14.01         Astwood           M5.04         Bernabe-Garcia         N2.08         Hadley         N10.07         Layé         S6.03         von Schacky         S14.02         Astwood           M5.05         Rioux         N3.01         Jones         N10.08         Su         S6.04         Galano         S										•
M4.11         Zhang         N2.03         Holub         N10.02         Yeates         S5.06         Dubourdeau         S13.05         Fauland           M4.12         Grillitsch         N2.04         Smuts         N10.03         Stark         S5.07         Souza Junior         S13.06         Liu           M5.01         Pu         N2.05         Niazmand         N10.04         Zhao         S5.08         Sioriki         S13.07         Liu           M5.02         Park         N2.06         Kostogrys         N10.05         Osumi         S6.01         Morrison         S13.08         Isaac           M5.03         Rodrigues         N2.07         de Roos         N10.06         Tatebayashi         S6.02         Bittner         S14.01         Astwood           M5.04         Bernabe-Garcia         N2.08         Hadley         N10.07         Layé         S6.03         von Schacky         S14.02         Astwood           M5.05         Rioux         N3.01         Jones         N10.08         Su         S6.04         Galano         S14.03         Astwood           M5.06         Clandinin         N3.02         Bell         N11.01         van der Wurff         S6.05         Armand         S14.04						•		,		
M4.12         Grillitsch         N2.04         Smuts         N10.03         Stark         S5.07         Souza Junior         S13.06         Liu           M5.01         Pu         N2.05         Niazmand         N10.04         Zhao         S5.08         Sioriki         S13.07         Liu           M5.02         Park         N2.06         Kostogrys         N10.05         Osumi         S6.01         Morrison         S13.08         Isaac           M5.03         Rodrigues         N2.07         de Roos         N10.06         Tatebayashi         S6.02         Bittner         S14.01         Astwood           M5.04         Bernabe-Garcia         N2.08         Hadley         N10.07         Layé         S6.03         von Schacky         S14.02         Astwood           M5.05         Rioux         N3.01         Jones         N10.08         Su         S6.04         Galano         S14.03         Astwood           M5.06         Clandinin         N3.02         Bell         N11.01         van der Wurff         S6.05         Armand         S14.04         Polreis           M5.07         Park         N3.03         Yurko-Mauro         N11.02         Sørensen         S6.06         Ghosh         S14.05								•		
M5.01         Pu         N2.05         Niazmand         N10.04         Zhao         S5.08         Sioriki         S13.07         Liu           M5.02         Park         N2.06         Kostogrys         N10.05         Osumi         S6.01         Morrison         S13.08         Isaac           M5.03         Rodrigues         N2.07         de Roos         N10.06         Tatebayashi         S6.02         Bittner         S14.01         Astwood           M5.04         Bernabe-Garcia         N2.08         Hadley         N10.07         Layé         S6.03         von Schacky         S14.02         Astwood           M5.05         Rioux         N3.01         Jones         N10.08         Su         S6.04         Galano         S14.03         Astwood           M5.06         Clandinin         N3.02         Bell         N11.01         van der Wurff         S6.05         Armand         S14.04         Polreis           M5.07         Park         N3.03         Yurko-Mauro         N11.02         Sørensen         S6.06         Ghosh         S14.05         Hall           M5.08         Daak         N3.04         Zayed         N11.03         Al-Ghannami         S6.07         Visioli         S14.06										
M5.02         Park         N2.06         Kostogrys         N10.05         Osumi         S6.01         Morrison         S13.08         Isaac           M5.03         Rodrigues         N2.07         de Roos         N10.06         Tatebayashi         S6.02         Bittner         S14.01         Astwood           M5.04         Bernabe-Garcia         N2.08         Hadley         N10.07         Layé         S6.03         von Schacky         S14.02         Astwood           M5.05         Rioux         N3.01         Jones         N10.08         Su         S6.04         Galano         S14.03         Astwood           M5.06         Clandinin         N3.02         Bell         N11.01         van der Wurff         S6.05         Armand         S14.04         Polreis           M5.07         Park         N3.03         Yurko-Mauro         N11.02         Sørensen         S6.06         Ghosh         S14.05         Hall           M5.08         Daak         N3.04         Zayed         N11.03         Al-Ghannami         S6.07         Visioli         S14.06         West           M5.09         Choque         N3.05         Baumgartner         N11.04         Lee         S6.08         Bandarra         S14.07<										
M5.03         Rodrigues         N2.07         de Roos         N10.06         Tatebayashi         S6.02         Bittner         S14.01         Astwood           M5.04         Bernabe-Garcia         N2.08         Hadley         N10.07         Layé         S6.03         von Schacky         S14.02         Astwood           M5.05         Rioux         N3.01         Jones         N10.08         Su         S6.04         Galano         S14.03         Astwood           M5.06         Clandinin         N3.02         Bell         N11.01         van der Wurff         S6.05         Armand         S14.04         Polreis           M5.07         Park         N3.03         Yurko-Mauro         N11.02         Sørensen         S6.06         Ghosh         S14.05         Hall           M5.08         Daak         N3.04         Zayed         N11.03         Al-Ghannami         S6.07         Visioli         S14.06         West           M5.09         Choque         N3.05         Baumgartner         N11.04         Lee         S6.08         Bandarra         S14.07         Li           M5.10         Aukema         N3.06         Scholefield         N11.05         Richardson         S7.01         Purcell         S1										
M5.04         Bernabe-Garcia         N2.08         Hadley         N10.07         Layé         S6.03         von Schacky         S14.02         Astwood           M5.05         Rioux         N3.01         Jones         N10.08         Su         S6.04         Galano         S14.03         Astwood           M5.06         Clandinin         N3.02         Bell         N11.01         van der Wurff         S6.05         Armand         S14.04         Polreis           M5.07         Park         N3.03         Yurko-Mauro         N11.02         Sørensen         S6.06         Ghosh         S14.05         Hall           M5.08         Daak         N3.04         Zayed         N11.03         Al-Ghannami         S6.07         Visioli         S14.06         West           M5.09         Choque         N3.05         Baumgartner         N11.04         Lee         S6.08         Bandarra         S14.07         Li           M5.10         Aukema         N3.06         Scholefield         N11.05         Richardson         S7.01         Purcell         S14.08         Ghasemi Fard           M5.11         Gregory         N3.07         Sushchik         N11.06         Bjarnadóttir         S7.02         Purcell         <										
M5.05         Rioux         N3.01         Jones         N10.08         Su         S6.04         Galano         S14.03         Astwood           M5.06         Clandinin         N3.02         Bell         N11.01         van der Wurff         S6.05         Armand         S14.04         Polreis           M5.07         Park         N3.03         Yurko-Mauro         N11.02         Sørensen         S6.06         Ghosh         S14.05         Hall           M5.08         Daak         N3.04         Zayed         N11.03         Al-Ghannami         S6.07         Visioli         S14.06         West           M5.09         Choque         N3.05         Baumgartner         N11.04         Lee         S6.08         Bandarra         S14.07         Li           M5.10         Aukema         N3.06         Scholefield         N11.05         Richardson         S7.01         Purcell         S14.08         Ghasemi Fard           M5.11         Gregory         N3.07         Sushchik         N11.06         Bjarnadóttir         S7.02         Purcell         S15.01         Abdullah           M5.12         Choque         N3.08         Arabani         N11.07         Hatanaka         S7.03         Rice         S15.02		•								
M5.06         Clandinin         N3.02         Bell         N11.01         van der Wurff         S6.05         Armand         S14.04         Polreis           M5.07         Park         N3.03         Yurko-Mauro         N11.02         Sørensen         S6.06         Ghosh         S14.05         Hall           M5.08         Daak         N3.04         Zayed         N11.03         Al-Ghannami         S6.07         Visioli         S14.06         West           M5.09         Choque         N3.05         Baumgartner         N11.04         Lee         S6.08         Bandarra         S14.07         Li           M5.10         Aukema         N3.06         Scholefield         N11.05         Richardson         S7.01         Purcell         S14.08         Ghasemi Fard           M5.11         Gregory         N3.07         Sushchik         N11.06         Bjarnadóttir         S7.02         Purcell         S15.01         Abdullah           M5.12         Choque         N3.08         Arabani         N11.07         Hatanaka         S7.03         Rice         S15.02         Wopereis           M6.01         Mantzioris         N4.01         Dijck-Brouwer         N11.08         Domenichiello         S7.04         Sánch								•		
M5.07         Park         N3.03         Yurko-Mauro         N11.02         Sørensen         S6.06         Ghosh         S14.05         Hall           M5.08         Daak         N3.04         Zayed         N11.03         Al-Ghannami         S6.07         Visioli         S14.06         West           M5.09         Choque         N3.05         Baumgartner         N11.04         Lee         S6.08         Bandarra         S14.07         Li           M5.10         Aukema         N3.06         Scholefield         N11.05         Richardson         S7.01         Purcell         S14.08         Ghasemi Fard           M5.11         Gregory         N3.07         Sushchik         N11.06         Bjarnadóttir         S7.02         Purcell         S15.01         Abdullah           M5.12         Choque         N3.08         Arabani         N11.07         Hatanaka         S7.03         Rice         S15.02         Wopereis           M6.01         Mantzioris         N4.01         Dijck-Brouwer         N11.08         Domenichiello         S7.04         Sánchez-Moreno         S15.03         Zock										
M5.08         Daak         N3.04         Zayed         N11.03         Al-Ghannami         S6.07         Visioli         S14.06         West           M5.09         Choque         N3.05         Baumgartner         N11.04         Lee         S6.08         Bandarra         S14.07         Li           M5.10         Aukema         N3.06         Scholefield         N11.05         Richardson         S7.01         Purcell         S14.08         Ghasemi Fard           M5.11         Gregory         N3.07         Sushchik         N11.06         Bjarnadóttir         S7.02         Purcell         S15.01         Abdullah           M5.12         Choque         N3.08         Arabani         N11.07         Hatanaka         S7.03         Rice         S15.02         Wopereis           M6.01         Mantzioris         N4.01         Dijck-Brouwer         N11.08         Domenichiello         S7.04         Sánchez-Moreno         S15.03         Zock										
M5.09 Choque N3.05 Baumgartner N11.04 Lee S6.08 Bandarra S14.07 Li M5.10 Aukema N3.06 Scholefield N11.05 Richardson S7.01 Purcell S14.08 Ghasemi Fard M5.11 Gregory N3.07 Sushchik N11.06 Bjarnadóttir S7.02 Purcell S15.01 Abdullah M5.12 Choque N3.08 Arabani N11.07 Hatanaka S7.03 Rice S15.02 Wopereis M6.01 Mantzioris N4.01 Dijck-Brouwer N11.08 Domenichiello S7.04 Sánchez-Moreno S15.03 Zock										
M5.10AukemaN3.06ScholefieldN11.05RichardsonS7.01PurcellS14.08Ghasemi FardM5.11GregoryN3.07SushchikN11.06BjarnadóttirS7.02PurcellS15.01AbdullahM5.12ChoqueN3.08ArabaniN11.07HatanakaS7.03RiceS15.02WopereisM6.01MantziorisN4.01Dijck-BrouwerN11.08DomenichielloS7.04Sánchez-MorenoS15.03Zock				•						
M5.11 Gregory N3.07 Sushchik N11.06 Bjarnadóttir S7.02 Purcell S15.01 Abdullah M5.12 Choque N3.08 Arabani N11.07 Hatanaka S7.03 Rice S15.02 Wopereis M6.01 Mantzioris N4.01 Dijck-Brouwer N11.08 Domenichiello S7.04 Sánchez-Moreno S15.03 Zock				•						
M5.12 Choque N3.08 Arabani N11.07 Hatanaka S7.03 Rice S15.02 Wopereis M6.01 Mantzioris N4.01 Dijck-Brouwer N11.08 Domenichiello S7.04 Sánchez-Moreno S15.03 Zock										
M6.01 Mantzioris N4.01 Dijck-Brouwer N11.08 Domenichiello S7.04 Sánchez-Moreno S15.03 Zock						•				
										•
M6.02 Kawashima N4.02 KOQTIGO NIZ.UI NOFOUZI JAVIdan S7.05 Voggt				•					515.03	∠OCK
	M6.02	kawashima	N4.UZ	πυαιιμύ	NIZ.UI	INOLOUZI JAVIDAN	31.05	voggt		

### POSTER LISTINGS BY DAY (Alphabetized by last name of the presenters)

POSTER SESS 29 JUNE / S	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
The effect of omega 3	S4.06 fatty acid supplementa- n D status of school chil-

Valger1ur Edda Benediktsdóttir . . . . . . . . M4.10 Phospholipid composition of lipid rafts from rat heart.

Maria Fernanda Cury-Boaventura....... S1.06 Effect of DHA-rich fish oil supplementation on the plasma lipid metabolites in marathon runners before and after acute exercise

Agnieszka Filipiak-Florkiewicz .......... N1.06 Lipid profile of egg yolks from laying hens fed diets supplemented with pomegranate seed oil

Kathryn Hopperton	Yu-Hong Lin	Anu NuoraN1.05
Amyloid- $\beta$ induced inflammation and its resolution by omega-3 polyunsaturated fatty acids in a mouse model of Alzheimer's Disease	Quantification of Endocannabinoids in Animal Organs and Human Fluids by Triple Quadrupole Gas Chromatography/Mass Spectrometry	The effects of two different cooking methods on the lipid oxidation of beef steaks and on the postprandial lipid response and oxidative stress
Giorgis Isaac	Mads Vendelbo Lind	state in humans  Noriko Osumi
Suzu Iwanaga	Stabilisation of long chain polyunsaturated fatty acids in human dried blood spots  Ge Liu	Jan Palmblad
Jitcy Joseph	for measuring fatty acid status Linda LjungbladM7.02 Medulloblastoma growth inhibited by LCPUFA DHA and EPA	OmegAD study.  Kira Piotrowitz
Saki Kakutani	Olesia Makhutova	Robert Purcell
Effect of way of cooking on content of essential polyunsaturated fatty acids in filets of zander	Julie Mason	Robert Purcell
Alex Kitson	sitive or resistant to trastuzumab (TRAS) and prevents TRAS resistance development  Peter McLennan	and identification of direct endothelial actions in vitro
levels or δ5- or δ6-desaturase expression compared with wild-type Kristina Klizaite	Resistance to muscle fatigue with low dose dietary fish oil supplement and membrane incorporation of DHA.	Harry Rice
The Role of LPCAT1 and LPCAT2 in Regulation of Lipid Droplets  Anna Kock	John Miklavcic	Valenzuela Rodrigo
Primary Neuroblastoma Sophie Layé	Unique changes in hepatic sphingolipid species after high-fat feeding in BALB/c mice correlate with protection from diet-induced glucose intolerance	partum α-linolenic acid intake from chia oil Hadis Sabour
developing brain  Jetty Lee	Shin-ya Morita	Nicholas SalemM4.06 Rat Whole Body Distribution of Omega-6 and Omega-3 Polyunsaturated Fatty Acids
exclusively suppressed enzymatic and non- enzymatic lipid peroxidation of DHA and EPA Duo Li	canalicular nonraft membranes  Hye-Kyung NaN7.08	Linda Samuelsson
N-3 polyunsaturated fatty acids modulate homocysteine metabolism	15-Deoxy-▲12,14-prostaglandin J2 Upregulates the Expression of 15-Hydroxyprostaglandin Dehydrogenase through DNA Methyltrasferase 1 Inactivation	Concepción Sánchez-Moreno
Duo Li	Razieh Niazmand	onion intake Svanhild Schønberg
Duo LiS7.07  Docosapentaenoic acid is responsible to mean platelet volume	parameters of purslane (Portulaca oleracea L) seed oil Laureane Nunes Masi	Anticancer properties mediated by PUFAs - DHA- induced stress response in human colon cancer cells
Lin Lin	Effects of fish oil supplementation on inflamma- tion and insulin resistance in mice fed a bal- anced or high fat diet	Gudrun Skuladottir

Hong Yang	Daniela Barros Mucci
Sesame oil Using Chromatography and Chemometrics	protective against neonatal hypoxic-ischemic brain injury? Mariela Bernabe-Garcia
Alison Yeates	Docosahexaenoic acid reduces the catabolic effect of sepsis on nutritional status of critically ill neonates
Shlomo Yehuda	Delplanque Bernadette
fatty acids Jiyao ZhangM4.11 Fatty acid desaturase 3 (Fads3) null mouse biochemical phenotype	Delplanque Bernadette
Jinping ZhaoN10.04 The absolute amount of plasma DHA increased significantly during pregnancy in healthy preg-	Elín BjarnadóttirN11.06 Fish Oils Supplementation During Pregnancy and Child Neurodevelopment
tional diabetes Chuan Zhou	Stephanie Caligiuri
Determination of 16 phthalate esters in edible vegetable oils by GC-MS/MS with QuEChERS	Reduces Blood Pressure in a Randomized, Double-Blinded, Placebo Controlled Clinical Trial Antonio Checa
POSTER SESSION II: 30 JUNE / MONDAY	Sphingolipid levels in cerebrospinal fluid serve as markers of disease progression in multiple sclerosis
Fish consumption for a short period of time improves cognitive ability of healthy Omani	Benjamin Choque
James Astwood	Benjamin Choque
James Astwood	M Tom Clandinin
James Astwood	Krista Coventry
3) and palmitoleic acid (16:1n-7)  Harold Aukema	Ahmed Daak
abnormalities in pcy mouse kidneys by dietary flax oil demonstrates that $\alpha$ -linolenic acid can	urase) and FADS2 (delta 5 desaturase) genes in homozygous sickle cell patients Albert de GraafS2.08
acid (DHA) to maintain DHA oxylipins levels Harold Aukema	Metabolic Syndrome simulator for personal nutritional advice  Baukje de Roos
Modulation of Adipogenesis by Oxylipins - Differential Effects on Lipid Droplet Formation and Adipokine Production  Karina Barros	Health effects of consuming 2 portions per week of Scottish farmed salmon raised on dif- ferent feeding regimes – the FISH DISH study
	Alison Yeates

lipid emulsion in critically ill elderly patients on cortisol, insulin and antioxidant enzymes

increases the risk of cardiovascular disease

Ashish Dhyani	Ingibjorg Hardardottir	Sachiko Juman
Samaneh Ghasemi Fard	lesterol metabolism and localization  Bruce Holub	The effect of n-3 polyunsaturated fatty acids on risk markers for cardiovascular disease and inflammation in patients with psoriatic arthritis  Federica Laguzzi
Kevin Hadley	Corinne Joffre	Chatarina Löfqvist

Rashudy Mahomedradja N5.08 Oxidized linoleic acid products in foods, a litera- ture review	Jason Polreis	Cornelius M Smuts
Linda Malan	David Pu	three distinct communities in South Africa Louise B. Sørensen
Asim Maqbool	Danuta Radzioch	A.V. Sorokin
Franca Marangoni	Marie Sannes Ramsvik	Alcione Souza Junior
Dietary linoleic acid increases tumor necrosis factor alpha in adult rat plasma  Amanda R Martins	dation in low-fat fed rats  Amalie Ribel-Madsen	Flávia Spreafico Fernandes
Influence of fish oil supplementation on skeletal muscle oxidative stress and mitochondrial func- tion in insulin resistant mice	on plasma levels of amino acids in young, healthy men with low or normal birth weight.  Alex Richardson	dren and adolescents with cystic fibrosis.  Toshiaki Sueyasu
Toru Moriguchi	Randomised Controlled Trials of Omega-3 LC-PUFA for Child Behaviour and Learning: Theoretical and Practical Considerations Vincent Rioux	on mood state in elderly Japanese men  Miyoung Suh
Emmanuel Mukwevho	Identification of FADS3 (Fatty Acid Desaturase 3) as a trans-vaccenate D13-desaturase in mammals Patrizia Rise	diet-induced obese rats  Maria das Graças Tavares do Carmo N2.02  Fatty acid content of biscuits commercialized in
lipid oxidation and accumulation as potential anti-obesity agents  Razieh Niazmand	Effects of an eight-week consumption of milk enriched with Omega 3 fatty acids on lipid pro- file in adult healthy volunteers	Brazil  Noemi Tejera
Comparative Fatty Acids Composition and oxida- tive stability index of Black cumin, Coriander and Dill Seeds oil	Hosana Rodrigues	3 fatty acid status: Studies in cells, rodents and humans Hisanori Tokuda
Tone-Kari Østbye	Adrien Rossary	Effect of long-chain polyunsaturated fatty acid on cognitive function in elderly Japanese men Inge van der Wurff
4-Desaturation of 7,10,13,16-22:4 To 4,7,10,13,16- 22:5 (Adrenic Acid -> Osbond Acid) Mediated by FADS2 in Human Cells Hui Gyu Park	Irina Shabalina	Food2Learn: Randomized control trial investi- gating influence of krill oil supplementation on learning, cognition, and behaviour in healthy adolescents. Design presentation
Human breast cancer cells stably expressed FADS2 synthesize sapienic acid (16:1n-10) from palmitic acid (16:0)	and coactivator demands  Karen Simmer	Clemens von Schacky
Anna Maria Pauter	emulsion (SMOF®) compared with olive oil based lipid emulsion (Clinoleic®) in term and near-term (>34 weeks)surgical neonates - A randomised	Anna Walczewska
Anna Petroni	controlled trial.  Karen Simmer	brane potential in human gingival fibroblasts.  Annette West
Natasa Petrovic	from RCTs  Eleni Sioriki	ferent structural forms

and their fish feeds

# POSTER SESSION III: 1 JULY / TUESDAY

Consumption: Estimation of Healthcare Savings in Canada
Samia S. Al-Ghannami
Eric Allain
Ali Arabi Arabani
Martine Armand
Hildur ArnardottirM3.03 Resolution of peritonitis is delayed in aged mice: DHA, Resolvins and Maresins shorten reso lution in vivo
Narcisa Bandarra
Jeannine Baumgartner
Gordon BellN3.02 Salmon products purchased from UK retailers in 2013: a survey of oil and fatty acid compositions
Guy Ben Zvi
Delplanque Bernadette
Ulrika Birberg Thornberg
Daniel Bittner
Robert Block

Rachel V. Gow
Kei Hamazaki
Lars Hellgren
Marie Hennebelle
Marie Hennebelle
Brandon Hidaka
Helena Idborg
Nicola Irvine
Thomas Jansson
Peter Jones
Hiroshi Kawashima
Alex Kitson
Kumar S. Kothapalli
Marije Kuipers

human neutrophils in the micromolar range

Kin Sum Leung	Katherine Ness	Andrew Scholefield
Docosahexaenoic Acid Metabolism  Evangeline Mantzioris	Effect of omega-3 polyunsaturated fatty acids on lipid profile in spinal cord Injury patients  Maretha Opperman	fish oil fatty acids on glucose tolerance and fatty acid status  Flavia Spreafico Fernandes
the risk of posttraumatic stress disorder Yutaka Matsuoka	Pro-resolving actions of a novel RvD1 analog qualifying as a lead immunoresolvant  Renata P. Assumpção	Flavia Spreafico Fernandes
Barbara J Meyer	ine growth restriction  Yongsoon Park	Associated with Elevated Trait Aggression and Impulsivity in Major Depressive Disorder  Marc Surette
Barbara J Meyer	Synergistic anti-depressant effects of N-3 polyunsaturated fatty acids and 17b-estradiol in ovariectomized rats after forced swimming test Natalie Parletta	Comparison of polyunsaturated fatty acids content in filets of anadromous and landlocked sockeye salmon Oncorhynchus nerka  Kim-Tiu Teng
The a-linolenic acid oxidative product protect immature neurons from oxidant injury and promote differentiation of oligodendrocyte progenitors  Roel Mocking	feasibility study (HELFIMED)  Theresa Powell	abdominal obesity  Veronika Tillander
Metabolism between Depression, Schizophrenia, Post-Traumatic Stress Disorder and Healthy Controls; Associations with Endocrinology, Neuroimaging, and Inflammation Martine Morrison	gpr40 (ffar1) in human gastric epithelial cells Amit Ringel	Exogenous acetate metabolism is suppressed in patients with fatty liver diseases.  Inge van der Wurff
those of refined pumpkin oil on cardiometabolic risk factors and disease development  Maria Mulhern	Martin Rossmeisl	there an early programming effect?  Francesco Visioli
eating population Yukiko Naito	Increased lipid oxidation and decreased lipid storage in myotubes from Plin2 knock-out mice Laura Sanborn	The Omega-3 Index - a review of the current state of the evidence  Peter Y. Wielinga

in life.

Ina Willenberg
Suzan Wopereis
Jeffrey Yao
Karin Yurko-Mauro
Zeinab Zayed
Peter Zock

Kudos and a heartfelt thank you to the ISSFAL 2014 Poster Presenters for their contributions to the field &

# THANK YOU 2014 CONGRESS FACULTY AND DELEGATES

ISSFAL also thanks all the delegates and faculty from all over the world who assembled for the 2014 Congress.

Meet us again in Cape Town, South Africa, in 2016!

If these topics and programme are of interest to you, visit www.issfal.org to learn more about ISSFAL

– the foremost international scientific society dealing exclusively with the health impact of dietary lipids.



EN	51
-	[ <b>[</b>
-	r.
-	Ξ
-	
-	
-	_
-	
_	
_	
_	
_	
_	
_	
_	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
_	
-	
_	
_	
_	
_	

ISSFAL 2014   28 JUNE – 2 JULY   STOCKHOLM, SWEDEN	

ISSFAL 2014   28 JUNE – 2 JULY   STOCKHOLM, SWEDEN	53
	1























International Society for the Study of Fatty Acids and Lipids



**Cape Town South Africa** 



DSM Nutritional Products, a leader in the development of polyunsaturated fatty acids, is a proud sponsor of the ISSFAL Congress.

DSM.COM

